{"text_format":"3","workbook":"xlsx","n_sheets":78,"sheets":["Cover","Unaudited Condensed Consolidate","Unaudited Condensed Consolida_2","Unaudited Condensed Consolida_3","Unaudited Condensed Consolida_4","Unaudited Condensed Consolida_5","Nature of Business and Organiza","Liquidity and Capital Resources","Inventory, net","Deposits and Other Current Asse","Property, Plant, and Equipment,","Accrued Expenses and Other Curr","Notes Payable","Related Party Transactions","Other Financing Liabilities","Leases","Commitments and Contingencies","Stockholders_ Equity","Stock-Based Compensation","Fair Value of Financial Instrum","Net Loss per Share","Subsequent Events","Pay vs Performance Disclosure","Insider Trading Arrangements","Nature of Business and Organi_2","Nature of Business and Organi_3","Inventory, net (Tables)","Deposits and Other Current As_2","Property, Plant, and Equipmen_2","Accrued Expenses and Other Cu_2","Notes Payable (Tables)","Related Party Transactions (Tab","Other Financing Liabilities (Ta","Stockholders_ Equity (Tables)","Stock-Based Compensation (Table","Fair Value of Financial Instr_2","Net Loss per Share (Tables)","Nature of Business and Organi_4","Nature of Business and Organi_5","Nature of Business and Organi_6","Nature of Business and Organi_7","Liquidity and Capital Resourc_2","Inventory, net - Schedule of In","Inventory, net - Narrative (Det","Deposits and Other Current As_3","Property, Plant, and Equipmen_3","Property, Plant, and Equipmen_4","Accrued Expenses and Other Cu_3","Notes Payable - Schedule of Not","Notes Payable - Schedule of N_2","Notes Payable - Schedule of Mat","Notes Payable - Secured SPA Not","Notes Payable - 2023 Unsecured ","Notes Payable - Unsecured Conve","Notes Payable - Junior Secured ","Notes Payable - 2024 Unsecured ","Notes Payable - 2025 March Unse","Notes Payable - Notes Payable, ","Notes Payable - Auto Loans Narr","Related Party Transactions - Sc","Related Party Transactions - _2","Related Party Transactions - Na","Other Financing Liabilities - N","Other Financing Liabilities - F","Commitments and Contingencies (","Stockholders_ Equity - Schedule","Stockholders_ Equity - Amendmen","Stockholders_ Equity - Series A","Stockholders' Equity - Common S","Stockholders_ Equity - Schedu_2","Stockholders_ Equity - Warrants","Stock-Based Compensation - Narr","Stock-Based Compensation - Stoc","Fair Value of Financial Instr_3","Fair Value of Financial Instr_4","Fair Value of Financial Instr_5","Net Loss per Share - Potentiall","Subsequent Events (Details)"],"cells_cut":4,"read":"whole","date_system":"1900"}

{"sheet":"Cover","index":0,"n_rows":43,"n_cols":3,"rows_kept":43,"merged":[[0,0,1,0]]}
["Cover - shares","3 Months Ended"]
[null,"Mar. 31, 2025","May 05, 2025"]
["Document Information [Line Items]"," "," "]
["Document Type","10-Q"," "]
["Document Quarterly Report","true"," "]
["Document Period End Date","Mar. 31,  2025"," "]
["Document Transition Report","false"," "]
["Entity File Number","001-39395"," "]
["Entity Registrant Name","Faraday Future Intelligent Electric Inc."," "]
["Entity Incorporation, State or Country Code","DE"," "]
["Entity Tax Identification Number","84-4720320"," "]
["Entity Address, Address Line One","18455 S. Figueroa Street"," "]
["Entity Address, City or Town","Gardena"," "]
["Entity Address, State or Province","CA"," "]
["Entity Address, Postal Zip Code","90248"," "]
["City Area Code","424"," "]
["Local Phone Number","276-7616"," "]
["Entity Current Reporting Status","No"," "]
["Entity Interactive Data Current","No"," "]
["Entity Filer Category","Non-accelerated Filer"," "]
["Entity Small Business","true"," "]
["Entity Emerging Growth Company","true"," "]
["Entity Ex Transition Period","false"," "]
["Entity Shell Company","false"," "]
["Entity Central Index Key","0001805521"," "]
["Amendment Flag","false"," "]
["Current Fiscal Year End Date","--12-31"," "]
["Document Fiscal Year Focus","2025"," "]
["Document Fiscal Period Focus","Q1"," "]
["Class A Common Stock"," "," "]
["Document Information [Line Items]"," "," "]
["Title of 12(b) Security","Class A common stock, par value $0.0001 per share"," "]
["Trading Symbol","FFAI"," "]
["Security Exchange Name","NASDAQ"," "]
["Entity Common Stock, Shares Outstanding"," ",{"v":97616087,"d":"97,616,087 "}]
["Redeemable Warrants"," "," "]
["Document Information [Line Items]"," "," "]
["Title of 12(b) Security","Redeemable warrants, exercisable for shares of Class A common stock at an exercise price of $110,400.00 per share"," "]
["Trading Symbol","FFAIW"," "]
["Security Exchange Name","NASDAQ"," "]
["Class B Common Stock"," "," "]
["Document Information [Line Items]"," "," "]
["Entity Common Stock, Shares Outstanding"," ",{"v":6667,"d":"6,667 "}]

{"sheet":"Unaudited Condensed Consolidate","index":1,"n_rows":52,"n_cols":3,"rows_kept":52}
["Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Current assets"," "," "]
["Cash",{"v":9458,"d":"$ 9,458"},{"v":7144,"d":"$ 7,144"}]
["Restricted cash",{"v":35,"d":"35 "},{"v":30,"d":"30 "}]
["Accounts receivable",{"v":664,"d":"664 "},{"v":0,"d":"0 "}]
["Inventory, net",{"v":27124,"d":"27,124 "},{"v":27486,"d":"27,486 "}]
["Deposits",{"v":33919,"d":"33,919 "},{"v":31094,"d":"31,094 "}]
["Other current assets",{"v":5271,"d":"5,271 "},{"v":6127,"d":"6,127 "}]
["Total current assets",{"v":76471,"d":"76,471 "},{"v":71881,"d":"71,881 "}]
["Property, plant and equipment, net",{"v":331465,"d":"331,465 "},{"v":348587,"d":"348,587 "}]
["Operating lease right-of-use assets, net",{"v":1208,"d":"1,208 "},{"v":1761,"d":"1,761 "}]
["Other non-current assets",{"v":1440,"d":"1,440 "},{"v":3171,"d":"3,171 "}]
["Total assets",{"v":410584,"d":"410,584 "},{"v":425400,"d":"425,400 "}]
["Current liabilities"," "," "]
["Accounts payable",{"v":70697,"d":"70,697 "},{"v":71414,"d":"71,414 "}]
["Accrued expenses and other current liabilities",{"v":61492,"d":"61,492 "},{"v":56754,"d":"56,754 "}]
["Other financing liabilities, current portion",{"v":803,"d":"803 "},{"v":761,"d":"761 "}]
["Operating lease liabilities, current portion",{"v":1364,"d":"1,364 "},{"v":2128,"d":"2,128 "}]
["Total current liabilities",{"v":188778,"d":"188,778 "},{"v":192707,"d":"192,707 "}]
["Other financing liabilities, long term portion",{"v":40489,"d":"40,489 "},{"v":38698,"d":"38,698 "}]
["Operating lease liabilities, long term portion",{"v":10,"d":"10 "},{"v":14,"d":"14 "}]
["Other liabilities",{"v":1075,"d":"1,075 "},{"v":1287,"d":"1,287 "}]
["Total liabilities",{"v":270776,"d":"270,776 "},{"v":310433,"d":"310,433 "}]
["Stockholders’ equity"," "," "]
["Preferred Stock, 0.0001 par value; 10,000,000 shares authorized; zero and one shares issued and outstanding as of March 31, 2025 and December 31, 2024 respectively",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Additional paid-in capital",{"v":4456374,"d":"4,456,374 "},{"v":4421563,"d":"4,421,563 "}]
["Accumulated other comprehensive income",{"v":8050,"d":"8,050 "},{"v":7744,"d":"7,744 "}]
["Accumulated deficit",{"v":-4324624,"d":"(4,324,624)"},{"v":-4314346,"d":"(4,314,346)"}]
["Total stockholders’ equity",{"v":139808,"d":"139,808 "},{"v":114967,"d":"114,967 "}]
["Total liabilities and stockholders’ equity",{"v":410584,"d":"410,584 "},{"v":425400,"d":"425,400 "}]
["Nonrelated Party"," "," "]
["Current liabilities"," "," "]
["Accrued expenses and other current liabilities",{"v":50388,"d":"50,388 "},{"v":45677,"d":"45,677 "}]
["Warrant liabilities",{"v":22498,"d":"22,498 "},{"v":28864,"d":"28,864 "}]
["Accrued interest",{"v":25,"d":"25 "},{"v":25,"d":"25 "}]
["Notes payable",{"v":4132,"d":"4,132 "},{"v":4224,"d":"4,224 "}]
["Notes payable, long-term portion",{"v":20542,"d":"20,542 "},{"v":45264,"d":"45,264 "}]
["Derivative call options",{"v":16064,"d":"16,064 "},{"v":29709,"d":"29,709 "}]
["Related Party"," "," "]
["Current liabilities"," "," "]
["Accrued expenses and other current liabilities",{"v":11104,"d":"11,104 "},{"v":11077,"d":"11,077 "}]
["Warrant liabilities",{"v":1126,"d":"1,126 "},{"v":0,"d":"0 "}]
["Accrued interest",{"v":22343,"d":"22,343 "},{"v":23227,"d":"23,227 "}]
["Notes payable",{"v":4298,"d":"4,298 "},{"v":5310,"d":"5,310 "}]
["Notes payable, long-term portion",{"v":2825,"d":"2,825 "},{"v":2754,"d":"2,754 "}]
["Derivative call options",{"v":993,"d":"993 "},{"v":0,"d":"0 "}]
["Class A Common Stock"," "," "]
["Stockholders’ equity"," "," "]
["Common stock",{"v":8,"d":"8 "},{"v":6,"d":"6 "}]
["Class B Common Stock"," "," "]
["Stockholders’ equity"," "," "]
["Common stock",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}]

{"sheet":"Unaudited Condensed Consolida_2","index":2,"n_rows":15,"n_cols":3,"rows_kept":15}
["Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares","Mar. 31, 2025","Dec. 31, 2024"]
["Preferred stock, par value (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Preferred stock, shares authorized (in shares)",{"v":10000000,"d":"10,000,000 "},{"v":10000000,"d":"10,000,000 "}]
["Preferred stock, shares issued (in shares)",{"v":0,"d":"0 "},{"v":1,"d":"1 "}]
["Preferred stock, shares outstanding (in shares)",{"v":0,"d":"0 "},{"v":1,"d":"1 "}]
["Class A Common Stock"," "," "]
["Common stock, par value (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Common stock, shares authorized (in shares)",{"v":124815625,"d":"124,815,625 "},{"v":99815625,"d":"99,815,625 "}]
["Common stock, shares issued (in shares)",{"v":86786748,"d":"86,786,748 "},{"v":65919127,"d":"65,919,127 "}]
["Common stock, shares outstanding (in shares)",{"v":86786748,"d":"86,786,748 "},{"v":65919127,"d":"65,919,127 "}]
["Class B Common Stock"," "," "]
["Common stock, par value (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Common stock, shares authorized (in shares)",{"v":4429688,"d":"4,429,688 "},{"v":4429688,"d":"4,429,688 "}]
["Common stock, shares issued (in shares)",{"v":6667,"d":"6,667 "},{"v":6667,"d":"6,667 "}]
["Common stock, shares outstanding (in shares)",{"v":6667,"d":"6,667 "},{"v":6667,"d":"6,667 "}]

{"sheet":"Unaudited Condensed Consolida_3","index":3,"n_rows":44,"n_cols":3,"rows_kept":44,"merged":[[0,0,1,0],[0,1,0,2]]}
["Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Revenue",{"v":316,"d":"$ 316"},{"v":2,"d":"$ 2"}]
["Cost of revenue",{"v":21381,"d":"21,381 "},{"v":20687,"d":"20,687 "}]
["Gross profit",{"v":-21065,"d":"(21,065)"},{"v":-20685,"d":"(20,685)"}]
["Operating expenses"," "," "]
["Research and development",{"v":6419,"d":"6,419 "},{"v":6688,"d":"6,688 "}]
["Sales and marketing",{"v":2629,"d":"2,629 "},{"v":2474,"d":"2,474 "}]
["General and administrative",{"v":13674,"d":"13,674 "},{"v":13848,"d":"13,848 "}]
["Loss (gain) on disposal on property, plant, and equipment",{"v":44,"d":"44 "},{"v":-87,"d":"(87)"}]
["Total operating expenses",{"v":22766,"d":"22,766 "},{"v":22923,"d":"22,923 "}]
["Loss from operations",{"v":-43831,"d":"(43,831)"},{"v":-43608,"d":"(43,608)"}]
["Other income, net",{"v":1784,"d":"1,784 "},{"v":530,"d":"530 "}]
["Loss before income taxes",{"v":-10268,"d":"(10,268)"},{"v":-48217,"d":"(48,217)"}]
["Income tax expense",{"v":-10,"d":"(10)"},{"v":0,"d":"0 "}]
["Net loss",{"v":-10278,"d":"(10,278)"},{"v":-48217,"d":"(48,217)"}]
["Total comprehensive loss"," "," "]
["Net loss",{"v":-10278,"d":"(10,278)"},{"v":-48217,"d":"(48,217)"}]
["Foreign currency translation adjustment",{"v":306,"d":"306 "},{"v":232,"d":"232 "}]
["Total comprehensive loss",{"v":-9972,"d":"$ (9,972)"},{"v":-47985,"d":"$ (47,985)"}]
["Class A Common Stock"," "," "]
["Net loss per share of Class A and B Common Stock attributable to common stockholders:"," "," "]
["Basic (in dollars per share)",{"v":-0.14,"d":"$ (0.14)"},{"v":-26.23,"d":"$ (26.23)"}]
["Diluted (in dollars per share)",{"v":-0.14,"d":"$ (0.14)"},{"v":-26.23,"d":"$ (26.23)"}]
["Weighted average common shares used in computing net loss per share of Class A and Class B Common Stock:"," "," "]
["Basic (in shares)",{"v":75749893,"d":"75,749,893 "},{"v":1837959,"d":"1,837,959 "}]
["Diluted (in shares)",{"v":75749893,"d":"75,749,893 "},{"v":1837959,"d":"1,837,959 "}]
["Class B Common Stock"," "," "]
["Net loss per share of Class A and B Common Stock attributable to common stockholders:"," "," "]
["Basic (in dollars per share)",{"v":-0.14,"d":"$ (0.14)"},{"v":-26.23,"d":"$ (26.23)"}]
["Diluted (in dollars per share)",{"v":-0.14,"d":"$ (0.14)"},{"v":-26.23,"d":"$ (26.23)"}]
["Weighted average common shares used in computing net loss per share of Class A and Class B Common Stock:"," "," "]
["Basic (in shares)",{"v":75749893,"d":"75,749,893 "},{"v":1837959,"d":"1,837,959 "}]
["Diluted (in shares)",{"v":75749893,"d":"75,749,893 "},{"v":1837959,"d":"1,837,959 "}]
["Nonrelated Party"," "," "]
["Operating expenses"," "," "]
["Change in fair value of notes payable, warrant liabilities, and derivative call options",{"v":51458,"d":"$ 51,458"},{"v":27885,"d":"$ 27,885"}]
["Loss on settlement of notes payable",{"v":-15920,"d":"(15,920)"},{"v":-11403,"d":"(11,403)"}]
["Interest expense",{"v":-2302,"d":"(2,302)"},{"v":-2225,"d":"(2,225)"}]
["Related Party"," "," "]
["Operating expenses"," "," "]
["Change in fair value of notes payable, warrant liabilities, and derivative call options",{"v":-277,"d":"(277)"},{"v":-7,"d":"(7)"}]
["Loss on settlement of notes payable",{"v":-1180,"d":"(1,180)"},{"v":-14295,"d":"(14,295)"}]
["Interest expense",{"v":0,"d":"$ 0"},{"v":-5094,"d":"$ (5,094)"}]

{"sheet":"Unaudited Condensed Consolida_4","index":4,"n_rows":26,"n_cols":10,"rows_kept":26}
["Unaudited Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands","Total","Notes Payable","Additional \u2028Paid-in \u2028Capital","Additional \u2028Paid-in \u2028Capital Notes Payable","Accumulated \u2028Other \u2028Comprehensive Income (Loss)","Accumulated Deficit","Class A Common Stock Common Stock","Class A Common Stock Common Stock Notes Payable","Class B Common Stock Common Stock"]
["Beginning balance (in shares) at Dec. 31, 2023"," "," "," "," "," "," ",{"v":1060833,"d":"1,060,833 "}," ",{"v":6667,"d":"6,667 "}]
["Beginning balance at Dec. 31, 2023",{"v":228236,"d":"$ 228,236"}," ",{"v":4180873,"d":"$ 4,180,873"}," ",{"v":5862,"d":"$ 5,862"},{"v":-3958499,"d":"$ (3,958,499)"},{"v":0,"d":"$ 0"}," ",{"v":0,"d":"$ 0"}]
["Increase (Decrease) in Stockholders' Equity [Roll Forward]"," "," "," "," "," "," "," "," "," "]
["Conversion of notes payable and accrued interest into Class A Common Stock (in shares)"," "," "," "," "," "," "," ",{"v":2923628,"d":"2,923,628 "}," "]
["Conversion of notes payable and accrued interest into Class A Common Stock"," ",{"v":20726,"d":"$ 20,726"}," ",{"v":20726,"d":"$ 20,726"}," "," "," "," "," "]
["Reverse stock split related round up share issuances (in shares)"," "," "," "," "," "," ",{"v":307,"d":"307 "}," "," "]
["Stock-based compensation",{"v":542,"d":"542 "}," ",{"v":542,"d":"542 "}," "," "," "," "," "," "]
["Foreign currency translation adjustment",{"v":232,"d":"232 "}," "," "," ",{"v":232,"d":"232 "}," "," "," "," "]
["Net loss",{"v":-48217,"d":"(48,217)"}," "," "," "," ",{"v":-48217,"d":"(48,217)"}," "," "," "]
["Ending balance (in shares) at Mar. 31, 2024"," "," "," "," "," "," ",{"v":3984768,"d":"3,984,768 "}," ",{"v":6667,"d":"6,667 "}]
["Ending balance at Mar. 31, 2024",{"v":201519,"d":"201,519 "}," ",{"v":4202141,"d":"4,202,141 "}," ",{"v":6094,"d":"6,094 "},{"v":-4006716,"d":"(4,006,716)"},{"v":0,"d":"$ 0"}," ",{"v":0,"d":"$ 0"}]
["Beginning balance (in shares) at Dec. 31, 2024"," "," "," "," "," "," ",{"v":65919127,"d":"65,919,127 "}," ",{"v":6667,"d":"6,667 "}]
["Beginning balance at Dec. 31, 2024",{"v":114967,"d":"114,967 "}," ",{"v":4421563,"d":"4,421,563 "}," ",{"v":7744,"d":"7,744 "},{"v":-4314346,"d":"(4,314,346)"},{"v":6,"d":"$ 6"}," ",{"v":0,"d":"$ 0"}]
["Increase (Decrease) in Stockholders' Equity [Roll Forward]"," "," "," "," "," "," "," "," "," "]
["Conversion of notes payable and accrued interest into Class A Common Stock (in shares)"," "," "," "," "," "," "," ",{"v":20081506,"d":"20,081,506 "}," "]
["Conversion of notes payable and accrued interest into Class A Common Stock"," ",{"v":32673,"d":"$ 32,673"}," ",{"v":32671,"d":"$ 32,671"}," "," "," ",{"v":2,"d":"$ 2"}," "]
["Settlement of HSL s.r.l. lawsuit with issuance of Class A Common Stock (in shares)"," "," "," "," "," "," ",{"v":774183,"d":"774,183 "}," "," "]
["Settlement of HSL s.r.l. lawsuit with issuance of Class A Common Stock",{"v":1185,"d":"1,185 "}," ",{"v":1185,"d":"1,185 "}," "," "," "," "," "," "]
["Stock-based compensation",{"v":301,"d":"301 "}," ",{"v":301,"d":"301 "}," "," "," "," "," "," "]
["Issuance of shares for RSU vesting net of tax withholdings (in shares)"," "," "," "," "," "," ",{"v":11932,"d":"11,932 "}," "," "]
["Chongqing related party debt restructuring",{"v":654,"d":"654 "}," ",{"v":654,"d":"654 "}," "," "," "," "," "," "]
["Foreign currency translation adjustment",{"v":306,"d":"306 "}," "," "," ",{"v":306,"d":"306 "}," "," "," "," "]
["Net loss",{"v":-10278,"d":"(10,278)"}," "," "," "," ",{"v":-10278,"d":"(10,278)"}," "," "," "]
["Ending balance (in shares) at Mar. 31, 2025"," "," "," "," "," "," ",{"v":86786748,"d":"86,786,748 "}," ",{"v":6667,"d":"6,667 "}]
["Ending balance at Mar. 31, 2025",{"v":139808,"d":"$ 139,808"}," ",{"v":4456374,"d":"$ 4,456,374"}," ",{"v":8050,"d":"$ 8,050"},{"v":-4324624,"d":"$ (4,324,624)"},{"v":8,"d":"$ 8"}," ",{"v":0,"d":"$ 0"}]

{"sheet":"Unaudited Condensed Consolida_5","index":5,"n_rows":64,"n_cols":3,"rows_kept":64,"merged":[[0,0,1,0],[0,1,0,2]]}
["Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Cash flows from operating activities"," "," "]
["Net loss",{"v":-10278,"d":"$ (10,278)"},{"v":-48217,"d":"$ (48,217)"}]
["Adjustments to reconcile net loss to net cash used in operating activities:"," "," "]
["Depreciation and amortization expense",{"v":17527,"d":"17,527 "},{"v":17728,"d":"17,728 "}]
["Amortization of operating lease right-of-use assets and intangible assets",{"v":553,"d":"553 "},{"v":749,"d":"749 "}]
["Non-cash interest expense",{"v":814,"d":"814 "},{"v":0,"d":"0 "}]
["Stock-based compensation",{"v":301,"d":"301 "},{"v":542,"d":"542 "}]
["Loss (gain) on disposal on property, plant, and equipment",{"v":44,"d":"44 "},{"v":-87,"d":"(87)"}]
["Gain from forgiveness of accounts payable and deposits, net",{"v":0,"d":"0 "},{"v":-518,"d":"(518)"}]
["HSL s.l.r. settlement adjustment",{"v":-295,"d":"(295)"},{"v":0,"d":"0 "}]
["Gain on foreign exchange",{"v":0,"d":"0 "},{"v":-2105,"d":"(2,105)"}]
["Change in fair value of notes payable, warrant liabilities, and derivative call options",{"v":-51458,"d":"(51,458)"},{"v":-27885,"d":"(27,885)"}]
["Change in fair value of related party notes payable and related party warrant liabilities",{"v":277,"d":"277 "},{"v":7,"d":"7 "}]
["Changes in operating assets and liabilities:"," "," "]
["Accounts receivables",{"v":-664,"d":"(664)"},{"v":0,"d":"0 "}]
["Deposits",{"v":-2823,"d":"(2,823)"},{"v":5955,"d":"5,955 "}]
["Inventory",{"v":362,"d":"362 "},{"v":4804,"d":"4,804 "}]
["Other current and non-current assets",{"v":2515,"d":"2,515 "},{"v":-1808,"d":"(1,808)"}]
["Accounts payable",{"v":-651,"d":"(651)"},{"v":3559,"d":"3,559 "}]
["Financial obligations on lease back transaction",{"v":0,"d":"0 "},{"v":751,"d":"751 "}]
["Operating lease liabilities",{"v":-703,"d":"(703)"},{"v":-755,"d":"(755)"}]
["Net cash used in operating activities",{"v":-20295,"d":"(20,295)"},{"v":-14719,"d":"(14,719)"}]
["Cash flows from investing activities"," "," "]
["Proceeds from the sale of equipment",{"v":0,"d":"0 "},{"v":87,"d":"87 "}]
["Payments for property and equipment",{"v":-1568,"d":"(1,568)"},{"v":-99,"d":"(99)"}]
["Net cash used in investing activities",{"v":-1568,"d":"(1,568)"},{"v":-12,"d":"(12)"}]
["Cash flows from financing activities"," "," "]
["Proceeds from other financial obligations",{"v":1133,"d":"1,133 "},{"v":0,"d":"0 "}]
["Payments of notes payable and other financing obligations",{"v":-309,"d":"(309)"},{"v":0,"d":"0 "}]
["Payments of notes payable issuance costs",{"v":-99,"d":"(99)"},{"v":-25,"d":"(25)"}]
["Net cash provided by financing activities",{"v":24601,"d":"24,601 "},{"v":12013,"d":"12,013 "}]
["Effect of exchange rate changes on cash and restricted cash",{"v":-419,"d":"(419)"},{"v":-2,"d":"(2)"}]
["Net (decrease) increase in cash and restricted cash",{"v":2319,"d":"2,319 "},{"v":-2720,"d":"(2,720)"}]
["Cash and restricted cash, beginning of period",{"v":7174,"d":"7,174 "},{"v":4025,"d":"4,025 "}]
["Cash and restricted cash, end of period",{"v":9493,"d":"9,493 "},{"v":1305,"d":"1,305 "}]
["Cash and restricted cash"," "," "]
["Cash",{"v":9458,"d":"9,458 "},{"v":407,"d":"407 "}]
["Restricted cash",{"v":35,"d":"35 "},{"v":898,"d":"898 "}]
["Cash, cash equivalents, restricted cash, and restricted cash equivalents",{"v":9493,"d":"9,493 "},{"v":1305,"d":"1,305 "}]
["Supplemental disclosure of cash flow information"," "," "]
["Cash paid for interest",{"v":1376,"d":"1,376 "},{"v":465,"d":"465 "}]
["Cash paid for taxes",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Supplemental disclosure of noncash investing and financing activities"," "," "]
["Additions of property and equipment included in accounts payable and accrued expenses",{"v":0,"d":"0 "},{"v":45424,"d":"45,424 "}]
["Settlement of HSL s.l.r. liability in Class A Common Stock",{"v":1185,"d":"1,185 "},{"v":0,"d":"0 "}]
["Conversion of notes payable, related party notes payable and accrued interest into Class A Common Stock",{"v":15573,"d":"15,573 "},{"v":9118,"d":"9,118 "}]
["Issuance of warrants with the SPA Portfolio Notes",{"v":15084,"d":"15,084 "},{"v":1,"d":"1 "}]
["Nonrelated Party"," "," "]
["Adjustments to reconcile net loss to net cash used in operating activities:"," "," "]
["Loss on settlement of notes payable",{"v":15920,"d":"15,920 "},{"v":11403,"d":"11,403 "}]
["Changes in operating assets and liabilities:"," "," "]
["Accrued expenses and other current and non-current liabilities",{"v":6945,"d":"6,945 "},{"v":1749,"d":"1,749 "}]
["Accrued interest expense",{"v":0,"d":"0 "},{"v":5114,"d":"5,114 "}]
["Cash flows from financing activities"," "," "]
["Proceeds from notes payable, net of original issuance discount",{"v":22000,"d":"22,000 "},{"v":9038,"d":"9,038 "}]
["Related Party"," "," "]
["Adjustments to reconcile net loss to net cash used in operating activities:"," "," "]
["Loss on settlement of notes payable",{"v":1180,"d":"1,180 "},{"v":14295,"d":"14,295 "}]
["Changes in operating assets and liabilities:"," "," "]
["Accrued expenses and other current and non-current liabilities",{"v":139,"d":"139 "},{"v":0,"d":"0 "}]
["Cash flows from financing activities"," "," "]
["Proceeds from notes payable, net of original issuance discount",{"v":1876,"d":"$ 1,876"},{"v":3000,"d":"$ 3,000"}]

{"sheet":"Nature of Business and Organiza","index":6,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Nature of Business and Organization, Basis of Presentation, and Summary of Significant Accounting Policies","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Organization, Consolidation and Presentation of Financial Statements [Abstract]"," "]
["Nature of Business and Organization, Basis of Presentation, and Summary of Significant Accounting Policies",{"$cut":{"chars":27815,"head":"Nature of Business and Organization, Basis of Presentation, and Summary of Significant Accounting Policies Nature of Business and Organization Unless otherwise stated or the context requires otherwise, references herein to the “Company,” “FFIE,” “FFAI,” “Faraday” “we,” “us,” and “our” mean Faraday Future Intelligent Electric Inc. and its wholly-owned subsidiaries, and controlled and managed entities. The Company is a holding company incorporated in the State of Delaware on February 11, 2020, conducts its operations through its subsidiaries and is headquartered in 18455 S. Figueroa Street, Gardena, CA 90248. The Company operates in a single operating segment and designs and engineers next-generation, intelligent, electric vehicles. The Company manufactures its vehicles at its production facility in Hanford, California, known as “FF ieFactory California” and has additional engineering, sales, and operations capabilities in China. The Company has created innovations in technology, products, and a user-centered business model that are being incorporated into its planned electric vehicle platform. Principles of Consolidation The Unaudited Condensed Consolidated Financial Statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“GAAP”) and include the accounts of the Company, its wholly-owned subsidiaries and all other entities in which the Company has a controlling financial interest, including the accounts of any variable interest entity, in which the Company has a controlling financial interest and for which it is the primary beneficiary in accordance with Accounting Standards Codification (“ASC”) 810, Consolidation (“ASC 810”). All intercompany transactions and balances have been eliminated upon consolidation. These Unaudited Condensed Consolidated Financial Statements do not include all disclosures that are normally included in the Annual audited financial statements prepared in accordance with GAAP and should be read in conjunction with the Company’s Audited Consolidated Financial Statements and notes thereto for the year ended December 31, 2024, included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 31, 2025, (the “Form 10-K”). Accordingly, the Unaudited Condensed Consolidated Balance Sheet as of March 31, 2025, has been derived from the Company’s Annual audited Consolidated Financial Statements but does not contain all of the footnote disclosures from the annual financial statements. The Company believes that the disclosures included in this Quarterly Report on Form 10-Q (this “Form 10-Q”) are adequate to make the information presented not misleading. In the opinion of management, the Unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position, results of operations, and cash flows for the periods presented. The accounting policies used in the preparation of these Unaudited Condensed Consolidated Financial Statements are the same as those disclosed in the audited Consolidated Financial Statement for the year ended December 31, 2024, included in the Form 10-K, except as described below. Our annual reporting period is the calendar year. The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the results to be expected for the 2025 full year or any future periods. Basis of Presentation Use of Estimates and Judgments The preparation of the Company’s Unaudited Condensed Consolidated Financial Statements in conformity with GAAP and in accordance with the rules and regulations of the SEC requires management to make estimates and assumptions which affect the reported amounts in the Unaudited Condensed Consolidated Financial Statements. Estimates are based on historical experience, where applicable, and other assumptions which management believes are reasonable under the circumstances. On an ongoing basis management evaluates its estimates, inclu"}}]

{"sheet":"Liquidity and Capital Resources","index":7,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Liquidity and Capital Resources and Going Concern","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Organization, Consolidation and Presentation of Financial Statements [Abstract]"," "]
["Liquidity and Capital Resources and Going Concern","Liquidity and Capital Resources and Going Concern The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the Unaudited Condensed Consolidated Financial Statements are issued. Based on its recurring losses from operations since inception and continued cash outflows from operating activities (all as described below), the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that these Unaudited Condensed Consolidated Financial Statements were issued. Preparation of Financial statements The Unaudited Condensed Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the Unaudited Condensed Consolidated Financial Statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. Capital Investment, SPA Portfolio Debt, and Future Equity Plans The Company has and will continue to devote subs tantial effort and, to the extent available, capital resources, to strategic planning, engineering, design, and development of its electric vehicle platform, development of vehicle models, finalizing the build out of the FF ieFactory California manufacturing facility, and capital raising. The Company incurred cumulative losses from operations, negative cash flows from operating activities, and has an accumulated deficit of $4,324.6 million, an unrestricted cash balance of $9.5 million and a negative working capital position of $112.3 million as of March 31, 2025. The Company delivered its first vehicles during 2023 and plans to launch its FX Series of vehicles, but expects to continue to generate significant operating losses for the foreseeable future. The Company has funded its operations and capital needs primarily through the issuance of notes payable and related party notes payable convertible notes (see Note 7, Notes Payable and Note 8, Related Party Transactions ), and the sale of common stock. Debt Commitments under SPA Portfolio Notes and Other Notes SPA Portfolio Notes : The Company has issued various financing arrangements collectively known as the SPA Portfolio Notes. These are categorized as follows: (i) Secured SPA Notes; (ii) 2023 Unsecured SPA Notes; (iii) Junior Secured SPA Notes; (iv) 2024 Unsecured SPA Notes and (v) 2025 March Unsecured SPA Notes. As of March 31, 2025, the SPA Portfolio Notes were in good standing. Pursuant to the SPA Portfolio Notes commitments (collectively the “SPA Commitments”) (see Note 7, Notes Payable and Note 8, Related Party Transactions ), the Company obtained commitments from several investors. As of March 31, 2025, the SPA Commitments totaled $655.5 million, of which $427.7 million was funded, $227.8 million remained to be funded, and $48.3 million in principal was outstanding. On March 31, 2025, Optional Commitments under the SPA Commitments totaled $467.0 million, of which $50.9 million was funded, $386.1 million remained to be funded, and $2.5 million was outstanding. The remaining amounts to be funded as of March 31, 2025, are subject to the achievement of delivery milestones, satisfaction of closing conditions, certain of which include minimum share price requirements, resolving disputes with investors, and satisfaction or waiver of other conditions, including for a portion of such financing an effective registration statement for the shares underlying the applicable notes. Other Financing Arrangements and Related Party Notes: Additional financing is provided via convertible debt instruments, equipment financing arrangements, and related party notes that support the Company’s operations and capital expenditures. As of March 31, 2025, the Company was in good standing on all of its other financing arrangements and Related Party Notes. The Company may be unable to satisfy the closing conditions under the SPA Commitments or obt ain additional incremental investors under the SPA Commitments or other debt or equity financing in a timely manner, on acceptable terms, or at all. Standby Equity Purchase Agreement, At-The-Market Offerin g , and Equity Issuance Constraints The Company has implemented a series of financing arrangements, including a Standby Equity Purchase Agreement with Yorkville and an At-The-Market offering. These initiatives are accompanied by equity issuance constraints, such as limitations imposed by authorized share counts and the impact of convertible securities and related provisions. Together, these elements define the Company’s approach to capital raising and its management of associated regulatory and contractual obligations . Standby Equity Purchase Agreement (“SEPA”) On November 11, 2022, the Company entered into the SEPA, which expires in November 2025. Under the terms of the SEPA, the Company may, at its option, issue and sell from time to time up to $200.0 million (which can be increased up to $350.0 million in the aggregate under the Company’s option) of Class A Common Stock to YA II PN Ltd. (“Yorkville”) , subject to certain limitations. As of March 31, 2025, the Company had the right to issue and sell up to an additional $192.5 million, or $342.5 million if the Company exercises its option under the SEPA. At-The-Market Offerin g On September 26, 2023, the Company entered into a sales agreement with Stifel, Nicolaus & Company, Incorporated, B. Riley Securities, Inc., A.G.P./Alliance Global Partners, Wedbush Securities Inc. and Maxim Group LLC, as sales agents, to sell shares of Class A Common Stock, from time to time, with aggregate gross sales proceeds of up to $90.0 million pursuant to the Registration Statement as an “at-the-market” offering under the Securities Act (the “ATM Program”). Under applicable SEC rules and regulations, because the Company failed to timely file its Form 10-K for the year ended December 31, 2023, as well as its Form 10-Q for the quarter ended March 31, 2024, the Company will not be eligible to access the ATM Program until August 1, 2025, at the earliest. Equity Issuance Constraints The Company’s ability to issue and sell additional shares of Common Stock or warrants to support ongoing capital needs is further constrained by the number of authorized shares. In addition to outstanding shares, the Company must also consider shares reserved for issuance under convertible debt, warrants or other obligations with equity rights. In addition, equity issuances can potentially trigger various anti-dilution features in the Company’s debt and equity instruments that increase the number of shares to be issued and/or reduce the exercise price. This could result in the Company having inadequate authorized shares to meet its outstanding commitments. Capital Needs, FX Series Production, and Bankruptcy Risk The Company projects that it will require substantial additional funds to continue operations and support production of the FF 91, and it also plans to initiate production of its FX Series of vehicles. If additional capital is not secured, the Company will not have sufficient resources to meet its obligations and continue operations, which could result in bankruptcy protection and asset liquidation, with equity holders receiving little to no recovery. The anticipated start of FX Series production is expected to generate new revenue streams and enhance operational performance, partially mitigating near-term cash flow pressures; however, if additional capital is not secured, the Company will not have sufficient resources to meet its obligations or continue operations, potentially resulting in bankruptcy protection, asset liquidation, and minimal or no recovery for equity holders. Funding Alternatives and Risks The Company continues to explore various funding and financing alternatives to fund its ongoing operations and to ramp up production. The particular funding and financing mechanisms, terms, timing, and amounts depend on the Company’s assessment of opportunities available in the marketplace and the circumstances of the business at the relevant time. However, there have been delays in securing additional funding commitments, which have exacerbated supply chain pressures, among other things. If the Company’s ongoing capital raising efforts are unsuccessful or significantly delayed, or if the Company experiences prolonged material adverse trends in its business, production will be delayed or decreased, and actual use of cash, production volume and revenue for 2025 will vary from the Company’s previously disclosed forecasts, and such variances may be material. While the Company is actively engaged in negotiations with potential financing sources, it may be unable to raise additional capital on terms acceptable to it or at all. In addition to the risk that the Company’s assumptions and analyses may prove incorrect, the projections may underestimate the professional fees and other costs to be incurred related to the pursuit of various financing options currently being considered and ongoing legal risks. Capital needed to fund the development of the Company’s remaining product portfolio will largely depend on market success and profitability of the FF 91 and the launch of the FX series, and the Company’s ability to accurately estimate and control costs. Apart from the FF 91 series and FX series, substantial additional capital would be required to fund operations, research, development, and design efforts for future vehicles. In addition, elevated U.S. import tariffs on electric vehicle components sourced from China could increase the Company's future manufacturing costs as production of the FX Series and other future vehicle models are introduced. While tariffs did not materially impact cost of goods sold for the three months ended March 31, 2025, due to limited production volume, continued reliance on China-based suppliers may contribute to higher input costs, pressure gross margins, and increase the Company's future funding needs. Going Concern and Future Capital Strategy"]

{"sheet":"Inventory, net","index":8,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Inventory, net","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Inventory Disclosure [Abstract]"," "]
["Inventory, net","Inventory, net Inventory, net, consists of the following as of: (in thousands) March 31, 2025 December 31, 2024 Raw materials (net of reserves) $ 26,773 $ 27,440 Work in progress 152 46 Finished goods 199 — $ 27,124 $ 27,486 The inventory reserve was $3.3 million and $3.3 million as of March 31, 2025 and December 31, 2024 , respectively."]

{"sheet":"Deposits and Other Current Asse","index":9,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Deposits and Other Current Assets","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"," "]
["Deposits and Other Current Assets","Deposits and Other Current Assets Deposits and other current assets consists of the following as of: (in thousands) March 31, 2025 December 31, 2024 Deposits Deposits for research and development, prototype and production parts, and other $ 32,143 $ 29,318 Deposits for goods and services yet to be received (“Future Work”) 1,776 1,776 $ 33,919 $ 31,094 Other current assets March 31, 2025 December 31, 2024 Prepaid expenses $ 4,022 $ 4,832 Other current assets 1,249 $ 1,295 $ 5,271 $ 6,127 Deposits for R&D, prototype and production parts, and other are recognized and reported as R&D expenses in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss when services are provided or as prototype parts are received. In addition, during the three months ended March 31, 2025 and 2024, the Company made deposits for inventory and property and equipment items which are classified as Deposits for goods and services yet to be received (“Future Work”). "]

{"sheet":"Property, Plant, and Equipment,","index":10,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Property, Plant, and Equipment, Net","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Property, Plant and Equipment [Abstract]"," "]
["Property, Plant, and Equipment, Net","Property, Plant, and Equipment, Net Property, plant, and equipment, net, consists of the following as of: (in thousands) March 31, 2025 December 31, 2024 Land, buildings and leasehold improvements $ 112,150 $ 111,443 Computer hardware 2,397 2,397 Tooling, machinery and equipment 318,251 319,313 Vehicles 695 245 Lease vehicles 1,872 3,121 Computer software 4,339 4,339 Construction in process 28,797 27,563 468,501 468,421 Less: Accumulated depreciation (137,036) (119,834) $ 331,465 $ 348,587 The Company’s CIP is primarily related to the construction of tooling, machinery and equipment for the FF ieFactory California. Tooling, machinery, and equi pment are either held at Company facilities, primarily the FF ieFactory California, or at the vendor’s location until the tooling, machinery and equipment is completed. Depreciation and amortization expe nse totale d $17.5 million and $17.7 million for the three months ended March 31, 2025 and 2024, respectively. For the three months ended March 31, 2025, the Company recognized a $44 thousand loss on disposal of property, plant, and equipment, which included the derecognition of approximately $0.2 million in accumulated depreciation. Asset Retirement Obligation Due to the build out of the FF ieFactory California, the Company has an asset retirement obligation (“ARO”) totaling $0.8 million and $0.8 million as of March 31, 2025 and December 31, 2024, respectively. The ARO is recorded to Other liabilities with a corresponding ARO asset within Land, buildings and leasehold improvements and Tooling, machinery, and equipment. The ARO asset is depreciated to operating expense over the remaining term of the lease through December 2027."]

{"sheet":"Accrued Expenses and Other Curr","index":11,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Accrued Expenses and Other Current Liabilities","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Payables and Accruals [Abstract]"," "]
["Accrued Expenses and Other Current Liabilities","Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities—which include both third-party and related-party balances—comprise the following items as of: (in thousands) March 31, 2025 December 31, 2024 Accrued payroll and benefits $ 28,859 $ 27,713 Accrued legal contingencies 6,615 9,091 Customer deposits 3,003 3,027 Other current liabilities 23,015 16,923 $ 61,492 $ 56,754 "]

{"sheet":"Notes Payable","index":12,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Notes Payable","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Debt Disclosure [Abstract]"," "]
["Notes Payable",{"$cut":{"chars":32767,"head":"Notes Payable The Company has entered into notes payable agreements with third parties. The tables below summarize these agreements as of March 31, 2025 and December 31, 2024, providing details on contractual maturity dates, contractual interest rates, unpaid principal balances, fair value adjustments, original issue discounts, including proceeds allocated to warrants, and net carrying values. March 31, 2025 (in thousands) Contractual Contractual Unpaid Principal Fair Value Original Issue Discount and Proceeds Allocated to Warrants Net Secured SPA Notes Various 10 % - 15% $ 2,500 $ 139 $ (250) $ 2,389 Junior Secured SPA Notes September 2029 10% 13,431 55 (7,426) 6,060 2024 Unsecured SPA Notes Various through January 2030 10% 30,015 12,279 (30,964) 11,330 2025 March Unsecured SPA Notes April 2030 10% 2,000 (44) (1,193) 763 Notes payable – China other Due on Demand —% 4,132 — — 4,132 $ 52,078 $ 12,429 $ (39,833) $ 24,674 Notes payable, current portion $ 4,132 Notes payable, long-term portion $ 20,542 December 31, 2024 (in thousands) Contractual Contractual Unpaid Principal Fair Value Original Issue Discount and Proceeds Allocated to Warrants Net Secured SPA Notes Various 10 % - 15% $ 3,118 $ 2,651 $ (312) $ 5,457 2023 Unsecured SPA Notes Various dates in 2029 10 % - 15% 4,380 2,844 (508) 6,716 Junior Secured SPA Notes September 2029 10% 28,840 13,163 (15,944) 26,059 2024 Unsecured SPA Notes December 2029 10% 10,015 8,741 (11,724) 7,032 Notes payable – China other Due on Demand —% 4,173 — — 4,173 Auto loans October 2026 7% 51 — — 51 $ 50,577 $ 27,399 $ (28,488) $ 49,488 Notes payable, current portion $ 4,224 Notes payable, long-term portion $ 45,264 Roll Forward of the Fair Value of Notes payable by Transaction Type The following table presents a roll forward of the Company’s Notes payable balances from December 31, 2024 to March 31, 2025 with third parties. The table summarizes beginning and ending balances by debt category and details changes during the period, including repayments, conversions, reclassifications, fair value adjustments, and other significant transactions. Categories of Debt (in thousands) Secured 2023 Junior 2024 2025 March Unsecured SPA Notes Notes Auto Total Balance as of December 31, 2024 (a) $ 5,457 $ 6,716 $ 26,059 $ 7,032 $ — $ 4,173 $ 51 $ 49,488 New Issuances (b) — — — 11,096 807 — 11,903 Repayment of Debt (c) — — — — — — (6) (6) Conversion of Debt to Equity (d) (589) (4,692) (9,564) — — — — (14,845) Fair Value Adjustments of Debt (e) (2,479) (2,024) (10,435) (6,798) (44) — — (21,780) Other Adjustments (f) — — — — — (41) (45) (86) Balance as of March 31, 2025 (g) $ 2,389 $ — $ 6,060 $ 11,330 $ 763 $ 4,132 $ — $ 24,674 (a) The carrying value for each note category, fair value or amortized cost depending on the election, as of December 31, 2024. (b) Debt instruments issued during the period, recorded at fair value upon issuance if the fair value option is elected, or at principal balance net of discounts. For those measured at fair value, the aggregate fair value adjustment at issuance represented a reduction of $10,097 thousand to the principal amount of the notes issued during the period, presented as a component of Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . (c) Cash repayments of principal amounts during the period. (d) Fair value of debt converted into equity during the period. (f) Adjustments to debt fair value due to the fair value option election, embedded derivatives, or anti-dilution provisions. These adjustments are presented as a component of Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . Line item Change in fair value of notes payable, warrant liabilities, and derivative call options also includes debt issuance costs of $429 thousand, which are separately identifiable from the fair value adjustments noted above. (f) Miscellan"}}]

{"sheet":"Related Party Transactions","index":13,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Related Party Transactions","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Related Party Transactions [Abstract]"," "]
["Related Party Transactions",{"$cut":{"chars":17632,"head":"Related Party Transactions March 31, 2025 (in thousands) Contractual Contractual Net Carrying Unsecured Convertible Note June 2025 (3) 4.27% $ 451 2025 March Unsecured SPA Notes April 2030 10.00% 143 Notes Payable — China April 2027 18.0 % (2) 4,215 Notes Payable on Demand — China Due on Demand —% 413 FFGP Note Various 2024 (1) 4.27% 1,576 Convertible FFGP Note May 2024 (1) 4.27% 250 Other Notes Due on Demand 12.0% 75 $ 7,123 Related party notes payable, current $ 4,298 Related party notes payable, long-term $ 2,825 _______________ (1) The term was extended upon receipt of waivers of enforcement rights and remedies under the loan agreements, as described below, with the expected settlement in 2025. (2) The restructured loan bears no stated interest, and the repayment schedule requires fixed installment payments through the contractual maturity date. If the Company fails to comply with the payment schedule, interest at a rate of 18.0% would be retroactively applied to the unpaid balance. During the term of the revised loan, the Company remained in compliance with the payment schedule, and no contingent interest has been recorded as of March 31, 2025. (3) Subsequent to March 31, 2025 and prior to the issuance of these financial statements, MHL exchanged the Unsecured Convertible Note due June 2025 into 2025 March Unsecured SPA Notes pursuant to the terms of the original agreement. As a result, management classified the Unsecured Convertible Note as a long-term related party debt instrument for the period ended March 31, 2025. December 31, 2024 (in thousands) Contractual Contractual Net Carrying Value Unsecured Convertible Note April 2024 (1) 4.27% $ 1,364 Notes Payable — China April 2027 18.0% 4,382 Notes Payable on Demand — China Due on Demand —% 417 FFGP Note Various (1) 4.27% 1,576 Convertible FFGP Note May 2024 (1) 4.27% 250 Other Notes Due on demand 12.00% 75 $ 8,064 Related party notes payable, current $ 5,310 Related party notes payable, long-term $ 2,754 _______________ (1) The term was extended upon receipt of waivers of enforcement rights and remedies under the loan agreements, as described below, with the expected settlement in 2025. Schedule of Principal Maturities of Related Party Notes Payable The future scheduled principal maturities of Related party notes payable as of March 31, 2025, are as follows: (in thousands) Years Ending December 31, Amount Due on demand $ 488 2025 (9 months remaining) 4,813 2026 1,983 2027 745 2028 — 2029 — 2030 376 Thereafter — $ 8,405 The Company has entered into various financing arrangements with related parties, categorized as follows: (i) Unsecured Convertible Note ; (ii) Unsecured Convertible Note ; (iii) 2025 March Unsecured SPA Notes; (iv) Notes Payable — China ; (v) Notes Payable on Demand — China ; (vi) FFGP Note ; and (vii) Convertible FFGP Note . 2023 Unsecured SPA Notes In May 2023, June 2023, and October 2023, the Company issued unsecured convertible notes to MHL, a related party, under the 2023 Unsecured SPA Notes as the anchor investor. (For information on the terms of this note, see Note 7, Notes Payable 2023 Unsecured SPA Notes issued to third-parties.) The Company elected the fair value o ption under ASC 825, Financial Instruments , for the 2023 Unsecured SPA Notes because the notes include features such as a contingently exercisable put option, which meets the definition of an embedded derivative. MHL converted $0.7 million of gross principal balance in exchange for 33,107 shares of Class A Common Stock during the quarter ended March 31, 2024. During the quarter ended March 31, 2024, the Company recognized a loss of $0.2 million on the settlement (conversion) of related party notes payable into shares of Class A Common stock and losses of $0.1 million, due to fair value adjustments under ASC 825. As of March 31, 2024 , there were no Unsecured Convertible Note In January 2024, the Company issued an unsecured convertible note to MHL, a related party, in a principal amount of $1.5 million. The note was due three months from the date of issuance ( April 2024 ), accr"}}]

{"sheet":"Other Financing Liabilities","index":14,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Other Financing Liabilities","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Organization, Consolidation and Presentation of Financial Statements [Abstract]"," "]
["Other Financing Liabilities","Other Financing Liabilities FF ieFactory California (“Hanford”) Financing Arrangement On October 19, 2023, the Company entered into a sale leaseback transaction whereby it has exercised its option to purchase its FF ieFactory California manufacturing facility located in Hanford California (the “Property”) and simultaneously completed a sale leaseback to Ocean West Capital Partners (“Landlord”) pursuant to that certain Lease Agreement, dated as of October 19, 2023, by and between the Tenant and 10701 Idaho Owner, LLC (the “Lease Agreement”). This Lease Agreement also allows the Tenant access to up to $12.0 million of tenant improvement allowance for the Property. The Lease Agreement is for a term of five years, with a monthly lease rate of $355,197, with a five Due to the inclusion of the purchase option in the lease agreement, the Company was considered to have continuing involvement and, thus, accounted for the transaction as a failed sale lease back, with the Property assets subject to the sale leaseback remaining on the balance sheet and the sale proceeds recorded as a liability in accordance with the financing method. The Company recognized a $1.1 million financing obligation at the completion of the transaction, which was recorded to the Other financing liabilities, long term portion on its Unaudited Condensed Consolidated Balance Sheets. No gain or loss was recorded on the failed sale and lease back. On March 14, 2024, the Company entered into the First Amendment to the Lease Agreement (the “First Amendment). The First Amendment established a repayment plan requiring the Company to pay an aggregate amount of $1.7 million of past due rent by March 31, 2024. The Company has an original Security Deposit balance of $1.5 million. In December 2024, the Landlord applied $0.6 million of the original Security Deposit to past due rent. In January 2025, the Company paid the Landlord $0.6 million that reinstated the Security Deposit balance. On August 27, 2024, the Company entered into the Second Amendment to the Lease Agreement (the “Second Amendment”). Under the terms of the original lease agreement, the Company expected to receive $12.0 million in tenant improvement allowance, the repayment of which was included in the scheduled financing obligation payments. In the Second Amendment, the Landlord agreed to fund up to $10.0 million of the costs associated with the replacement of the Property’s roof and the remaining $2.0 million for other improvement costs. The $2.0 million may be reduced by incremental actual costs incurred for the roof replacement and the remaining amount will be contingent on the Company funding up to 66.67% of the other improvement costs. As of March 31, 2025 and December 31, 2024, the Company had a leasehold improvement balance of $8.0 million and $6.9 million, respectively, within Property, plant and equipment, net, reflecting amounts funded through the tenant improvement allowance. The repayment of the tenant improvement allowance are included in the scheduled financing obligation payments. For the quarters ended March 31, 2025 and 2024, the Company recorded interest expense of $1.9 million and $1.7 million, respectively. The financial liability as of March 31, 2025 and 2024 was $36.5 million and $33.7 million, respectively. Collateralized Loan Overview and T erms The Collateralized Loan was entered into on July 11, 2024, with Utica Leaseco, LLC. The loan is secured by machinery and equipment owned by the Company. It bears an effective interest rate of 23% and requires 51 monthly payments of $0.1 million, concluding with a $0.5 million balloon payment in October 2028. The loan terms include provisions for adjusting monthly payments based on fluctuations in the prime rate. Summary of Collateralized Loan Activity As of March 31, 2025 and December 31, 2024, the carrying value of the Collateralized Loan was $4.1 million and $4.3 million , respectively. Of these amounts $0.8 million and $0.8 million, respectively, were included in Other financing liabilities, current portion and $3.3 million and $3.5 million, respectively, were included in Other financing liabilities, long term portion in the Unaudited Condensed Consolidated Balance Sheets . For the three months ended March 31, 2025, the Company repaid $0.2 million of Collateralized Loan principal. The future scheduled principal maturities of financing obligations as of March 31, 2025 are as follows: (in thousands) Years Ending December 31, Amount 2025 ( 9 months remaining) $ 582 2026 951 2027 1,189 2028 60,455 $ 63,177 "]

{"sheet":"Leases","index":15,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Leases","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Leases [Abstract]"," "]
["Leases","Leases The Company determines if an arrangement is a lease at its commencement if the Company is both able to identify an asset and conclude the Company has the right to control the identified asset. Leases are classified as finance or operating based on the principle of whether or not the lease is effectively a financed purchase by the lessee. An ROU asset represents the Company’s right to use an underlying asset for the lease term and a lease liability represents the Company’s obligation to make lease payments related to the lease. The Company recognizes operating and finance lease ROU assets and liabilities at the commencement date based on the present value of lease payments over the lease term. The lease term includes renewal options when it is reasonably certain that the option will be exercised and excludes termination options. The Company’s leases do not provide an implicit rate. Therefore, the Company uses its incremental borrowing rate based on information available at the commencement date to determine the present value of lease payments. The incremental borrowing rate used is estimated based on what the Company would be required to pay for a collateralized loan for a similar asset over a similar term. The Company’s leases do not include any material residual value guarantees, or bargain purchase options. To the extent that the Company’s agreements have variable lease payments, the Company includes variable lease payments that depend on an index or a rate in the measurement and classification of a lease and exclude those that depend on facts or circumstances occurring after the commencement date, other than the passage of time. Lease expense for operating leases is recognized on a straight-line basis over the lease term and is recorded in operating expenses in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. Amortization of ROU assets on finance leases is recorded on a straight-line basis within operating expenses in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. Interest expense incurred on finance lease liabilities is recorded in Interest expense in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has elected not to recognize ROU assets and lease liabilities that arise from short-term (12 months or less) leases for any class of underlying asset. Additionally, the Company does not separate lease and non-lease components. Operating leases are included in Operating lease right-of-use assets, net, Operating lease liabilities, current portion and Operating lease liabilities, long term portion in the Company's Unaudited Condensed Consolidated Balance Sheets. The Company’s lease arrangements primarily consist of corporate office, store, and vehicle lease agreements. The leases expire on various dates through 2027."]
["Leases","Leases The Company determines if an arrangement is a lease at its commencement if the Company is both able to identify an asset and conclude the Company has the right to control the identified asset. Leases are classified as finance or operating based on the principle of whether or not the lease is effectively a financed purchase by the lessee. An ROU asset represents the Company’s right to use an underlying asset for the lease term and a lease liability represents the Company’s obligation to make lease payments related to the lease. The Company recognizes operating and finance lease ROU assets and liabilities at the commencement date based on the present value of lease payments over the lease term. The lease term includes renewal options when it is reasonably certain that the option will be exercised and excludes termination options. The Company’s leases do not provide an implicit rate. Therefore, the Company uses its incremental borrowing rate based on information available at the commencement date to determine the present value of lease payments. The incremental borrowing rate used is estimated based on what the Company would be required to pay for a collateralized loan for a similar asset over a similar term. The Company’s leases do not include any material residual value guarantees, or bargain purchase options. To the extent that the Company’s agreements have variable lease payments, the Company includes variable lease payments that depend on an index or a rate in the measurement and classification of a lease and exclude those that depend on facts or circumstances occurring after the commencement date, other than the passage of time. Lease expense for operating leases is recognized on a straight-line basis over the lease term and is recorded in operating expenses in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. Amortization of ROU assets on finance leases is recorded on a straight-line basis within operating expenses in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. Interest expense incurred on finance lease liabilities is recorded in Interest expense in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has elected not to recognize ROU assets and lease liabilities that arise from short-term (12 months or less) leases for any class of underlying asset. Additionally, the Company does not separate lease and non-lease components. Operating leases are included in Operating lease right-of-use assets, net, Operating lease liabilities, current portion and Operating lease liabilities, long term portion in the Company's Unaudited Condensed Consolidated Balance Sheets. The Company’s lease arrangements primarily consist of corporate office, store, and vehicle lease agreements. The leases expire on various dates through 2027."]

{"sheet":"Commitments and Contingencies","index":16,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Commitments and Contingencies","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Commitments and Contingencies Disclosure [Abstract]"," "]
["Commitments and Contingencies",{"$cut":{"chars":32767,"head":"Commitments and Contingencies The Company is, from time to time, subject to claims and disputes arising in the normal course of business. In the opinion of management, the outcome of any such claims and disputes cannot be predicted with certainty. Legal Proceedings Against the Company As of March 31, 2025 and December 31, 2024 , the Company had accrued legal contingencies of $6.6 million and $9.1 million , respectively, recorded within Accrued expenses and other current liabilities and Accounts payable for potential financial exposure related to ongoing legal matters, primarily related to breach of contracts and employment matters, which are deemed both probable of loss and reasonably estimable. Class and Derivative Actions Zhou v. Faraday Future Intelligent Electric Inc. f/k/a Property Solutions Acquisition Corp. et al., Case No. 2:21-cv-009914 (U.S. District Court – Central District of California). On December 23, 2021, a putative class action lawsuit alleging violations of the Exchange Act was filed in the United States District Court, Central District of California, against the Company and its former Chief Executive Officer and Chief Financial Officer, and its then-Chief Product and User Ecosystem Officer (who was promoted to Global Co-CEO in April 2025), as well as the Co-CEOs of Property Solutions Acquisition Corp. (“PSAC”). On May 6, 2022, the appointed lead plaintiffs in the Zhou putative class action filed an amended complaint alleging violations of Sections 10(b), 14(a) and 20(a) of the Exchange Act, Sections 11 and 15 of the Securities Act , and related “control” person claims for secondary liability under those statutes, seeking unspecified damages. Following motion to dismiss briefing and the subsequent court-ordered dismissal of several of the plaintiffs’ claims, answers were filed and the parties agreed to participate in mediation. On April 27, 2023, the court granted the parties’ joint motion for a temporary stay pending mediation. The parties thereafter participated in a private mediation on June 29, 2023. After further discussions and negotiations, the parties reached an agreement-in-principle to settle the Zhou putative class action. Although denying all allegations, the Company nevertheless agreed to settle the Zhou putative class action for a non-reversionary cash payment of $7.5 million to be funded entirely by the Company’s insurers for the benefit of the settlement class, in exchange for the release of all claims that were or could have been asserted against the Company. The court thereafter granted preliminary approval of the settlement on November 7, 2023, and scheduled a hearing for final approval of the settlement to take place on March 18, 2024. On January 23, 2024, the ostensible lead plaintiff in the Consolidated Delaware Class Action discussed below, filed an Objection to final approval of the settlement (the “Objection”) to which the Company and the other defendants responded on March 11, 2024. On March 18, 2024, the court overruled the Objection in its entirety and entered an Order finally approving the Zhou putative class action settlement. Farazmand v. Breitfeld et al. , Case No. 2:22-cv-01570 (U.S. District Court – Central District of California). Zhou v Breitfeld et al. , Case No. 2:22-cv-01852 (U.S. District Court – Central District of California). Moubarak v. Breitfeld et al. , Case No. 1:22-cv-00467 (U.S. District Court – District of Delaware). Wang v. Breitfeld et al. , Case No. 1:22-cv-00525 (U.S. District Court – District of Delaware). Wallace v. Breitfeld et al. , Case No. 2023-0639-KSJM (Delaware Court of Chancery). Ashkan Farazmand and Wangjun Zhou v. Breitfeld, et al., Case No. 2023-1283 (Delaware Court of Chancery). On March 8 (Farazmand) and March 21 (Zhou), 2022, putative stockholder derivative lawsuits were respectively filed in the United States District Court, Central District of California and were subsequently consolidated in an action entitled In re Faraday Future Intelligent Electric Inc. Case No. 2:22-cv-1570 (the “California Federal Derivative Action”). The Cali"}}]

{"sheet":"Stockholders_ Equity","index":17,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Stockholders’ Equity","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Equity [Abstract]"," "]
["Stockholders’ Equity","Stockholders’ Equity The number of authorized, issued and outstanding stock, were as follows: March 31, 2025 Authorized Issued Shares Preferred Stock 10,000,000 — Class A Common Stock 124,815,625 86,786,748 Class B Common Stock 4,429,688 6,667 139,245,313 86,793,415 December 31, 2024 Authorized Issued Shares Preferred Stock 10,000,000 1 Class A Common Stock 99,815,625 65,919,127 Class B Common Stock 4,429,688 6,667 114,245,313 65,925,795 Amendments to the Company’s Certificate of Incorporation On the Closing Date of the Business Combination, the Company’s shareholders adopted the Company’s Second Amended and Restated Certificate of Incorporation. The amendment set forth the rights, privileges, and preferences of the Common Stock. The amendment authorizes the issuance of 10,000,000 shares of Preferred Stock with such designations, rights and preferences as may be determined from time to time by the Board. The Board is empowered, without stockholder approval, to issue the Preferred Stock with dividend, liquidation, conversion, voting or other rights which could adversely affect the voting power or other rights of the holders of Common Stock; provided that any issuance of preferred stock with more than one vote per share will require the prior approval of the holders of a majority of the outstanding shares of Class B Common Stock. Increase in Authorized Shares and Reverse Stock Split (February 2024) On February 5, 2024, the Company filed an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, with the office of the Secretary of the State of Delaware to effect an increase in the authorized shares of Common Stock from 3,860,938 to 34,748,438. At a special meeting of the Company’s stockholders held on February 5, 2024, the Company’s stockholders approved an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Common Stock by a ratio of 1-for-3 (the “Second Reverse Stock Split”), with such action to be effected at such time and date, if at all, as determined by the Board within one year after the conclusion of the Special Meeting and a corresponding reduction in the total number of shares of Common Stock the Company is authorized to issue. On February 23, 2024, the Company filed a second amendment to the Company’s Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect this reverse stock split and to set the number of authorized shares of Common Stock to 11,582,813 (which is 34,748,438 divided by 3). Pursuant to the Certificate of Amendment, effective on February 29, 2024, every three shares of the issued and outstanding Common Stock was automatically converted into one share of Common Stock, without any change in par value per share and the number of authorized shares of Common Stock was reduced to 11,582,813. No fractional shares of Common Stock were issued as a result of the Second Reverse Stock Split. Stockholders who would otherwise have received a fractional share were instead issued a full share in lieu of such fractional share. Increase in Authorized Shares, Reverse Stock Split, Adjustments to Share Reserves (July/August 2024) At the annual meeting of the Company’s stockholders held on July 31, 2024, the Company’s stockholders approved an increase in the authorized shares of Common Stock from 11,582,813 to 104,245,313, increasing the total number of authorized shares of the Common Stock and preferred stock from 12,582,813 to 114,245,313. On August 1, 2024, the Company filed an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, with the office of the Secretary of State of the State of Delaware to effect such increase. Also at the annual meeting of the Company’s stockholders held on July 31, 2024, the Company’s stockholders approved an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect the reverse stock split of the outstanding Common Stock by a ratio of between 1-for-2 and 1-for-40, with such ratio to be determined in the discretion of the Board and with such action to be effected at such time and date, if at all, as determined by the Board within one year after the conclusion of the annual meeting, and a corresponding reduction in the total number of shares of Common Stock the Company is authorized to issue. The Board subsequently approved the implementation of the 1-for-40 stock split ratio (the “Third Reverse Stock Split”), and the Company filed an amendment (the “Fourth Certificate of Amendment”) to the Company’s Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Third Reverse Stock Split and to set the number of authorized shares of Common Stock to 104,245,313. Pursuant to the Fourth Certificate of Amendment, effective after market close on August 16, 2024 (the “Effective Time”), every 40 shares of the issued and outstanding Common Stock were automatically converted into one share of Common Stock, without any change in par value per share, and the number of authorized shares of Common Stock were reduced to 104,245,313. The Class A Common Stock began trading on The Nasdaq Capital Market on a split-adjusted basis for the August 2024 Reverse Stock Split at the opening of trading on August 19, 2024, under the symbol “FFIE” with a new CUSIP number (307359 885). The Class B Common Stock also received a new CUSIP number (307359 877). The Company’s Public Warrants continued to trade on The Nasdaq Capital Market under the symbol “FFIEW,” with the CUSIP number unchanged. However, under the terms of the applicable warrant agreement, the number of shares of Class A Common Stock issuable upon exercise of each warrant was proportionately decreased, and the exercise price adjusted. Accordingly, for the Company’s warrants trading under the symbol “FFIEW,” every 40 warrants became exercisable for one share of Class A Common Stock at an exercise price of $110,400.00 per share of Class A Common Stock. At the Effective Time, the number of shares of Common Stock reserved for issuance under the 2021 SI Plan (as defined below), the Company’s Smart King Ltd. Equity Incentive Plan, and the Company’s Smart King Ltd. Special Talent Incentive Plan (collectively, the “Plans”), as well as the number of shares subject to the then-outstanding awards under each of the Plans, were proportionately adjusted, using the 1-for-40 ratio, rounded down to the nearest whole share. In addition, the exercise price of the then-outstanding options under each of the Plans was proportionately adjusted, using the 1-for-40 ratio, rounded up to the nearest whole cent. Proportionate adjustments were made to the number of shares of Common Stock issuable upon exercise or conversion of the Company’s outstanding warrants and convertible securities, as well as the applicable exercise or conversion prices. Change in Trading Symbols (March 2025) Effective March 10, 2025, the Class A Common Stock and Public Warrants currently trade under the new ticker symbols “FFAI” and “FFAIW,” respectively, on The Nasdaq Capital Market. Increase in Authorized Shares (March 2025) At the special meeting of the Company’s stockholders held on March 7, 2025, the Company’s stockholders approved an increase in the authorized shares of Common Stock from 104,245,313 to 129,245,313, increasing the total number of authorized shares of the Common Stock and preferred stock from 114,245,313 to 139,245,313. On March 10, 2025, the Company filed a Fifth Certificate of Amendment (the “Fifth Certificate of Amendment”) to the Company’s Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect such increase. Series A Preferred Stock On January 28, 2025, in connection with a purchase agreement entered into with Mr. Aydt, the Company’s Global Co-CEO, the Company filed a Series A Certificate of Designation with the Secretary of State of the State of Delaware. The Series A Certificate of Designation designated one share of the Company’s Preferred Stock as Series A preferred stock, par value $0.0001 per share and established the preferences, rights and limitations thereof. The closing of the sale and purchase of the shares of the Series A Preferred was completed on January 28, 2025 for a purchase price of $100.00. The Series A Preferred Stock was redeemed on March 7, 2025, for a redemption price of $100.00, following the special meeting of stockholders. Common Stock Voting The holders of Class A Common Stock and Class B Common Stock are entitled to one vote for each share held of record on all matters to be voted on by stockholders until the occurrence of a Qualifying Equity Market Capitalization, following which holders of Class B Common Stock shall be entitled to ten votes per share and shall continue to be entitled to ten votes per share regardless of whether the Qualifying Equity Market Capitalization shall continue to exist or not thereafter. Conversion Shares of Class B Common Stock have the right to convert into shares of Class A Common Stock at any time at the rate of one share of Class A Common Stock for each share of Class B Common Stock. Class A Common Stock does not have the right to convert into Class B Common Stock. Liquidation In the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the Corporation, after payment or provision for payment of the debts and other liabilities of the Corporation, the holders of the shares of the Common Stock shall be entitled to receive all the remaining assets of the Corporation available for distribution to its stockholders, ratably in proportion to the number of shares of the Common Stock held by them. Warrants The number of outstanding warrants to purchase the Company’s Class A Common Stock as of March 31, 2025 were as follows: Number of Warrants Exercise Price Expiration Date Ares Warrants 5,776,657 $1.16 August 5, 2027 SPA Warrants 15,238 $1.16 Various through November 1, 2031 Junior SPA Warrants 5,931,638 $1.16 Various through September 30, 2029 2024 Unsecured SPA Warrants 25,874,953 $1.39 Various through January 21, 2030 2025 March Unsecured SPA Warrants 3,438,357 $1.55 April 4, 2030 Public Warrants 2,453 $110,400.00 July 21, 2026 Private Warrants 12 $110,400.00 July 21, 2026 41,039,308 The number of outstanding warrants to purchase the Company’s Class A Common Stock as of December 31, 2024 were as follows: Number of Warrants Exercise Price Expiration Date Ares warrants 5,776,657 $ 1.16 August 5, 2027 SPA Warrants 15,238 $ 1.16 Various through November 1, 2031 Junior SPA Warrants 5,931,638 $ 1.16 Various through September 30, 2029 2024 Unsecured SPA Warrants 10,788,746 $ 1.39 December 31, 2029 Public Warrants 2,453 $ 110,400.00 July 21, 2026 Private Warrants 12 $ 110,400.00 July 21, 2026 22,514,744 There were no warrants exercised for the three months ended March 31, 2025 or during the three months ended March 31, 2024. The above Ares warrants and SPA Portfolio Note warrants contain full ratchet anti-dilution price protection that requires the exercise price to be adjusted if the Company sells shares of Common Stock below the current exercise price. There were not any dilutive events during the three months ended March 31, 2025 and 2024. Insufficient Authorized Shares From time to time, certain of the Company’s equity-linked financial instruments may be classified as derivative liabilities under ASC 815, Derivatives and Hedging , due to the Company having insufficient authorized shares to fully settle the equity-linked financial instruments in shares. In such case, the Company applies a sequencing policy under ASC 815-40, Contracts in Entity’s Own Equity"]

{"sheet":"Stock-Based Compensation","index":18,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Stock-Based Compensation","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Share-Based Payment Arrangement [Abstract]"," "]
["Stock-Based Compensation","Stock-Based Compensation 2021 Plan In July 2021, the Company adopted the 2021 Stock Incentive Plan (“2021 Plan”). The 2021 Plan allows the Board to grant up to 5,164 incentive and nonqualified stock options, restricted shares, unrestricted shares, restricted share units, and other stock-based awards for the Class A Common Stock to employees, directors, and non-employees. The number of shares of Class A Common Stock available under the 2021 Plan will increase annually on the first day of each calendar year, beginning with the calendar year ending December 31, 2024, and continuing until (and including) the calendar year ending December 31, 2031. Annual increases are equal to the lesser of (i) 5 percent of the number of shares of Class A Common Stock issued and outstanding on December 31 of the immediately preceding fiscal year and (ii) an amount determined by the Board. As of the effective date of the 2021 Plan, no further stock awards have been or will be granted under the EI Plan or STI Plan (defined below). At the annual meeting of stockholders held on July 31, 2024, the Company’s stockholders approved (among other proposals) an amendment to the 2021 Plan to increase the number of shares of Class A Common Stock available for issuance under the 2021 Plan by an additional 2,206,324 shares, subject to proportionate adjustment for stock splits and similar events as provided in the 2021 Plan. As of March 31, 2025 and 2024 the Company had 535,027 and 2,469,957 shares of Class A Common Stock available for future issuance under the 2021 SI Plan. Option Awards As of March 31, 2025, the total unrecognized stock-based compensation expense for stock options granted under the 2021 Plan was less than $0.1 million, which is expected to be recognized over a weighted average period of 2.62 years. There were no options granted under the 2021 Plan during the three months ended March 31, 2025. Restricted Stock Units As of March 31, 2025, the total unrecognized stock-based compensation expense for RSUs granted under the 2021 Plan was $0.5 million which is expected to be recognized over a weighted average period of 1.51 years. EI Plan On February 1, 2018, the Board adopted the Equity Incentive Plan (“EI Plan”), under which the Board authorized the grant of up to 4,416 incentive and nonqualified stock options, restricted stock, unrestricted stock, restricted stock units, and other stock-based awards for Legacy FF’s Class A Ordinary Stock to employees, directors and non-employees. On the closing date and in connection with the Business Combination, each of the Legacy FF’s outstanding options under the EI Plan immediately prior to the closing of the Business Combination remained outstanding and converted into the right to purchase the Company’s Class A Common Stock based on the Exchange Ratio. As of March 31, 2025, the total unrecognized stock-based compensation expense for stock options granted under the EI Plan was less than $0.1 million which is expected to be recognized over a weighted average period of 1.61 years. STI Plan On May 2, 2019, the Company adopted its Special Talent Incentive Plan (“STI Plan”) under which the Board may grant up to 1,472 incentive and nonqualified stock options, restricted shares, unrestricted shares, restricted share units, and other stock-based awards for Legacy FF’s Class A Ordinary Stock to employees, directors, and non-employees. The STI Plan does not specify a limit on the number of stock options that can be issued under the plan. Per the terms of the STI Plan the Company must reserve and keep available a sufficient number of shares to satisfy the requirements of the STI Plan. As of March 31, 2025, the total unrecognized stock-based compensation expense for stock options granted under the STI Plan was less than $0.1 million, which is expected to be recognized over a weighted average period of approximately 1.66 years. Stock-based compensation expense The following table presents stock-based compensation expense for all of the Company’s 2021 Plan, EI Plan, STI Plan and Common Units of FF Global included in each respective expense category in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss is as follows: Three Months Ended March 31, (in thousands) 2025 2024 Research and development $ 268,299 $ 375,350 Sales and marketing 22,700 63,330 General and administrative 10,078 103,491 $ 301,077 $ 542,171 "]

{"sheet":"Fair Value of Financial Instrum","index":19,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Fair Value of Financial Instruments","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Fair Value Disclosures [Abstract]"," "]
["Fair Value of Financial Instruments","Fair Value of Financial Instruments Notes Payable & Related Party Notes Payable The Company has elected to measure certain notes payable and related party notes payable at fair value. Specifically, the SPA Portfolio Notes or notes convertible into SPA Portfolio Notes as they contain embedded liquidation premiums with conversion rights that represent embedded derivatives (see Note 7, Notes Payable and Note 8, Related Party Transactions ). The Company uses a binomial lattice model and discounted cash flow methodology to value the notes carried at fair value. The significant assumptions used in the models include the volatility of the Class A Common Stock, the Company’s expectations around the full ratchet anti-dilution and other triggering events, the Company’s debt discount rate based on a CCC rating, annual dividend yield, the risk free rate, and the expected life of the instrument. Fair value measurements associated with the notes payable and related party notes payable represent Level 3 valuations under the fair value hierarchy. The fair value adjustments related to notes payables and related party notes payable were recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options or Change in fair value of related party notes payable, warrant liabilities, and derivative call options, respectively, in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. For notes payable and related party notes payable where the Company did not elect the fair value option pursuant to ASC 825, Financial Instruments, SPA Portfolio Note Warrants The Company is required to measure certain SPA Portfolio Note warrants at fair value. The Company uses a Monte Carlo simulation model to measure the fair value of the liability classified SPA Warrants, where the significant assumptions used include the volatility of the Company’s Class A Common Stock, the Company’s expectations around the full ratchet anti-dilution and other triggering events, the contractual term of the warrant, the risk-free rate and annual dividend yield. Fair value measurements associated with the liability-classified warrants represent Level 3 valuations under the fair value hierarchy. The fair value adjustments related to the liability classified warrants were recorded in Change in fair value of notes payable, warrant liabilities, and derivative call options or Change in fair value of related party notes payable, warrant liabilities, and derivative call options, in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss Derivative Call Options Holders of the Junior Secured SPA Notes, the 2024 Unsecured SPA Notes, and 2025 March Unsecured SPA Notes were issued Incremental Warrants to purchase additional notes on the same terms and conditions up to the amounts originally funded under their commitments. The Company estimates the fair value of the Incremental Warrants using both a binomial lattice model and Monte Carlo simulation to value the Incremental Warrants as the Incremental Warrants entitle the holder to the relevant SPA Portfolio Note and SPA Portfolio Warrant upon exercise. The significant assumptions used include the volatility of the Company’s Class A Common Stock, the Company’s expectations around the full ratchet anti-dilution and other triggering events, the contractual term of the Incremental Warrants, the risk-free rate and annual dividend yield. The underlying convertible notes and the warrants issuable upon the exercise of the Incremental Warrant were assumed to be exercisable up to the maximum allowable amount. Additionally, the terms of these instruments were presumed to be consistent with those of the convertible notes and warrants issued in connection with the Incremental Warrants. Fair value measurements associated with the liability-classified derivatives represent Level 3 valuations under the fair value hierarchy. Recurring Fair Value Measurements Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The following tables present financial assets and liabilities remeasured on a recurring basis by level within the fair value hierarchy: March 31, 2025 (in thousands) Level 1 Level 2 Level 3 Liabilities: Warrant liabilities 1 $ — $ — $ 23,624 Derivative call options 1 $ — $ — 17,057 Notes payable 1 $ — $ — 21,136 _______________ 1 Includes both related party and non-related party balances for the Company’s notes payable and warrant liabilities. December 31, 2024 (in thousands) Level 1 Level 2 Level 3 Liabilities: Warrant liabilities 1 $ — $ — $ 28,864 Derivative call options 1 29,709 Notes payable 1 — — 46,628 _______________ 1 Includes both related party and non-related party balances for the Company’s notes payable and warrant liabilities. There were not any transfers of assets and liabilities between Level 1, Level 2 and Level 3 of the fair value measurement hierarchy during the three months ended March 31, 2025 and the year ended December 31, 2024. The carrying amounts of the Company’s financial assets and liabilities, including cash, restricted cash, deposits, accounts payable, accrued liabilities and notes payable, other than the SPA Portfolio Notes, approximate fair value because of their short-term nature or contractually defined value. The following table summarizes the activity of Level 3 fair value measurements: (in thousands) Warrant Liabilities 1 Derivative Call Option 1 Notes Payable 1 Balance as of December 31, 2024 $ 28,864 $ 29,709 $ 46,628 Additions 16,341 2 19,730 2 12,525 3 Change in fair value measurements (21,581) (32,382) (22,445) Conversions of notes to Class A Common Stock — — (15,572) Balance as of March 31, 2025 $ 23,624 $ 17,057 $ 21,136 _______________ 1 Includes both related party and non-related party balances for the Company’s notes payable and warrant liabilities. 2 Addition to Warrant Liabilities and Derivative Call Option are included as loss in line items Change in fair value of notes payable, warrant liabilities, and derivative call options and Change in fair value of related party notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . This information is presented to facilitate reconciliation to the related amounts reported in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . 3 Additions of Notes Payable measured at fair value are presented net of the initial fair value adjustment recorded at issuance. This adjustment, which reduced the principal amount of the Notes Payable by $11,349 thousand upon initial recognition, is presented as gain in the line items Change in fair value of notes payable, warrant liabilities, and derivative call options and Change in fair value of related party notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . In addition, the line item Change in fair value of notes payable, warrant liabilities, and derivative call options includes a loss of $429 thousand, and the line item Change in fair value of related party notes payable, warrant liabilities, and derivative call options includes a loss of $76 thousand, both of which relate to debt issuance costs. These costs are separately identifiable from the fair value adjustments described above and are not included in the Additions of Notes Payable This information is presented to facilitate reconciliation to the related amounts reported in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . Net Loss Per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted-average number of shares issued and shares to be issued under the commitment to issue shares, as these shares are issuable for no consideration. Diluted net loss per share attributable to common stockholders adjusts the basic net loss per share attributable to common stockholders and the weighted-average number of shares issued and shares to be issued under the commitment to issue shares for potentially dilutive instruments. The following data shows the amounts used in computing net loss per share and the effect on net loss and the weighted-average number of shares as follows: Three Months Ended March 31, (in thousands, except share and per share amounts) 2025 2024 Net loss $ (10,278) $ (48,217) Weighted average shares used in computing net loss per share of Class A and B Common Stock: Basic 75,749,893 1,837,959 Diluted 75,749,893 1,837,959 Net loss per share of Class A and B Common Stock attributable to common stockholders: Basic $ (0.14) $ (26.23) Diluted $ (0.14) $ (26.23) The net loss per common share was the same for the Class A Common Stock and Class B Common Stock because they are entitled to the same liquidation and dividend rights and are therefore combined in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss."]

{"sheet":"Net Loss per Share","index":20,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Net Loss per Share","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Earnings Per Share [Abstract]"," "]
["Net Loss per Share","Net Loss per Share Potentially Dilutive Shares The Company reported net losses for all periods presented, resulting in all potentially dilutive Common Stock equivalents being considered antidilutive and excluded from the calculation of net loss per share. The table below presents the potentially dilutive shares that were excluded from the computation of diluted net loss per share of Common Stock attributable to Common Stock stockholders due to their antidilutive effect: Three Months Ended March 31, 2025 2024 Shares issuable upon conversion of SPA Portfolio Notes 44,298,705 2,331,077 Shares issuable upon conversion of Unsecured Convertible Notes 1,809,969 390,601 Shares issuable upon exercise of equity classified SPA Portfolio Note warrants 15,238 13,968 Shares issuable upon exercise of liability classified SPA Portfolio Note warrants 35,244,948 — Other warrants 5,776,657 228,482 Stock-based compensation awards – Options 2,514 2,731 Stock-based compensation awards – RSUs 155,134 21,439 Public warrants 2,453 2,453 Private warrants 12 12 87,305,630 2,990,763 "]

{"sheet":"Subsequent Events","index":21,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Subsequent Events","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Subsequent Events [Abstract]"," "]
["Subsequent Events","Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that t he Unaudited Condensed Consolidated Financial Statements were issued. Subsequent SPA Portfolio Notes Activity Subsequent to March 31, 2025, the Company received gross proceeds in connection with issuance of 2024 Unsecured SPA Notes to third parties totaling $6.6 million with due dates ranging from April 4, 2030 through May 2, 2030 at 10.00% interest. Principal and accrued interest are convertible at the option of the holder into Common Stock of the Company at a conversion price per share equal to the lower of a) stated conversion price or b) lowest VWAP of the five trading days immediately prior to the day on which lender provides conversion notice. Additionally, $10.6 million of principal and $0.9 million of interest of the Company’s SPA Portfolio Notes were converted into 10,894,406 shares of the Company’s Class A Common Stock. Series B Preferred Stock On March 21, 2025, the Company entered into the 2025 March Unsecured SPA pursuant to which the Company agreed to issue, among other securities, shares of Series B Preferred Stock. The Series B Preferred stock are a newly designated class of the Company’s authorized and unissued preferred stock, par value $0.0001 per share. In connection with the initial closing under the 2025 March Unsecured SPA, on April 3, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock with the Secretary of State of the State of Delaware (the “Series B Certificate of Designation”). On April 9, 2025, the Company filed a Certificate of Correction to the Certificate to correct a clerical error with the Secretary of State of the State of Delaware. The Series B Certificate of Designation designates 9,000,000 shares of the Series B Preferred Stock and establishes and designates the preferences, rights and limitations thereof. The Series B Certificate of Designation became effective upon filing. Sale of Collateral Securing Loan with Utica On April 18, 2025, certain non-essential equipment securing the Company’s collateralized loan with Utica Leaseco, LLC was sold at auction for approximately $0.7 million in gross proceeds. The sale was conducted with the lender’s consent and involved surplus assets. In accordance with the loan and subordination agreements, all proceeds from the auction were retained by Utica and applied toward the Company’s obligations under the loan. The Company did not receive any of the sale proceeds. The equipment had been previously expensed as research and development costs in prior periods and was not included in property, plant and equipment as of March 31, 2025. The transaction did not affect scheduled debt repayments or require reclassification of the loan balance. The Company will evaluate any further accounting implications in future reporting periods. Envisage Settlement On March 28, 2025, the Company entered into a Settlement and Release Agreement (the “Envisage Settlement and Release Agreement”) with Envisage Group Developments Inc. USA (“Envisage”) to resolve a $1.5 million judgment stemming from an arbitration award related to several purchase orders and invoices under an Engineering Services Agreement previously executed between the Company and Envisage. As part of the Envisage Settlement and Release Agreement, the Company agreed to satisfy $425 thousand of the settlement through the issuance of Class A common stock, with the number of shares based on the $1.08 per share closing price on April 7, 2025—the trading day prior to the issuance. On April 8, 2025, the Company issued 393,519 shares of its Class A common stock to Envisage. The Company has filed a Form S-1 registration statement to register these shares for resale, which is currently under SEC review and has not yet been declared effective. The Company also agreed to pay the remaining $375 thousand in cash, payable in four equal monthly installments from March through June 2025. Both parties mutually released all claims, demands, and liabilities related to the matter."]

{"sheet":"Pay vs Performance Disclosure","index":22,"n_rows":4,"n_cols":3,"rows_kept":4,"merged":[[0,0,1,0],[0,1,0,2]]}
["Pay vs Performance Disclosure - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Pay vs Performance Disclosure"," "," "]
["Net loss",{"v":-10278,"d":"$ (10,278)"},{"v":-48217,"d":"$ (48,217)"}]

{"sheet":"Insider Trading Arrangements","index":23,"n_rows":7,"n_cols":2,"rows_kept":7,"merged":[[0,0,1,0]]}
["Insider Trading Arrangements","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Trading Arrangements, by Individual"," "]
["Rule 10b5-1 Arrangement Adopted","false"]
["Non-Rule 10b5-1 Arrangement Adopted","false"]
["Rule 10b5-1 Arrangement Terminated","false"]
["Non-Rule 10b5-1 Arrangement Terminated","false"]

{"sheet":"Nature of Business and Organi_2","index":24,"n_rows":15,"n_cols":2,"rows_kept":15,"merged":[[0,0,1,0]]}
["Nature of Business and Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Policies)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Organization, Consolidation and Presentation of Financial Statements [Abstract]"," "]
["Principles of Consolidation","The Unaudited Condensed Consolidated Financial Statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“GAAP”) and include the accounts of the Company, its wholly-owned subsidiaries and all other entities in which the Company has a controlling financial interest, including the accounts of any variable interest entity, in which the Company has a controlling financial interest and for which it is the primary beneficiary in accordance with Accounting Standards Codification (“ASC”) 810, Consolidation (“ASC 810”). All intercompany transactions and balances have been eliminated upon consolidation. These Unaudited Condensed Consolidated Financial Statements do not include all disclosures that are normally included in the Annual audited financial statements prepared in accordance with GAAP and should be read in conjunction with the Company’s Audited Consolidated Financial Statements and notes thereto for the year ended December 31, 2024, included in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 31, 2025, (the “Form 10-K”). Accordingly, the Unaudited Condensed Consolidated Balance Sheet as of March 31, 2025, has been derived from the Company’s Annual audited Consolidated Financial Statements but does not contain all of the footnote disclosures from the annual financial statements. The Company believes that the disclosures included in this Quarterly Report on Form 10-Q (this “Form 10-Q”) are adequate to make the information presented not misleading. In the opinion of management, the Unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position, results of operations, and cash flows for the periods presented. The accounting policies used in the preparation of these Unaudited Condensed Consolidated Financial Statements are the same as those disclosed in the audited Consolidated Financial Statement for the year ended December 31, 2024, included in the Form 10-K, except as described below. Our annual reporting period is the calendar year. The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the results to be expected for the 2025 full year or any future periods."]
["Basis of Presentation","The Unaudited Condensed Consolidated Financial Statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“GAAP”) and include the accounts of the Company, its wholly-owned subsidiaries and all other entities in which the Company has a controlling financial interest, including the accounts of any variable interest entity, in which the Company has a controlling financial interest and for which it is the primary beneficiary in accordance with Accounting Standards Codification (“ASC”) 810, Consolidation (“ASC 810”). All intercompany transactions and balances have been eliminated upon consolidation."]
["Use of Estimates and Judgments","Use of Estimates and Judgments The preparation of the Company’s Unaudited Condensed Consolidated Financial Statements in conformity with GAAP and in accordance with the rules and regulations of the SEC requires management to make estimates and assumptions which affect the reported amounts in the Unaudited Condensed Consolidated Financial Statements. Estimates are based on historical experience, where applicable, and other assumptions which management believes are reasonable under the circumstances. On an ongoing basis management evaluates its estimates, including those related to the: (i) recognition and disclosure of contingent liabilities, including litigation reserves; (ii) fair value of related party notes payable and notes payable; (iii) calculations for evaluating potential long-term asset impairment; and (iv) valuation of warrants and other derivative instruments. Such estimates often require the selection of appropriate valuation methodologies and financial models and may involve significant judgment in evaluating ranges of assumptions and financial inputs. Actual results may differ from those estimates under different assumptions, financial inputs, or circumstances. Given the global economic climate, estimates are subject to additional volatility. As of the date of filing the Company’s Unaudited Condensed Consolidated Financial Statements on this Form 10-Q with the SEC for the period ended March 31, 2025, the Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or to revise the carrying value of its assets or liabilities. However, these estimates and judgments may change as new events occur and additional information is obtained, which may result in changes being recognized in the Company’s Unaudited Condensed Consolidated Financial Statements in future periods. Actual results could differ from those estimates and any such differences may have a material impact on the Company’s Unaudited Condensed Consolidated Financial Statements."]
["Reverse Stock Splits and Recasting of Per-Share Amounts","Reverse Stock Splits and Recasting of Per-Share Amounts On August 4, 2024, the Board approved the implementation of a 1-for-40 reverse stock split (the “Third Reverse Stock Split”) of the Common Stock and set the number of authorized shares of Common Stock to 104,245,313. The Third Reverse Stock Split was effected after market close on August 16, 2024, and shares of the Class A Common Stock par value $0.0001 per share and the Public Warrants began trading on a split-adjusted basis as of market open on August 19, 2024. "]
["Segments","Segments The Company operates in one operating segment and one reportable segment. T he Company’s two Global Co-Chief Executive Officers (“Global Co-CEOs”), acting jointly serving as Co-Chief Operating Decision Makers (“CODMs”), regularly evaluate the Company’s financial performance using consolidated financial information at the total-company level. The CODMs receive regular financial and operational reporting that focuses primarily on the Company's consolidated loss from operations, overall cash flows, liquidity, and strategic initiatives. Management has identified Loss from operations, as presented in the Company's Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss, as the primary measure used by the CODMs to evaluate the performance of the business and allocate resources. This measure is critical for a going concern that must carefully manage its cash outflows, particularly given that the timing of its cash inflows is influenced by external investor decisions. The Company defines “significant segment expense” as controllable operating costs that are regularly provided to and reviewed by management, which include the expenses presented in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss as Cost of revenue, Research and development, Sales and marketing, and General and administrative. Management closely tracks its expenditure on these key expense categories through regular reviews of cash balances, near‑term cash flow projections, monthly management reports, and project management reports. The CODMs, work in close collaboration with the Company’s business leaders to establish critical operational targets, set project timelines, and adjust spending plans. These leaders are responsible for implementing its strategic plans and revising targets and deadlines based on continuous internal communications and review meetings, thereby ensuring that any deviations from target spending or project timelines are promptly addressed. This rigorous oversight supports the Company’s strategic objectives to focus business activities on production, sales, and leasing of its FF 91 vehicles, and the planned launch of the FX Series vehicles. In addition, the Company defines “other segment items” as other operating expense adjustments that arise from lease or other impairments, gains and losses on the sale or disposition of its fixed assets, or other market‑driven factors that impact Loss from operations presented in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss and are not part of the Company’s recurring and controllable operating costs . By segregating these “Other Segment Items” from “Loss from operations,” the Company provides investors with a clear view of the expenses that management can directly influence versus those driven by external factors. Other potentially reportable items, such as separate automotive sales and leasing revenues (currently immaterial), geographic information, depreciation expense, interest expense, or other segment-specific activities, are not separately reviewed by the CODMs. Accordingly, these detailed segment components do not influence the CODMs’ decision-making or resource allocation processes and thus are not separately disclosed."]
["Property, Plant and Equipment, Net","Property, Plant and Equipment, Net Property, plant and equipment are stated at cost less accumulated depreciation and amortization. Expenditures for major renewals and betterments are capitalized, while minor replacements, maintenance and repairs, which do not extend the assets lives, are charged to operating expense as incurred. Upon sale or disposition, the cost and related accumulated depreciation or amortization are removed from the Unaudited Condensed Consolidated Balance Sheets and any gain or loss is included in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. Depreciation and amortization on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets and for leasehold improvements, over the term of the lease, if shorter. Useful Life Buildings 39 Building improvements 15 Computer hardware 5 Tooling, machinery, and equipment 5 to 10 Vehicles 5 Lease vehicles 7 Computer software 3 Leasehold improvements Shorter of 15 years or term of the lease Construction in process (“CIP”) consists of the construction activities related to the FF ieFactory California production facility in plant and tooling, machinery and equipment being built to serve the manufacturing of production vehicles. These assets are depreciated once put into service. The amounts capitalized in CIP that are held at vendor sites relate to the completed portion of work-in-progress of tooling, machinery and equipment built based on the Company’s specific needs. The Company may incur storage fees or interest fees related to CIP which are expensed as incurred. CIP is presented within Property, Plant, and Equipment, Net in the Unaudited Condensed Consolidated Balance Sheets."]
["Impairment of Long-Lived Assets","Impairment of Long-Lived Assets The Company reviews its long-lived assets, consisting primarily of property and equipment and right-of-use assets (“ROU”), for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset groups) may not be recoverable. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is determined by comparing the forecasted undiscounted cash flows attributable to such assets, including any cash flows upon their eventual disposition, to the assets carrying values. If the carrying value of the assets exceeds the forecasted undiscounted cash flows, then the assets are written down to their fair value. Assets classified as held for sale are also assessed for impairment and such amounts are determined at the lower of the carrying amount or fair value, less costs to sell the asset. During 2024, the Company recorded an impairment charge related to its right-of-use assets. See Note 10, Leases"]
["Revenue Recognition","Revenue Recognition The following table disaggregates our revenue by major source: Three Months Ended March 31, (in thousands) 2025 2024 Automotive sales $ — $ — Automotive leasing - Sales type 265 — Automotive leasing - Operating type 51 2 $ 316 $ 2 Automotive Sales Revenue The Company began the production of its first vehicle the FF 91 Futurist (the “FF 91,” “FF 91 Futurist”, or “FF 91 2.0 Futurist Alliance”) in March 2023 and started making deliveries to customers in August 2023. The Company recognizes automotive sales revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. Automotive sales revenue includes cash deliveries of new vehicles, and specific other features and services including home charger, charger installation, twenty-four-seven roadside assistance, over-the-air (“OTA”) software updates, internet connectivity and destination fees that meet the definition of a performance obligation under ASC 606. Revenue is recognized when control of the vehicle transfers upon delivery to the customer. Payments are typically received at the point control transfers or according to payment terms customary to the business as specified in the sales contract. Vehicle contracts do not contain a significant financing component. For obligations related to automotive sales, transaction prices are allocated among performance obligations based on relative standalone selling prices, determined using market prices, estimated internal costs, and comparable third-party offerings. The transaction price is allocated among the performance obligations in proportion to the standalone selling price of its performance obligations. Other features and services as discussed above are provisioned upon transfer of control of the vehicle and are required to be recognized on a straight-line basis over the performance period, as the Company has a stand-ready obligation to deliver such services to the customer. However, due to immateriality, revenue from other features and services are combined with the vehicle performance obligation and recognized upon the transfer of the vehicle. The Company provides certain customers with a residual value guarantee which may or may not be exercised in the future. Residual value guarantees provided to customers had an immaterial impact on revenue for the three months ended March 31, 2025 and 2024 . Automotive Leasing Revenue The Company accounts for its automotive leasing revenue program under ASC 606 and ASC Topic 842, Leases (“ASC 842”). Operating Leasing Program : The Company offers a vehicle operating leasing program in the U.S., allowing qualifying customers to lease a vehicle directly from the Company for a lease term of up to 36 months. At the end of the lease term, customers are generally required to return the vehicle to the Company, at which point the Company may either sell or re-lease the returned vehicle. Leasing revenue from operating leases is recognized on a straight-line basis over the lease term, as long as collectability is probable in accordance with ASC 842. If collectability of lease payments is not probable at lease commencement, lease income is recognized on a cash basis, meaning payments received are recorded as revenue only when collected. Depreciation expense related to leased vehicles is recorded in cost of automotive leasing revenue on a straight-line basis over the lease term, reflecting the expected residual value of the vehicles at lease termination. Upfront payments related to lease agreements are deferred and recognized as revenue on a straight-line basis over the respective lease term. Taxes collected from customers in connection with automotive leasing transactions are excluded from the transaction price and reported separately in accordance with ASC 606. Sales-Type Leasing Program : The Company enters into sales-type lease arrangements in accordance with ASC 842, under which customers generally have the option to purchase the leased vehicle at the end of the lease term, which is typically 36 months. The lease is classified as a sales-type lease when the Company concludes that the customer is reasonably certain to exercise the purchase option and, as a result, the Company expects the customer to obtain title to the vehicle upon completion of all contractual payments. At lease commencement, if collectability of the lease payments is probable, the Company derecognizes the leased vehicle and recognizes: • Automotive leasing revenue for the present value of lease payments and any guaranteed residual value; and • Automotive leasing cost of revenue for the carrying value of the leased vehicle. If collectability is not deemed probable at lease commencement, revenue recognition is deferred, and lease payments received are recorded as a deposit liability. The leased vehicle remains on the Company’s balance sheet until collectability becomes probable, at which point revenue recognition is triggered. The Company recognizes a net investment in sales-type leases, which includes both the lease receivable and the unguaranteed residual asset. The unguaranteed residual asset represents the estimated fair value of the leased vehicle at the end of the lease term that is not guaranteed by the lessee or any third party. As of March 31, 2025, the carrying amount of unguaranteed residual assets included in the net investment in sales-type leases, and presented within accounts receivable, was approximately $0.3 million. The estimate of unguaranteed residual value reflects management’s judgment, informed by historical residual value experience, current market conditions, and the anticipated future utility of the leased assets. Co-creation Arrangements As part of the Company’s Futurist Product Officers (“FPO”) Co-Creation Delivery program, which began in August 2023, the Company has entered into co-creation agreements with certain customers. This arrangement leverages select sales and leasing customers to provide valuable driving data, insights, marketing, and brand awareness for the FF 91 vehicle. In exchange for these services, the Company compensates customers through either a monthly consulting fee or a discount on their lease payments. The services provided are considered distinct and could be purchased separately from a third party. Management conducted a detailed evaluation of each customer’s services under the co-creation agreement, established relevant data points, and assigned a fair value to the services provided. Any payments exceeding the fair value of these services are treated as consideration paid to the customer and recorded as a reduction of revenue. For the three months ended March 31, 2025 and 2024, the Company recognized $0 in co-creation fees as a reduction of revenue in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. Additionally, the Company recorded $0.14 million and $0.16 million Customer Deposits The Company’s customers may reserve a vehicl e and preorder certain services by making a customer deposit, which is fully refundable at any time. Refundable deposits, for vehicle reservations and services, received from customers prior to an executed vehicle purchase agreement are recorded as customer deposits within Accrued expenses and other current liabilities on the Company’s Unaudited Condensed Consolidated Balance Sheets. Customer deposits we re $3.0 million and $3.0 million as of March 31, 2025 and December 31, 2024 , respectively. Deferred Revenue When vehicle purchase agreements are executed, the consideration for the vehicle and any accompanying products and services must be paid in advance before the transfer of products or se rvices by the Company. Unlike customer deposits, which are refundable, these advance payments are non-refundable. The Company recognizes revenue when control of the vehicle or related services transfers to the customer and defers revenue only when payments are received for undelivered products or services. Deferred revenue represents the total transaction price allocated to performance obligations that remain unsatisfied or partially unsatisfied as of the balance sheet date. As of March 31, 2025 and December 31, 2024 d eferred revenue related to products and services w"]
["Cost of Revenue","Cost of Revenue Automotive Sales Revenue Cost of automotive sales revenue includes direct and indirect materials, labor costs, manufacturing overhead, including depreciation costs of tooling and machinery, shipping and logistic costs, vehicle connectivity costs, and reserves for estimated warranty expenses. Cost of automotive sales revenues also includes adjustments to warranty expense. Cost of services and other revenue includes costs associated with providing non-warranty after-sales services, costs for retail merchandise, and costs to provide vehicle insurance. Cost of services and other revenue also includes direct parts and material. Cost of services and other revenue was immaterial for the three months ended March 31, 2025 and 2024. Automotive Leasing Program"]
["Warranties","Warranties The Company provides a manufacturer’s warranty on all vehicles sold. The warranty covers the rectification of reported defects via repair, replacement, or adjustment of faulty parts or components. The warranty does not cover any item that fails due to normal wear and tear. This assurance-type warranty does not create a performance obligation separate from the vehicle. Management tracks warranty claims by vehicle ID, owner, and date. As the Company continues to manufacture and sell more vehicles it will reassess and evaluate its warranty claims for purposes of its warranty accrual. Three Months Ended March 31, (in thousands) 2025 2024 Accrued warranty- beginning of period $ 545 $ 684 Provision for warranty (56) 38 Warranty costs incurred (45) (64) Accrued warranty- end of period $ 444 $ 658 "]
["Income Taxes","Income Taxes The Company accounts for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recognized for temporary differences between the financial reporting and income tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years when those temporary differences are anticipated to reverse. A valuation allowance is established if it is more likely than not that some or all of the deferred tax assets will not be realized. The carrying value of deferred tax assets is adjusted to reflect the amount that is more likely than not to be realized. As of March 31, 2025 and December 31, 2024, the Company maintained a full valuation allowance against its net deferred tax assets, based on the conclusion that it is more likely than not the assets will not be realized. The Company applies the guidance in ASC 740-10, Income Taxes , to account for uncertain tax positions. This guidance requires a two-step approach: (1) determine whether it is more likely than not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation; and (2) measure the tax benefit as the largest amount that is more likely than not to be realized upon settlement. The Company evaluates its tax positions based on a number of factors and may update its assessments as facts and circumstances change. The Company is subject to taxation in the U.S. federal jurisdiction, the state of California, and China. The income tax provision for each period represents the aggregate estimated tax expense or benefit for these jurisdictions. The income tax provision had a $10 thousand impact for the three months ended March 31, 2025, and no impact for the three months ended March 31, 2024, on the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company recognizes interest and penalties on unrecognized tax benefits as a component of income tax expense. There were no material interest or penalties for the three months ended March 31, 2025 and 2024."]
["Recent Accounting Pronouncements","Recent Accounting Pronouncements In early 2025, the Financial Accounting Standards Board (“FASB”) issued several ASUs to enhance financial reporting and provide clearer guidance on various accounting topics. As a December 31 year-end filer and a Smaller Reporting Company (“SRC”), the Company is required to adopt these ASUs in accordance with the effective dates applicable to SRCs. The Company is currently evaluating the impact of these ASUs on the Company’s financial statements and related disclosures. Below is a summary of these ASUs: Recently issued accounting pronouncements not yet adopted In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . This ASU enhances the transparency of income tax disclosures by requiring more detailed information about the rate reconciliation and income taxes paid, disaggregated by jurisdiction. This update is effective for the Company beginning January 1, 2026, and will first apply to the Company’s December 31, 2026, Form 10-K, with early adoption permitted. In December 2024, the FASB issued ASU 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40 ). This ASU requires public business entities to disclose additional details about certain expenses in the notes to financial statements, such as inventory purchases, employee compensation, depreciation, and intangible asset amortization. This standard is effective for the Company beginning January 1, 2027, and will first apply to the Company’s December 31, 2027, Form 10-K, with early adoption permitted. In January 2025, the FASB issued ASU 2025-04, Leases (Topic 842): Common Control Arrangements . This ASU provides new guidance on lease arrangements between entities under common control, clarifying the criteria for determining whether a lease exists and how to account for such transactions. This update is effective for the Company beginning January 1, 2026, and will first apply to the Company’s December 31, 2026, Form 10-K, with early adoption permitted."]

{"sheet":"Nature of Business and Organi_3","index":25,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["Nature of Business and Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Organization, Consolidation and Presentation of Financial Statements [Abstract]"," "]
["Schedule of Property, Plant and Equipment, Net","Depreciation and amortization on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets and for leasehold improvements, over the term of the lease, if shorter. Useful Life Buildings 39 Building improvements 15 Computer hardware 5 Tooling, machinery, and equipment 5 to 10 Vehicles 5 Lease vehicles 7 Computer software 3 Leasehold improvements Shorter of 15 years or term of the lease Property, plant, and equipment, net, consists of the following as of: (in thousands) March 31, 2025 December 31, 2024 Land, buildings and leasehold improvements $ 112,150 $ 111,443 Computer hardware 2,397 2,397 Tooling, machinery and equipment 318,251 319,313 Vehicles 695 245 Lease vehicles 1,872 3,121 Computer software 4,339 4,339 Construction in process 28,797 27,563 468,501 468,421 Less: Accumulated depreciation (137,036) (119,834) $ 331,465 $ 348,587 "]
["Schedule of Disaggregation of Revenue","The following table disaggregates our revenue by major source: Three Months Ended March 31, (in thousands) 2025 2024 Automotive sales $ — $ — Automotive leasing - Sales type 265 — Automotive leasing - Operating type 51 2 $ 316 $ 2 "]
["Schedule of Standard Product Warranty Accrual","Three Months Ended March 31, (in thousands) 2025 2024 Accrued warranty- beginning of period $ 545 $ 684 Provision for warranty (56) 38 Warranty costs incurred (45) (64) Accrued warranty- end of period $ 444 $ 658 "]

{"sheet":"Inventory, net (Tables)","index":26,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Inventory, net (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Inventory Disclosure [Abstract]"," "]
["Schedule of Inventory, Current","Inventory, net, consists of the following as of: (in thousands) March 31, 2025 December 31, 2024 Raw materials (net of reserves) $ 26,773 $ 27,440 Work in progress 152 46 Finished goods 199 — $ 27,124 $ 27,486 "]

{"sheet":"Deposits and Other Current As_2","index":27,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Deposits and Other Current Assets (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"," "]
["Schedule of Deposits and Other Current Assets","Deposits and other current assets consists of the following as of: (in thousands) March 31, 2025 December 31, 2024 Deposits Deposits for research and development, prototype and production parts, and other $ 32,143 $ 29,318 Deposits for goods and services yet to be received (“Future Work”) 1,776 1,776 $ 33,919 $ 31,094 Other current assets March 31, 2025 December 31, 2024 Prepaid expenses $ 4,022 $ 4,832 Other current assets 1,249 $ 1,295 $ 5,271 $ 6,127 "]

{"sheet":"Property, Plant, and Equipmen_2","index":28,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Property, Plant, and Equipment, Net (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Property, Plant and Equipment [Abstract]"," "]
["Schedule of Property and Equipment, Net","Depreciation and amortization on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets and for leasehold improvements, over the term of the lease, if shorter. Useful Life Buildings 39 Building improvements 15 Computer hardware 5 Tooling, machinery, and equipment 5 to 10 Vehicles 5 Lease vehicles 7 Computer software 3 Leasehold improvements Shorter of 15 years or term of the lease Property, plant, and equipment, net, consists of the following as of: (in thousands) March 31, 2025 December 31, 2024 Land, buildings and leasehold improvements $ 112,150 $ 111,443 Computer hardware 2,397 2,397 Tooling, machinery and equipment 318,251 319,313 Vehicles 695 245 Lease vehicles 1,872 3,121 Computer software 4,339 4,339 Construction in process 28,797 27,563 468,501 468,421 Less: Accumulated depreciation (137,036) (119,834) $ 331,465 $ 348,587 "]

{"sheet":"Accrued Expenses and Other Cu_2","index":29,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Accrued Expenses and Other Current Liabilities (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Payables and Accruals [Abstract]"," "]
["Schedule of Accrued Expenses and Other Current Liabilities","Accrued expenses and other current liabilities—which include both third-party and related-party balances—comprise the following items as of: (in thousands) March 31, 2025 December 31, 2024 Accrued payroll and benefits $ 28,859 $ 27,713 Accrued legal contingencies 6,615 9,091 Customer deposits 3,003 3,027 Other current liabilities 23,015 16,923 $ 61,492 $ 56,754 "]

{"sheet":"Notes Payable (Tables)","index":30,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["Notes Payable (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Debt Disclosure [Abstract]"," "]
["Schedule of Notes Payable","The Company has entered into notes payable agreements with third parties. The tables below summarize these agreements as of March 31, 2025 and December 31, 2024, providing details on contractual maturity dates, contractual interest rates, unpaid principal balances, fair value adjustments, original issue discounts, including proceeds allocated to warrants, and net carrying values. March 31, 2025 (in thousands) Contractual Contractual Unpaid Principal Fair Value Original Issue Discount and Proceeds Allocated to Warrants Net Secured SPA Notes Various 10 % - 15% $ 2,500 $ 139 $ (250) $ 2,389 Junior Secured SPA Notes September 2029 10% 13,431 55 (7,426) 6,060 2024 Unsecured SPA Notes Various through January 2030 10% 30,015 12,279 (30,964) 11,330 2025 March Unsecured SPA Notes April 2030 10% 2,000 (44) (1,193) 763 Notes payable – China other Due on Demand —% 4,132 — — 4,132 $ 52,078 $ 12,429 $ (39,833) $ 24,674 Notes payable, current portion $ 4,132 Notes payable, long-term portion $ 20,542 December 31, 2024 (in thousands) Contractual Contractual Unpaid Principal Fair Value Original Issue Discount and Proceeds Allocated to Warrants Net Secured SPA Notes Various 10 % - 15% $ 3,118 $ 2,651 $ (312) $ 5,457 2023 Unsecured SPA Notes Various dates in 2029 10 % - 15% 4,380 2,844 (508) 6,716 Junior Secured SPA Notes September 2029 10% 28,840 13,163 (15,944) 26,059 2024 Unsecured SPA Notes December 2029 10% 10,015 8,741 (11,724) 7,032 Notes payable – China other Due on Demand —% 4,173 — — 4,173 Auto loans October 2026 7% 51 — — 51 $ 50,577 $ 27,399 $ (28,488) $ 49,488 Notes payable, current portion $ 4,224 Notes payable, long-term portion $ 45,264 The future scheduled principal maturities of Related party notes payable as of March 31, 2025, are as follows: (in thousands) Years Ending December 31, Amount Due on demand $ 488 2025 (9 months remaining) 4,813 2026 1,983 2027 745 2028 — 2029 — 2030 376 Thereafter — $ 8,405 "]
["Schedule of Notes Payable Rollforward","The following table presents a roll forward of the Company’s Notes payable balances from December 31, 2024 to March 31, 2025 with third parties. The table summarizes beginning and ending balances by debt category and details changes during the period, including repayments, conversions, reclassifications, fair value adjustments, and other significant transactions. Categories of Debt (in thousands) Secured 2023 Junior 2024 2025 March Unsecured SPA Notes Notes Auto Total Balance as of December 31, 2024 (a) $ 5,457 $ 6,716 $ 26,059 $ 7,032 $ — $ 4,173 $ 51 $ 49,488 New Issuances (b) — — — 11,096 807 — 11,903 Repayment of Debt (c) — — — — — — (6) (6) Conversion of Debt to Equity (d) (589) (4,692) (9,564) — — — — (14,845) Fair Value Adjustments of Debt (e) (2,479) (2,024) (10,435) (6,798) (44) — — (21,780) Other Adjustments (f) — — — — — (41) (45) (86) Balance as of March 31, 2025 (g) $ 2,389 $ — $ 6,060 $ 11,330 $ 763 $ 4,132 $ — $ 24,674 (a) The carrying value for each note category, fair value or amortized cost depending on the election, as of December 31, 2024. (b) Debt instruments issued during the period, recorded at fair value upon issuance if the fair value option is elected, or at principal balance net of discounts. For those measured at fair value, the aggregate fair value adjustment at issuance represented a reduction of $10,097 thousand to the principal amount of the notes issued during the period, presented as a component of Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . (c) Cash repayments of principal amounts during the period. (d) Fair value of debt converted into equity during the period. (f) Adjustments to debt fair value due to the fair value option election, embedded derivatives, or anti-dilution provisions. These adjustments are presented as a component of Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . Line item Change in fair value of notes payable, warrant liabilities, and derivative call options also includes debt issuance costs of $429 thousand, which are separately identifiable from the fair value adjustments noted above. (f) Miscellaneous changes not captured in other columns, such as currency adjustments and reclassification to accrued expenses. (g) The carrying value for each note category, fair value or amortized cost depending on the election, as of March 31, 2025. The following table presents a roll forward of the Company’s Notes payable balances from December 31, 2023 to December 31, 2024 with third parties. The table summarizes beginning and ending balances by debt category and details changes during the period, including repayments, conversions, reclassifications, fair value adjustments, and other significant transactions. Categories of Debt (in thousands) Secured 2023 Unsecured Notes Auto Total Balance as of December 31, 2023 (a) $ 74,232 $ 11,938 $ — $ 4,898 $ 82 $ 91,150 New Issuances (b) 1,457 — 7,577 — — 9,034 Repayment of Debt, including periodic interest on debt carried at fair value (c) — — — — (10) (10) Conversion of Debt to Equity (d) (8,683) — — — — (8,683) Fair Value Adjustments of Debt (e) (25,118) (2,888) 285 — — (27,721) Other Adjustments (f) — (1) — (1) Balance as of March 31, 2024 (g) $ 41,888 $ 9,050 $ 7,862 $ 4,897 $ 72 $ 63,769 (a) The carrying value for each note category, fair value or amortized cost depending on the election, as of December 31, 2023. (b) Debt instruments issued during the period, recorded at fair value upon issuance if the fair value option is elected, or at principal balance net of discounts. For those measured at fair value, the aggregate fair value adjustment at issuance represented a reduction of $166 thousand to the principal amount of the notes issued during the period, presented as a component of Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . (c) Cash repayments of principal amount and periodic interest, where fair value option is elected, during the period. (d) Fair value of debt converted into equity during the period. (e) Adjustments to debt fair value due to the fair value option election, embedded derivatives, or anti-dilution provisions. These adjustments are presented as a component of Change in fair value of notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . Line item Change in fair value of notes payable, warrant liabilities, and derivative call options also includes debt issuance costs of $25 thousand, which are separately identifiable from the fair value adjustments noted above. (f) Miscellaneous changes not captured in other columns, such as currency adjustments. (g) The carrying value for each note category, fair value or amortized cost depending on the election, as of March 31, 2024."]
["Schedule of Maturities of Long-term Debt","The future scheduled principal maturities of Notes payable as of March 31, 2025, are as follows: (in thousands) Due on demand $ 4,132 2025 — 2026 — 2027 — 2028 2,500 2029 25,946 2030 19,500 Thereafter — $ 52,078 "]

{"sheet":"Related Party Transactions (Tab","index":31,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Related Party Transactions (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Related Party Transactions [Abstract]"," "]
["Schedule of Debt","The tables below summarize the related party note payable agreements as of March 31, 2025 and December 31, 2024, providing details on contractual maturity dates, contractual interest rates, and net carrying values. March 31, 2025 (in thousands) Contractual Contractual Net Carrying Unsecured Convertible Note June 2025 (3) 4.27% $ 451 2025 March Unsecured SPA Notes April 2030 10.00% 143 Notes Payable — China April 2027 18.0 % (2) 4,215 Notes Payable on Demand — China Due on Demand —% 413 FFGP Note Various 2024 (1) 4.27% 1,576 Convertible FFGP Note May 2024 (1) 4.27% 250 Other Notes Due on Demand 12.0% 75 $ 7,123 Related party notes payable, current $ 4,298 Related party notes payable, long-term $ 2,825 _______________ (1) The term was extended upon receipt of waivers of enforcement rights and remedies under the loan agreements, as described below, with the expected settlement in 2025. (2) The restructured loan bears no stated interest, and the repayment schedule requires fixed installment payments through the contractual maturity date. If the Company fails to comply with the payment schedule, interest at a rate of 18.0% would be retroactively applied to the unpaid balance. During the term of the revised loan, the Company remained in compliance with the payment schedule, and no contingent interest has been recorded as of March 31, 2025. (3) Subsequent to March 31, 2025 and prior to the issuance of these financial statements, MHL exchanged the Unsecured Convertible Note due June 2025 into 2025 March Unsecured SPA Notes pursuant to the terms of the original agreement. As a result, management classified the Unsecured Convertible Note as a long-term related party debt instrument for the period ended March 31, 2025. December 31, 2024 (in thousands) Contractual Contractual Net Carrying Value Unsecured Convertible Note April 2024 (1) 4.27% $ 1,364 Notes Payable — China April 2027 18.0% 4,382 Notes Payable on Demand — China Due on Demand —% 417 FFGP Note Various (1) 4.27% 1,576 Convertible FFGP Note May 2024 (1) 4.27% 250 Other Notes Due on demand 12.00% 75 $ 8,064 Related party notes payable, current $ 5,310 Related party notes payable, long-term $ 2,754 _______________ (1) The term was extended upon receipt of waivers of enforcement rights and remedies under the loan agreements, as described below, with the expected settlement in 2025."]
["Schedule of Notes Payable","The Company has entered into notes payable agreements with third parties. The tables below summarize these agreements as of March 31, 2025 and December 31, 2024, providing details on contractual maturity dates, contractual interest rates, unpaid principal balances, fair value adjustments, original issue discounts, including proceeds allocated to warrants, and net carrying values. March 31, 2025 (in thousands) Contractual Contractual Unpaid Principal Fair Value Original Issue Discount and Proceeds Allocated to Warrants Net Secured SPA Notes Various 10 % - 15% $ 2,500 $ 139 $ (250) $ 2,389 Junior Secured SPA Notes September 2029 10% 13,431 55 (7,426) 6,060 2024 Unsecured SPA Notes Various through January 2030 10% 30,015 12,279 (30,964) 11,330 2025 March Unsecured SPA Notes April 2030 10% 2,000 (44) (1,193) 763 Notes payable – China other Due on Demand —% 4,132 — — 4,132 $ 52,078 $ 12,429 $ (39,833) $ 24,674 Notes payable, current portion $ 4,132 Notes payable, long-term portion $ 20,542 December 31, 2024 (in thousands) Contractual Contractual Unpaid Principal Fair Value Original Issue Discount and Proceeds Allocated to Warrants Net Secured SPA Notes Various 10 % - 15% $ 3,118 $ 2,651 $ (312) $ 5,457 2023 Unsecured SPA Notes Various dates in 2029 10 % - 15% 4,380 2,844 (508) 6,716 Junior Secured SPA Notes September 2029 10% 28,840 13,163 (15,944) 26,059 2024 Unsecured SPA Notes December 2029 10% 10,015 8,741 (11,724) 7,032 Notes payable – China other Due on Demand —% 4,173 — — 4,173 Auto loans October 2026 7% 51 — — 51 $ 50,577 $ 27,399 $ (28,488) $ 49,488 Notes payable, current portion $ 4,224 Notes payable, long-term portion $ 45,264 The future scheduled principal maturities of Related party notes payable as of March 31, 2025, are as follows: (in thousands) Years Ending December 31, Amount Due on demand $ 488 2025 (9 months remaining) 4,813 2026 1,983 2027 745 2028 — 2029 — 2030 376 Thereafter — $ 8,405 "]

{"sheet":"Other Financing Liabilities (Ta","index":32,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Other Financing Liabilities (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Organization, Consolidation and Presentation of Financial Statements [Abstract]"," "]
["Schedule of Maturities of Finance Lease Liabilities","The future scheduled principal maturities of financing obligations as of March 31, 2025 are as follows: (in thousands) Years Ending December 31, Amount 2025 ( 9 months remaining) $ 582 2026 951 2027 1,189 2028 60,455 $ 63,177 "]

{"sheet":"Stockholders_ Equity (Tables)","index":33,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Stockholders’ Equity (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Equity [Abstract]"," "]
["Schedule of Authorized, Issued and Outstanding Stock","The number of authorized, issued and outstanding stock, were as follows: March 31, 2025 Authorized Issued Shares Preferred Stock 10,000,000 — Class A Common Stock 124,815,625 86,786,748 Class B Common Stock 4,429,688 6,667 139,245,313 86,793,415 December 31, 2024 Authorized Issued Shares Preferred Stock 10,000,000 1 Class A Common Stock 99,815,625 65,919,127 Class B Common Stock 4,429,688 6,667 114,245,313 65,925,795 "]
["Schedule of Stockholders' Equity Note, Warrants or Rights","The number of outstanding warrants to purchase the Company’s Class A Common Stock as of March 31, 2025 were as follows: Number of Warrants Exercise Price Expiration Date Ares Warrants 5,776,657 $1.16 August 5, 2027 SPA Warrants 15,238 $1.16 Various through November 1, 2031 Junior SPA Warrants 5,931,638 $1.16 Various through September 30, 2029 2024 Unsecured SPA Warrants 25,874,953 $1.39 Various through January 21, 2030 2025 March Unsecured SPA Warrants 3,438,357 $1.55 April 4, 2030 Public Warrants 2,453 $110,400.00 July 21, 2026 Private Warrants 12 $110,400.00 July 21, 2026 41,039,308 The number of outstanding warrants to purchase the Company’s Class A Common Stock as of December 31, 2024 were as follows: Number of Warrants Exercise Price Expiration Date Ares warrants 5,776,657 $ 1.16 August 5, 2027 SPA Warrants 15,238 $ 1.16 Various through November 1, 2031 Junior SPA Warrants 5,931,638 $ 1.16 Various through September 30, 2029 2024 Unsecured SPA Warrants 10,788,746 $ 1.39 December 31, 2029 Public Warrants 2,453 $ 110,400.00 July 21, 2026 Private Warrants 12 $ 110,400.00 July 21, 2026 22,514,744 "]

{"sheet":"Stock-Based Compensation (Table","index":34,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Stock-Based Compensation (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Share-Based Payment Arrangement [Abstract]"," "]
["Schedule of Stock-Based Compensation Expense Included in Each Respective Expense Category","The following table presents stock-based compensation expense for all of the Company’s 2021 Plan, EI Plan, STI Plan and Common Units of FF Global included in each respective expense category in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss is as follows: Three Months Ended March 31, (in thousands) 2025 2024 Research and development $ 268,299 $ 375,350 Sales and marketing 22,700 63,330 General and administrative 10,078 103,491 $ 301,077 $ 542,171 "]

{"sheet":"Fair Value of Financial Instr_2","index":35,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["Fair Value of Financial Instruments (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Fair Value Disclosures [Abstract]"," "]
["Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis","The following tables present financial assets and liabilities remeasured on a recurring basis by level within the fair value hierarchy: March 31, 2025 (in thousands) Level 1 Level 2 Level 3 Liabilities: Warrant liabilities 1 $ — $ — $ 23,624 Derivative call options 1 $ — $ — 17,057 Notes payable 1 $ — $ — 21,136 _______________ 1 Includes both related party and non-related party balances for the Company’s notes payable and warrant liabilities. December 31, 2024 (in thousands) Level 1 Level 2 Level 3 Liabilities: Warrant liabilities 1 $ — $ — $ 28,864 Derivative call options 1 29,709 Notes payable 1 — — 46,628 _______________ 1 Includes both related party and non-related party balances for the Company’s notes payable and warrant liabilities."]
["Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation","The following table summarizes the activity of Level 3 fair value measurements: (in thousands) Warrant Liabilities 1 Derivative Call Option 1 Notes Payable 1 Balance as of December 31, 2024 $ 28,864 $ 29,709 $ 46,628 Additions 16,341 2 19,730 2 12,525 3 Change in fair value measurements (21,581) (32,382) (22,445) Conversions of notes to Class A Common Stock — — (15,572) Balance as of March 31, 2025 $ 23,624 $ 17,057 $ 21,136 _______________ 1 Includes both related party and non-related party balances for the Company’s notes payable and warrant liabilities. 2 Addition to Warrant Liabilities and Derivative Call Option are included as loss in line items Change in fair value of notes payable, warrant liabilities, and derivative call options and Change in fair value of related party notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . This information is presented to facilitate reconciliation to the related amounts reported in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . 3 Additions of Notes Payable measured at fair value are presented net of the initial fair value adjustment recorded at issuance. This adjustment, which reduced the principal amount of the Notes Payable by $11,349 thousand upon initial recognition, is presented as gain in the line items Change in fair value of notes payable, warrant liabilities, and derivative call options and Change in fair value of related party notes payable, warrant liabilities, and derivative call options in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss . In addition, the line item Change in fair value of notes payable, warrant liabilities, and derivative call options includes a loss of $429 thousand, and the line item Change in fair value of related party notes payable, warrant liabilities, and derivative call options includes a loss of $76 thousand, both of which relate to debt issuance costs. These costs are separately identifiable from the fair value adjustments described above and are not included in the Additions of Notes Payable This information is presented to facilitate reconciliation to the related amounts reported in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss ."]
["Schedule of Earnings Per Share, Basic and Diluted","The following data shows the amounts used in computing net loss per share and the effect on net loss and the weighted-average number of shares as follows: Three Months Ended March 31, (in thousands, except share and per share amounts) 2025 2024 Net loss $ (10,278) $ (48,217) Weighted average shares used in computing net loss per share of Class A and B Common Stock: Basic 75,749,893 1,837,959 Diluted 75,749,893 1,837,959 Net loss per share of Class A and B Common Stock attributable to common stockholders: Basic $ (0.14) $ (26.23) Diluted $ (0.14) $ (26.23)"]

{"sheet":"Net Loss per Share (Tables)","index":36,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Net Loss per Share (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Earnings Per Share [Abstract]"," "]
["Schedule of Antidilutive Shares Excluded From Calculation of Diluted Net Loss Per Share","The table below presents the potentially dilutive shares that were excluded from the computation of diluted net loss per share of Common Stock attributable to Common Stock stockholders due to their antidilutive effect: Three Months Ended March 31, 2025 2024 Shares issuable upon conversion of SPA Portfolio Notes 44,298,705 2,331,077 Shares issuable upon conversion of Unsecured Convertible Notes 1,809,969 390,601 Shares issuable upon exercise of equity classified SPA Portfolio Note warrants 15,238 13,968 Shares issuable upon exercise of liability classified SPA Portfolio Note warrants 35,244,948 — Other warrants 5,776,657 228,482 Stock-based compensation awards – Options 2,514 2,731 Stock-based compensation awards – RSUs 155,134 21,439 Public warrants 2,453 2,453 Private warrants 12 12 87,305,630 2,990,763 "]

{"sheet":"Nature of Business and Organi_4","index":37,"n_rows":25,"n_cols":11,"rows_kept":25,"merged":[[0,0,1,0],[0,2,0,3]]}
["Nature of Business and Organization, Basis of Presentation, and Summary of Significant Accounting Policies - Narrative (Details)",null,"3 Months Ended"]
[null,"Aug. 04, 2024 $ / shares shares","Mar. 31, 2025 USD ($) segment","Mar. 31, 2024 USD ($)","Mar. 06, 2025 shares","Dec. 31, 2024 USD ($)","Aug. 31, 2024 shares","Jul. 31, 2024 shares","Feb. 23, 2024 shares","Feb. 05, 2024 shares","Feb. 04, 2024 shares"]
["Organization, Consolidation and Presentation of Financial Statements [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Number of operating segments | segment"," ",{"v":1,"d":"1 "}," "," "," "," "," "," "," "," "]
["Stockholder's equity, stock split, conversion ratio",0.025," "," "," "," "," "," "," "," "," "]
["Common stock, shares authorized (in shares) | shares",{"v":104245313,"d":"104,245,313 "}," "," ",{"v":104245313,"d":"104,245,313 "}," ",{"v":104245313,"d":"104,245,313 "},{"v":104245313,"d":"104,245,313 "},{"v":11582813,"d":"11,582,813 "},{"v":34748438,"d":"34,748,438 "},{"v":3860938,"d":"3,860,938 "}]
["Common stock, par value (in dollars per share) | $ / shares",{"v":0.0001,"d":"$ 0.0001"}," "," "," "," "," "," "," "," "," "]
["Number of reportable segments | segment"," ",{"v":1,"d":"1 "}," "," "," "," "," "," "," "," "]
["Impairment charges"," ",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}," "," "," "," "," "," "," "]
["Term of contract (in months)"," ","36 months"," "," "," "," "," "," "," "," "]
["Sales-type lease, term of contract"," ","36 months"," "," "," "," "," "," "," "," "]
["Accounts receivable"," ",{"v":664000,"d":"$ 664,000"}," "," ",{"v":0,"d":"$ 0"}," "," "," "," "," "]
["Customer deposits"," ",{"v":3003000,"d":"3,003,000 "}," "," ",{"v":3027000,"d":"3,027,000 "}," "," "," "," "," "]
["Deferred revenue"," ",{"v":0,"d":"0 "}," "," ",{"v":0,"d":"$ 0"}," "," "," "," "," "]
["Income tax benefit (expense)"," ",{"v":10000,"d":"10,000 "},{"v":0,"d":"0 "}," "," "," "," "," "," "," "]
["Penalties and interest expense"," ",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "," "," "," "," "," "," "]
["Sales-type Leases"," "," "," "," "," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Accounts receivable"," ",{"v":300000,"d":"300,000 "}," "," "," "," "," "," "," "," "]
["Revenue From Contract With Customer, Excluding Assessed Tax"," "," "," "," "," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Co-creation fees"," ",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "," "," "," "," "," "," "]
["Marketing Expense"," "," "," "," "," "," "," "," "," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Co-creation fees"," ",{"v":140000,"d":"$ 140,000"},{"v":160000,"d":"$ 160,000"}," "," "," "," "," "," "," "]

{"sheet":"Nature of Business and Organi_5","index":38,"n_rows":28,"n_cols":2,"rows_kept":28}
["Nature of Business and Organization, Basis of Presentation, and Summary of Significant Accounting Policies - Schedule of Property and Equipment (Details)","Mar. 31, 2025"]
["Buildings"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Useful Life \u2028(in years)","39 years"]
["Building improvements"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Useful Life \u2028(in years)","15 years"]
["Computer hardware"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Useful Life \u2028(in years)","5 years"]
["Tooling, machinery, and equipment | Minimum"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Useful Life \u2028(in years)","5 years"]
["Tooling, machinery, and equipment | Maximum"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Useful Life \u2028(in years)","10 years"]
["Vehicles"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Useful Life \u2028(in years)","5 years"]
["Lease vehicles"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Useful Life \u2028(in years)","7 years"]
["Computer software"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Useful Life \u2028(in years)","3 years"]
["Leasehold improvements | Minimum"," "]
["Property, Plant and Equipment [Line Items]"," "]
["Useful Life \u2028(in years)","15 years"]

{"sheet":"Nature of Business and Organi_6","index":39,"n_rows":13,"n_cols":3,"rows_kept":13,"merged":[[0,0,1,0],[0,1,0,2]]}
["Nature of Business and Organization, Basis of Presentation, and Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Organization, Consolidation and Presentation of Financial Statements [Line Items]"," "," "]
["Revenue",{"v":316,"d":"$ 316"},{"v":2,"d":"$ 2"}]
["Automotive sales"," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Items]"," "," "]
["Revenue",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Automotive leasing - Sales type"," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Items]"," "," "]
["Revenue",{"v":265,"d":"265 "},{"v":0,"d":"0 "}]
["Automotive leasing - Operating type"," "," "]
["Organization, Consolidation and Presentation of Financial Statements [Line Items]"," "," "]
["Revenue",{"v":51,"d":"$ 51"},{"v":2,"d":"$ 2"}]

{"sheet":"Nature of Business and Organi_7","index":40,"n_rows":7,"n_cols":3,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2]]}
["Nature of Business and Organization, Basis of Presentation, and Summary of Significant Accounting Policies - Schedule of Warranties (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Movement in Standard Product Warranty Accrual [Roll Forward]"," "," "]
["Accrued warranty- beginning of period",{"v":545,"d":"$ 545"},{"v":684,"d":"$ 684"}]
["Provision for warranty",{"v":-56,"d":"(56)"},{"v":38,"d":"38 "}]
["Warranty costs incurred",{"v":-45,"d":"(45)"},{"v":-64,"d":"(64)"}]
["Accrued warranty- end of period",{"v":444,"d":"$ 444"},{"v":658,"d":"$ 658"}]

{"sheet":"Liquidity and Capital Resourc_2","index":41,"n_rows":27,"n_cols":6,"rows_kept":27}
["Liquidity and Capital Resources and Going Concern (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024","Mar. 31, 2024","Sep. 26, 2023","Nov. 11, 2022"]
["Debt Instrument [Line Items]"," "," "," "," "," "]
["Accumulated deficit",{"v":-4324624,"d":"$ (4,324,624)"},{"v":-4314346,"d":"$ (4,314,346)"}," "," "," "]
["Cash",{"v":9458,"d":"9,458 "},{"v":7144,"d":"$ 7,144"},{"v":407,"d":"$ 407"}," "," "]
["Working capital",{"v":-112300,"d":"(112,300)"}," "," "," "," "]
["Standby Equity Purchase Agreement"," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "]
["Option to increase commitment amount"," "," "," "," ",{"v":350000,"d":"$ 350,000"}]
["Class A Common Stock | Standby Equity Purchase Agreement"," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "]
["Commitment amount",{"v":342500,"d":"342,500 "}," "," "," ",{"v":200000,"d":"$ 200,000"}]
["Additional commitment amount",{"v":192500,"d":"192,500 "}," "," "," "," "]
["Class A Common Stock | Sales Agreement | Sales Agents"," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "]
["Commitment amount"," "," "," ",{"v":90000,"d":"$ 90,000"}," "]
["SPA Notes | Committed Debt"," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "]
["Aggregate principal amount",{"v":655500,"d":"655,500 "}," "," "," "," "]
["Funded",{"v":427700,"d":"427,700 "}," "," "," "," "]
["To be funded",{"v":227800,"d":"227,800 "}," "," "," "," "]
["Outstanding",{"v":48300,"d":"48,300 "}," "," "," "," "]
["SPA Notes | Optional Debt"," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "]
["Aggregate principal amount",{"v":467000,"d":"467,000 "}," "," "," "," "]
["Funded",{"v":50900,"d":"50,900 "}," "," "," "," "]
["To be funded",{"v":386100,"d":"386,100 "}," "," "," "," "]
["Outstanding",{"v":2500,"d":"$ 2,500"}," "," "," "," "]

{"sheet":"Inventory, net - Schedule of In","index":42,"n_rows":6,"n_cols":3,"rows_kept":6}
["Inventory, net - Schedule of Inventory (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Inventory Disclosure [Abstract]"," "," "]
["Raw materials (net of reserves)",{"v":26773,"d":"$ 26,773"},{"v":27440,"d":"$ 27,440"}]
["Work in progress",{"v":152,"d":"152 "},{"v":46,"d":"46 "}]
["Finished goods",{"v":199,"d":"199 "},{"v":0,"d":"0 "}]
["Inventory, net",{"v":27124,"d":"$ 27,124"},{"v":27486,"d":"$ 27,486"}]

{"sheet":"Inventory, net - Narrative (Det","index":43,"n_rows":3,"n_cols":3,"rows_kept":3}
["Inventory, net - Narrative (Details) - USD ($) $ in Millions","Mar. 31, 2025","Dec. 31, 2024"]
["Inventory Disclosure [Abstract]"," "," "]
["Inventory reserve",{"v":3.3,"d":"$ 3.3"},{"v":3.3,"d":"$ 3.3"}]

{"sheet":"Deposits and Other Current As_3","index":44,"n_rows":9,"n_cols":3,"rows_kept":9}
["Deposits and Other Current Assets - Deposits and Other Current Assets (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Deposits"," "," "]
["Deposits for research and development, prototype and production parts, and other",{"v":32143,"d":"$ 32,143"},{"v":29318,"d":"$ 29,318"}]
["Deposits for goods and services yet to be received (“Future Work”)",{"v":1776,"d":"1,776 "},{"v":1776,"d":"1,776 "}]
["Deposits",{"v":33919,"d":"33,919 "},{"v":31094,"d":"31,094 "}]
["Other current assets"," "," "]
["Prepaid expenses",{"v":4022,"d":"4,022 "},{"v":4832,"d":"4,832 "}]
["Other current assets",{"v":1249,"d":"1,249 "},{"v":1295,"d":"1,295 "}]
["Other current assets",{"v":5271,"d":"$ 5,271"},{"v":6127,"d":"$ 6,127"}]

{"sheet":"Property, Plant, and Equipmen_3","index":45,"n_rows":26,"n_cols":3,"rows_kept":26}
["Property, Plant, and Equipment, Net (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property and equipment, gross",{"v":468501,"d":"$ 468,501"},{"v":468421,"d":"$ 468,421"}]
["Less: Accumulated depreciation",{"v":-137036,"d":"(137,036)"},{"v":-119834,"d":"(119,834)"}]
["Property, plant and equipment, net",{"v":331465,"d":"331,465 "},{"v":348587,"d":"348,587 "}]
["Land, buildings and leasehold improvements"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property and equipment, gross",{"v":112150,"d":"112,150 "},{"v":111443,"d":"111,443 "}]
["Computer hardware"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property and equipment, gross",{"v":2397,"d":"2,397 "},{"v":2397,"d":"2,397 "}]
["Tooling, machinery, and equipment"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property and equipment, gross",{"v":318251,"d":"318,251 "},{"v":319313,"d":"319,313 "}]
["Vehicles"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property and equipment, gross",{"v":695,"d":"695 "},{"v":245,"d":"245 "}]
["Lease vehicles"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property and equipment, gross",{"v":1872,"d":"1,872 "},{"v":3121,"d":"3,121 "}]
["Computer software"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property and equipment, gross",{"v":4339,"d":"4,339 "},{"v":4339,"d":"4,339 "}]
["Construction in process"," "," "]
["Property, Plant and Equipment [Line Items]"," "," "]
["Property and equipment, gross",{"v":28797,"d":"$ 28,797"},{"v":27563,"d":"$ 27,563"}]

{"sheet":"Property, Plant, and Equipmen_4","index":46,"n_rows":7,"n_cols":4,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2]]}
["Property, Plant, and Equipment, Net - Narrative (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024"]
["Property, Plant and Equipment [Abstract]"," "," "," "]
["Depreciation",{"v":17500,"d":"$ 17,500"},{"v":17700,"d":"$ 17,700"}," "]
["Gain (loss) on disposition of property plant equipment",{"v":-44,"d":"(44)"},{"v":87,"d":"$ 87"}," "]
["Accumulated depreciation, depletion and amortization, sale or disposal of property, plant and equipment",{"v":200,"d":"200 "}," "," "]
["Asset retirement obligation",{"v":800,"d":"$ 800"}," ",{"v":800,"d":"$ 800"}]

{"sheet":"Accrued Expenses and Other Cu_3","index":47,"n_rows":7,"n_cols":3,"rows_kept":7}
["Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Accounts Payable and Accrued Liabilities, Current [Abstract]"," "," "]
["Accrued payroll and benefits",{"v":28859,"d":"$ 28,859"},{"v":27713,"d":"$ 27,713"}]
["Accrued legal contingencies",{"v":6615,"d":"6,615 "},{"v":9091,"d":"9,091 "}]
["Customer deposits",{"v":3003,"d":"3,003 "},{"v":3027,"d":"3,027 "}]
["Other current liabilities",{"v":23015,"d":"23,015 "},{"v":16923,"d":"16,923 "}]
["Accrued expenses and other current liabilities",{"v":61492,"d":"$ 61,492"},{"v":56754,"d":"$ 56,754"}]

{"sheet":"Notes Payable - Schedule of Not","index":48,"n_rows":75,"n_cols":5,"rows_kept":75}
["Notes Payable - Schedule of Notes Payable (Details) - USD ($) $ in Thousands","Mar. 31, 2025","Mar. 21, 2025","Dec. 31, 2024","Mar. 31, 2024"]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Fair Value Measurement Adjustments",{"v":10097,"d":"$ 10,097"}," "," ",{"v":166,"d":"$ 166"}]
["Nonrelated Party"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Notes payable",{"v":4132,"d":"4,132 "}," ",{"v":4224,"d":"$ 4,224"}," "]
["Notes payable, long-term portion",{"v":20542,"d":"20,542 "}," ",{"v":45264,"d":"45,264 "}," "]
["Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Unpaid Principal Balance",{"v":52078,"d":"52,078 "}," ",{"v":50577,"d":"50,577 "}," "]
["Fair Value Measurement Adjustments",{"v":12429,"d":"12,429 "}," ",{"v":27399,"d":"27,399 "}," "]
["Original Issue Discount and Proceeds Allocated to Warrants",{"v":-39833,"d":"(39,833)"}," ",{"v":-28488,"d":"(28,488)"}," "]
["Net Carrying Value",{"v":24674,"d":"24,674 "}," ",{"v":49488,"d":"49,488 "}," "]
["Secured SPA Notes | Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Unpaid Principal Balance",{"v":2500,"d":"2,500 "}," ",{"v":3118,"d":"3,118 "}," "]
["Fair Value Measurement Adjustments",{"v":139,"d":"139 "}," ",{"v":2651,"d":"2,651 "}," "]
["Original Issue Discount and Proceeds Allocated to Warrants",{"v":-250,"d":"(250)"}," ",{"v":-312,"d":"(312)"}," "]
["Net Carrying Value",{"v":2389,"d":"$ 2,389"}," ",{"v":5457,"d":"5,457 "}," "]
["2023 Unsecured SPA Notes | Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Unpaid Principal Balance"," "," ",{"v":4380,"d":"4,380 "}," "]
["Fair Value Measurement Adjustments"," "," ",{"v":2844,"d":"2,844 "}," "]
["Original Issue Discount and Proceeds Allocated to Warrants"," "," ",{"v":-508,"d":"(508)"}," "]
["Net Carrying Value"," "," ",{"v":6716,"d":"$ 6,716"}," "]
["Junior Secured SPA Notes | Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Contractual Interest Rates",{"v":0.1,"d":"10%"}," ",{"v":0.1,"d":"10%"}," "]
["Unpaid Principal Balance",{"v":13431,"d":"$ 13,431"}," ",{"v":28840,"d":"$ 28,840"}," "]
["Fair Value Measurement Adjustments",{"v":55,"d":"55 "}," ",{"v":13163,"d":"13,163 "}," "]
["Original Issue Discount and Proceeds Allocated to Warrants",{"v":-7426,"d":"(7,426)"}," ",{"v":-15944,"d":"(15,944)"}," "]
["Net Carrying Value",{"v":6060,"d":"$ 6,060"}," ",{"v":26059,"d":"$ 26,059"}," "]
["2024 Unsecured SPA Notes | Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Contractual Interest Rates",{"v":0.1,"d":"10%"}," ",{"v":0.1,"d":"10%"}," "]
["Unpaid Principal Balance",{"v":30015,"d":"$ 30,015"}," ",{"v":10015,"d":"$ 10,015"}," "]
["Fair Value Measurement Adjustments",{"v":12279,"d":"12,279 "}," ",{"v":8741,"d":"8,741 "}," "]
["Original Issue Discount and Proceeds Allocated to Warrants",{"v":-30964,"d":"(30,964)"}," ",{"v":-11724,"d":"(11,724)"}," "]
["Net Carrying Value",{"v":11330,"d":"$ 11,330"}," ",{"v":7032,"d":"$ 7,032"}," "]
["2025 March Unsecured SPA Notes"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Contractual Interest Rates"," ",{"v":0.1,"d":"10%"}," "," "]
["2025 March Unsecured SPA Notes | Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Contractual Interest Rates",{"v":0.1,"d":"10%"},{"v":0.18,"d":"18%"}," "," "]
["Unpaid Principal Balance",{"v":2000,"d":"$ 2,000"}," "," "," "]
["Fair Value Measurement Adjustments",{"v":-44,"d":"(44)"}," "," "," "]
["Original Issue Discount and Proceeds Allocated to Warrants",{"v":-1193,"d":"(1,193)"}," "," "," "]
["Net Carrying Value",{"v":763,"d":"$ 763"}," "," "," "]
["Notes payable – China other | Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Contractual Interest Rates",{"v":0,"d":"0%"}," ",{"v":0,"d":"0%"}," "]
["Unpaid Principal Balance",{"v":4132,"d":"$ 4,132"}," ",{"v":4173,"d":"$ 4,173"}," "]
["Fair Value Measurement Adjustments",{"v":0,"d":"0 "}," ",{"v":0,"d":"0 "}," "]
["Original Issue Discount and Proceeds Allocated to Warrants",{"v":0,"d":"0 "}," ",{"v":0,"d":"0 "}," "]
["Net Carrying Value",{"v":4132,"d":"$ 4,132"}," ",{"v":4173,"d":"$ 4,173"}," "]
["Auto loans | Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Contractual Interest Rates"," "," ",{"v":0.07,"d":"7%"}," "]
["Unpaid Principal Balance"," "," ",{"v":51,"d":"$ 51"}," "]
["Fair Value Measurement Adjustments"," "," ",{"v":0,"d":"0 "}," "]
["Original Issue Discount and Proceeds Allocated to Warrants"," "," ",{"v":0,"d":"0 "}," "]
["Net Carrying Value"," "," ",{"v":51,"d":"$ 51"}," "]
["Minimum | Secured SPA Notes | Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Contractual Interest Rates",{"v":0.1,"d":"10%"}," ",{"v":0.1,"d":"10%"}," "]
["Minimum | 2023 Unsecured SPA Notes | Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Contractual Interest Rates",{"v":0.1,"d":"10%"}," ",{"v":0.1,"d":"10%"}," "]
["Maximum | Secured SPA Notes | Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Contractual Interest Rates",{"v":0.15,"d":"15%"}," ",{"v":0.15,"d":"15%"}," "]
["Maximum | 2023 Unsecured SPA Notes | Notes Payable"," "," "," "," "]
["Debt Outstanding [Abstract]"," "," "," "," "]
["Contractual Interest Rates",{"v":0.15,"d":"15%"}," ",{"v":0.15,"d":"15%"}," "]

{"sheet":"Notes Payable - Schedule of N_2","index":49,"n_rows":93,"n_cols":4,"rows_kept":93,"merged":[[0,0,1,0],[0,1,0,2]]}
["Notes Payable - Schedule of Note Payable Rollforward (Details) - USD ($)","3 Months Ended",null,"12 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024"]
["Notes Payable [Roll Forward]"," "," "," "]
["Fair Value Measurement Adjustments",{"v":10097000,"d":"$ 10,097,000"},{"v":166000,"d":"$ 166,000"}," "]
["Debt issuance costs, net",{"v":429000,"d":"429,000 "},{"v":25000,"d":"25,000 "}," "]
["Notes Payable"," "," "," "]
["Notes Payable [Roll Forward]"," "," "," "]
["Beginning balance",{"v":49488000,"d":"49,488,000 "},{"v":91150000,"d":"91,150,000 "},{"v":91150000,"d":"$ 91,150,000"}]
["New Issuances",{"v":11903000,"d":"11,903,000 "},{"v":9034000,"d":"9,034,000 "}," "]
["Repayments of Debt",{"v":-6000,"d":"(6,000)"},{"v":-10000,"d":"(10,000)"}," "]
["Conversion of Debt to Equity",{"v":-14845000,"d":"(14,845,000)"},{"v":-8683000,"d":"(8,683,000)"}," "]
["Fair Value Adjustments of Debt",{"v":-21780000,"d":"(21,780,000)"},{"v":-27721000,"d":"(27,721,000)"}," "]
["Other Adjustments",{"v":-86000,"d":"(86,000)"},{"v":-1000,"d":"(1,000)"}," "]
["Ending balance",{"v":24674000,"d":"24,674,000 "},{"v":63769000,"d":"63,769,000 "},{"v":49488000,"d":"49,488,000 "}]
["Fair Value Measurement Adjustments",{"v":12429000,"d":"12,429,000 "}," ",{"v":27399000,"d":"27,399,000 "}]
["Secured SPA Notes | Notes Payable"," "," "," "]
["Notes Payable [Roll Forward]"," "," "," "]
["Beginning balance",{"v":5457000,"d":"5,457,000 "},{"v":74232000,"d":"74,232,000 "},{"v":74232000,"d":"74,232,000 "}]
["New Issuances",{"v":0,"d":"0 "},{"v":1457000,"d":"1,457,000 "}," "]
["Repayments of Debt",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Conversion of Debt to Equity",{"v":-589000,"d":"(589,000)"},{"v":-8683000,"d":"(8,683,000)"}," "]
["Fair Value Adjustments of Debt",{"v":-2479000,"d":"(2,479,000)"},{"v":-25118000,"d":"(25,118,000)"}," "]
["Other Adjustments",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Ending balance",{"v":2389000,"d":"2,389,000 "},{"v":41888000,"d":"41,888,000 "},{"v":5457000,"d":"5,457,000 "}]
["Fair Value Measurement Adjustments",{"v":139000,"d":"139,000 "}," ",{"v":2651000,"d":"2,651,000 "}]
["2023 Unsecured SPA Notes | Notes Payable"," "," "," "]
["Notes Payable [Roll Forward]"," "," "," "]
["Beginning balance",{"v":6716000,"d":"6,716,000 "},{"v":11938000,"d":"11,938,000 "},{"v":11938000,"d":"11,938,000 "}]
["New Issuances",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Repayments of Debt",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Conversion of Debt to Equity",{"v":-4692000,"d":"(4,692,000)"},{"v":0,"d":"0 "}," "]
["Fair Value Adjustments of Debt",{"v":-2024000,"d":"(2,024,000)"},{"v":-2888000,"d":"(2,888,000)"}," "]
["Other Adjustments",{"v":0,"d":"0 "}," "," "]
["Ending balance",{"v":0,"d":"0 "},{"v":9050000,"d":"9,050,000 "},{"v":6716000,"d":"6,716,000 "}]
["Fair Value Measurement Adjustments"," "," ",{"v":2844000,"d":"2,844,000 "}]
["Unsecured Convertible Note | Notes Payable"," "," "," "]
["Notes Payable [Roll Forward]"," "," "," "]
["Beginning balance"," ",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["New Issuances"," ",{"v":7577000,"d":"7,577,000 "}," "]
["Repayments of Debt"," ",{"v":0,"d":"0 "}," "]
["Conversion of Debt to Equity"," ",{"v":0,"d":"0 "}," "]
["Fair Value Adjustments of Debt"," ",{"v":285000,"d":"285,000 "}," "]
["Other Adjustments"," "," "," "]
["Ending balance",{"v":0,"d":"0 "},{"v":7862000,"d":"7,862,000 "}," "]
["Junior Secured SPA Notes | Notes Payable"," "," "," "]
["Notes Payable [Roll Forward]"," "," "," "]
["Beginning balance",{"v":26059000,"d":"26,059,000 "}," "," "]
["New Issuances",{"v":0,"d":"0 "}," "," "]
["Repayments of Debt",{"v":0,"d":"0 "}," "," "]
["Conversion of Debt to Equity",{"v":-9564000,"d":"(9,564,000)"}," "," "]
["Fair Value Adjustments of Debt",{"v":-10435000,"d":"(10,435,000)"}," "," "]
["Other Adjustments",{"v":0,"d":"0 "}," "," "]
["Ending balance",{"v":6060000,"d":"6,060,000 "}," ",{"v":26059000,"d":"26,059,000 "}]
["2024 Unsecured SPA Notes | Notes Payable"," "," "," "]
["Notes Payable [Roll Forward]"," "," "," "]
["Beginning balance",{"v":7032000,"d":"7,032,000 "}," "," "]
["New Issuances",{"v":11096000,"d":"11,096,000 "}," "," "]
["Repayments of Debt",{"v":0,"d":"0 "}," "," "]
["Conversion of Debt to Equity",{"v":0,"d":"0 "}," "," "]
["Fair Value Adjustments of Debt",{"v":-6798000,"d":"(6,798,000)"}," "," "]
["Other Adjustments",{"v":0,"d":"0 "}," "," "]
["Ending balance",{"v":11330000,"d":"11,330,000 "}," ",{"v":7032000,"d":"7,032,000 "}]
["Fair Value Measurement Adjustments",{"v":12279000,"d":"12,279,000 "}," ",{"v":8741000,"d":"8,741,000 "}]
["2025 March Unsecured SPA Notes | Notes Payable"," "," "," "]
["Notes Payable [Roll Forward]"," "," "," "]
["Beginning balance",{"v":0,"d":"0 "}," "," "]
["New Issuances",{"v":807000,"d":"807,000 "}," "," "]
["Repayments of Debt",{"v":0,"d":"0 "}," "," "]
["Conversion of Debt to Equity",{"v":0,"d":"0 "}," "," "]
["Fair Value Adjustments of Debt",{"v":-44000,"d":"(44,000)"}," "," "]
["Other Adjustments",{"v":0,"d":"0 "}," "," "]
["Ending balance",{"v":763000,"d":"763,000 "}," ",{"v":0,"d":"0 "}]
["Fair Value Measurement Adjustments",{"v":-44000,"d":"(44,000)"}," "," "]
["Notes payable – China other | Notes Payable"," "," "," "]
["Notes Payable [Roll Forward]"," "," "," "]
["Beginning balance",{"v":4173000,"d":"4,173,000 "},{"v":4898000,"d":"4,898,000 "},{"v":4898000,"d":"4,898,000 "}]
["New Issuances"," ",{"v":0,"d":"0 "}," "]
["Repayments of Debt",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Conversion of Debt to Equity",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Fair Value Adjustments of Debt",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Other Adjustments",{"v":-41000,"d":"(41,000)"},{"v":-1000,"d":"(1,000)"}," "]
["Ending balance",{"v":4132000,"d":"4,132,000 "},{"v":4897000,"d":"4,897,000 "},{"v":4173000,"d":"4,173,000 "}]
["Fair Value Measurement Adjustments",{"v":0,"d":"0 "}," ",{"v":0,"d":"0 "}]
["Auto loans | Notes Payable"," "," "," "]
["Notes Payable [Roll Forward]"," "," "," "]
["Beginning balance",{"v":51000,"d":"51,000 "},{"v":82000,"d":"82,000 "},{"v":82000,"d":"82,000 "}]
["New Issuances",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Repayments of Debt",{"v":-6000,"d":"(6,000)"},{"v":-10000,"d":"(10,000)"}," "]
["Conversion of Debt to Equity",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Fair Value Adjustments of Debt",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Other Adjustments",{"v":-45000,"d":"(45,000)"},{"v":0,"d":"0 "}," "]
["Ending balance",{"v":0,"d":"$ 0"},{"v":72000,"d":"$ 72,000"},{"v":51000,"d":"51,000 "}]
["Fair Value Measurement Adjustments"," "," ",{"v":0,"d":"$ 0"}]

{"sheet":"Notes Payable - Schedule of Mat","index":50,"n_rows":11,"n_cols":3,"rows_kept":11}
["Notes Payable - Schedule of Maturities of Long-term Debt (Details) - Notes Payable - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Debt Instrument [Line Items]"," "," "]
["Due on demand",{"v":4132,"d":"$ 4,132"}," "]
["2025",{"v":0,"d":"0 "}," "]
["2026",{"v":0,"d":"0 "}," "]
["2027",{"v":0,"d":"0 "}," "]
["2028",{"v":2500,"d":"2,500 "}," "]
["2029",{"v":25946,"d":"25,946 "}," "]
["2030",{"v":19500,"d":"19,500 "}," "]
["Thereafter",{"v":0,"d":"0 "}," "]
["Unpaid Principal Balance",{"v":52078,"d":"$ 52,078"},{"v":50577,"d":"$ 50,577"}]

{"sheet":"Notes Payable - Secured SPA Not","index":51,"n_rows":79,"n_cols":9,"rows_kept":79,"merged":[[0,0,1,0],[0,2,0,3]]}
["Notes Payable - Secured SPA Notes Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands",null,"3 Months Ended",null,"6 Months Ended"]
[null,"Aug. 02, 2024","Mar. 31, 2025","Mar. 31, 2024","Jun. 30, 2024","Jan. 28, 2025","Dec. 31, 2024","Dec. 21, 2024","Sep. 05, 2024"]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Payments of notes payable issuance costs"," ",{"v":99,"d":"$ 99"},{"v":25,"d":"$ 25"}," "," "," "," "," "]
["Notes Payable"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Gain (loss) on fair value adjustment of debts"," ",{"v":21780,"d":"$ 21,780"},{"v":27721,"d":"27,721 "}," "," "," "," "," "]
["Secured SPA Notes | Notes Payable"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Debt instrument, fixed conversion price percentage"," ",{"v":0.9,"d":"90%"}," "," "," "," "," "," "]
["Conversion price (in dollars per share)"," ",{"v":1.16,"d":"$ 1.16"}," ",{"v":29.33,"d":"$ 29.33"}," "," "," "," "]
["Debt instrument, term (in years)"," ","6 years"," "," "," "," "," "," "]
["Notes payable"," ",{"v":2400,"d":"$ 2,400"}," "," "," ",{"v":5500,"d":"$ 5,500"}," "," "]
["Proceeds from debt, net of issuance costs"," "," ",{"v":1500,"d":"$ 1,500"}," "," "," "," "," "]
["Aggregate principal amount"," ",{"v":600,"d":"$ 600"}," "," "," "," "," "," "]
["Shares issued from conversion (in shares)"," ",{"v":602902,"d":"602,902 "},{"v":2937946,"d":"2,937,946 "}," "," "," "," "," "]
["Gain (loss) on fair value adjustment of debts"," ",{"v":2479,"d":"$ 2,479"},{"v":25118,"d":"$ 25,118"}," "," "," "," "," "]
["Payments of notes payable issuance costs"," "," ",{"v":0,"d":"0 "}," "," "," "," "," "]
["Debt conversion, converted amount"," "," ",{"v":18300,"d":"18,300 "}," "," "," "," "," "]
["Secured SPA Notes | Notes Payable | Class A Common Stock"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Redemption price, percentage"," "," "," ",{"v":1.05,"d":"105%"}," "," "," "," "]
["Gain (loss) extinguishments of debt"," ",{"v":-300,"d":"$ (300)"},{"v":-11400,"d":"(11,400)"}," "," "," "," "," "]
["Secured SPA Notes | Notes Payable | Metaverse Horizon Limited and V W Investment Holding Limited"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Percent of purchaser's conversion shares"," ",{"v":0.33,"d":"33%"}," "," "," "," "," "," "]
["SPA Notes | Notes Payable"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Conversion price (in dollars per share)",{"v":29.33,"d":"$ 29.33"}," "," "," "," "," "," "," "]
["SPA Notes | Notes Payable | Class A Common Stock"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Redemption price, percentage",{"v":0.9,"d":"90%"}," "," "," "," "," "," "," "]
["Junior Secured SPA Notes | Notes Payable"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," "," "," "," "," "," "," ",{"v":0.1,"d":"10%"}]
["Conversion price (in dollars per share)"," "," "," "," ",{"v":5.24,"d":"$ 5.24"}," ",{"v":1.16,"d":"$ 1.16"},{"v":5.24,"d":"$ 5.24"}]
["Debt instrument, term (in years)"," ","1 year"," "," "," "," "," "," "]
["Proceeds from debt, net of issuance costs"," ",{"v":7600,"d":"$ 7,600"}," "," "," "," "," "," "]
["Gain (loss) on fair value adjustment of debts"," ",{"v":10435,"d":"10,435 "}," "," "," "," "," "," "]
["Payments of notes payable issuance costs"," ",{"v":0,"d":"$ 0"}," "," "," "," "," "," "]
["Junior Secured SPA Notes | Notes Payable | Class A Common Stock"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Shares issued from conversion (in shares)"," ",{"v":113958070,"d":"113,958,070 "}," "," "," "," "," "," "]
["Gain (loss) extinguishments of debt"," ",{"v":-12800,"d":"$ (12,800)"}," "," "," "," "," "," "]
["Debt conversion, converted amount"," ",{"v":15400,"d":"$ 15,400"}," "," "," "," "," "," "]
["2024 Unsecured SPA Notes | Notes Payable"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," ",{"v":0.1,"d":"10%"}," "," "," ",{"v":0.1,"d":"10%"}," "," "]
["Conversion price (in dollars per share)"," ",{"v":1.16,"d":"$ 1.16"}," "," ",{"v":1.16,"d":"$ 1.16"}," ",{"v":1.16,"d":"$ 1.16"}," "]
["Debt instrument, term (in years)"," ","1 year"," "," "," "," "," "," "]
["Notes payable"," ",{"v":11300,"d":"$ 11,300"}," "," "," ",{"v":7000,"d":"$ 7,000"}," "," "]
["Proceeds from debt, net of issuance costs"," ",{"v":20000,"d":"20,000 "}," "," "," "," "," "," "]
["Gain (loss) on fair value adjustment of debts"," ",{"v":6798,"d":"6,798 "}," "," "," "," "," "," "]
["Payments of notes payable issuance costs"," ",{"v":0,"d":"$ 0"}," "," "," "," "," "," "]
["Unsecured Convertible Note | Notes Payable"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Conversion price (in dollars per share)"," ",{"v":1.16,"d":"$ 1.16"}," "," "," "," "," "," "]
["Debt instrument, term (in years)"," ","6 years"," "," "," "," "," "," "]
["Notes payable"," "," "," "," "," ",{"v":6700,"d":"$ 6,700"}," "," "]
["Proceeds from debt, net of issuance costs"," ",{"v":0,"d":"$ 0"}," "," "," "," "," "," "]
["Shares issued from conversion (in shares)"," ",{"v":4167764,"d":"4,167,764 "}," "," "," "," "," "," "]
["Gain (loss) on fair value adjustment of debts"," ",{"v":2024,"d":"$ 2,024"},{"v":2888,"d":"$ 2,888"}," "," "," "," "," "]
["Debt conversion, converted amount"," ",{"v":4400,"d":"$ 4,400"}," "," "," "," "," "," "]
["Unsecured Convertible Note | Notes Payable | Class A Common Stock"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Debt instrument, fixed conversion price percentage"," ",{"v":0.9,"d":"90%"}," "," "," "," "," "," "]
["Gain (loss) extinguishments of debt"," ",{"v":-2800,"d":"$ (2,800)"}," "," "," "," "," "," "]
["Minimum | Secured SPA Notes | Notes Payable"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," ",{"v":0.1,"d":"10%"}," "," "," ",{"v":0.1,"d":"10%"}," "," "]
["Minimum | Unsecured Convertible Note | Notes Payable"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," ",{"v":0.1,"d":"10%"}," "," "," ",{"v":0.1,"d":"10%"}," "," "]
["Maximum | Secured SPA Notes | Notes Payable"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," ",{"v":0.15,"d":"15%"}," "," "," ",{"v":0.15,"d":"15%"}," "," "]
["Maximum | Unsecured Convertible Note | Notes Payable"," "," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," ",{"v":0.15,"d":"15%"}," "," "," ",{"v":0.15,"d":"15%"}," "," "]

{"sheet":"Notes Payable - 2023 Unsecured ","index":52,"n_rows":42,"n_cols":8,"rows_kept":42,"merged":[[0,0,1,0],[0,1,0,2]]}
["Notes Payable - 2023 Unsecured SPA Notes Narrative (Details) - Notes Payable - USD ($) $ / shares in Units, $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Jan. 28, 2025","Dec. 31, 2024","Dec. 21, 2024","Sep. 05, 2024","Dec. 31, 2023"]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Notes and loans payable",{"v":24674,"d":"$ 24,674"},{"v":63769,"d":"$ 63,769"}," ",{"v":49488,"d":"$ 49,488"}," "," ",{"v":91150,"d":"$ 91,150"}]
["Gain (loss) on fair value adjustment of debts",{"v":21780,"d":"$ 21,780"},{"v":27721,"d":"27,721 "}," "," "," "," "," "]
["Unsecured Convertible Note"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Conversion price (in dollars per share)",{"v":1.16,"d":"$ 1.16"}," "," "," "," "," "," "]
["Debt instrument, term (in years)","6 years"," "," "," "," "," "," "]
["Notes and loans payable",{"v":0,"d":"$ 0"},{"v":9050,"d":"9,050 "}," ",{"v":6716,"d":"6,716 "}," "," ",{"v":11938,"d":"$ 11,938"}]
["Notes payable"," "," "," ",{"v":6700,"d":"6,700 "}," "," "," "]
["Proceeds from debt, net of issuance costs",{"v":0,"d":"0 "}," "," "," "," "," "," "]
["Debt conversion, converted amount",{"v":4400,"d":"$ 4,400"}," "," "," "," "," "," "]
["Shares issued from conversion (in shares)",{"v":4167764,"d":"4,167,764 "}," "," "," "," "," "," "]
["Gain (loss) on fair value adjustment of debts",{"v":2024,"d":"$ 2,024"},{"v":2888,"d":"2,888 "}," "," "," "," "," "]
["Gain (loss) on fair value adjustment of debts, favorable, net"," ",{"v":2900,"d":"$ 2,900"}," "," "," "," "," "]
["Unsecured Convertible Note | Class A Common Stock"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Debt instrument, fixed conversion price percentage",{"v":0.9,"d":"90%"}," "," "," "," "," "," "]
["Gain (loss) extinguishments of debt",{"v":-2800,"d":"$ (2,800)"}," "," "," "," "," "," "]
["Unsecured SPA Notes"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Percent of purchaser's conversion shares",{"v":0.33,"d":"33%"}," "," "," "," "," "," "]
["Junior Secured SPA Notes"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," "," "," "," "," ",{"v":0.1,"d":"10%"}," "]
["Conversion price (in dollars per share)"," "," ",{"v":5.24,"d":"$ 5.24"}," ",{"v":1.16,"d":"$ 1.16"},{"v":5.24,"d":"$ 5.24"}," "]
["Debt instrument, term (in years)","1 year"," "," "," "," "," "," "]
["Notes and loans payable",{"v":6060,"d":"$ 6,060"}," "," ",{"v":26059,"d":"$ 26,059"}," "," "," "]
["Proceeds from debt, net of issuance costs",{"v":7600,"d":"7,600 "}," "," "," "," "," "," "]
["Gain (loss) on fair value adjustment of debts",{"v":10435,"d":"10,435 "}," "," "," "," "," "," "]
["Junior Secured SPA Notes | Class A Common Stock"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Debt conversion, converted amount",{"v":15400,"d":"$ 15,400"}," "," "," "," "," "," "]
["Shares issued from conversion (in shares)",{"v":113958070,"d":"113,958,070 "}," "," "," "," "," "," "]
["Gain (loss) extinguishments of debt",{"v":-12800,"d":"$ (12,800)"}," "," "," "," "," "," "]
["Minimum | Unsecured Convertible Note"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Notes payable bearing interest rate",{"v":0.1,"d":"10%"}," "," ",{"v":0.1,"d":"10%"}," "," "," "]
["Maximum | Unsecured Convertible Note"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Notes payable bearing interest rate",{"v":0.15,"d":"15%"}," "," ",{"v":0.15,"d":"15%"}," "," "," "]

{"sheet":"Notes Payable - Unsecured Conve","index":53,"n_rows":14,"n_cols":5,"rows_kept":14,"merged":[[0,0,1,0],[0,1,0,2]]}
["Notes Payable - Unsecured Convertible Notes Narrative (Details) - USD ($) $ in Thousands","3 Months Ended",null,"12 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024","Dec. 31, 2023"]
["Debt Instrument [Line Items]"," "," "," "," "]
["Payments of notes payable issuance costs",{"v":99,"d":"$ 99"},{"v":25,"d":"$ 25"}," "," "]
["Notes Payable"," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "]
["Notes and loans payable",{"v":24674,"d":"24,674 "},{"v":63769,"d":"63,769 "},{"v":49488,"d":"$ 49,488"},{"v":91150,"d":"$ 91,150"}]
["Fair value adjustments of debt",{"v":21780,"d":"$ 21,780"},{"v":27721,"d":"27,721 "}," "," "]
["Unsecured Convertible Note | Notes Payable"," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "]
["Debt instrument, term (in years)","3 months"," ","3 months"," "]
["Notes payable bearing interest rate",{"v":0.0427,"d":"4.27%"}," ",{"v":0.0427,"d":"4.27%"}," "]
["Notes and loans payable",{"v":0,"d":"$ 0"},{"v":7862,"d":"7,862 "}," ",{"v":0,"d":"$ 0"}]
["Fair value adjustments of debt"," ",{"v":-285,"d":"$ (285)"}," "," "]

{"sheet":"Notes Payable - Junior Secured ","index":54,"n_rows":28,"n_cols":8,"rows_kept":28,"merged":[[0,0,1,0],[0,1,0,2]]}
["Notes Payable - Junior Secured SPA Note Narrative (Details) $ / shares in Units, $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025 USD ($) trading_day shares","Mar. 31, 2024 USD ($)","Jan. 28, 2025 $ / shares","Dec. 31, 2024 USD ($)","Dec. 21, 2024 $ / shares","Sep. 05, 2024 $ / shares shares","Dec. 31, 2023 USD ($)"]
["Junior SPA Warrants"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Percent of purchaser's conversion shares"," "," "," "," "," ",{"v":1,"d":"100%"}," "]
["Debt instrument, term (in years)","5 years"," "," "," "," "," "," "]
["Junior SPA Warrants | Class A Common Stock"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Warrants rights (in shares) | shares"," "," "," "," "," ",{"v":202768,"d":"202,768 "}," "]
["Notes Payable"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Notes and loans payable",{"v":24674,"d":"$ 24,674"},{"v":63769,"d":"$ 63,769"}," ",{"v":49488,"d":"$ 49,488"}," "," ",{"v":91150,"d":"$ 91,150"}]
["Fair value adjustments of debt",{"v":21780,"d":"$ 21,780"},{"v":27721,"d":"$ 27,721"}," "," "," "," "," "]
["Junior Secured SPA Notes | Notes Payable"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Contractual Interest Rates"," "," "," "," "," ",{"v":0.1,"d":"10%"}," "]
["Debt instrument, floor price (in dollars per share) | $ / shares"," "," "," "," "," ",{"v":1.05,"d":"$ 1.05"}," "]
["Debt instrument, convertible, threshold consecutive trading days | trading_day",{"v":5,"d":"5 "}," "," "," "," "," "," "]
["Debt instrument, fixed price (in dollars per share) | $ / shares"," "," "," "," "," ",1.16," "]
["Debt instrument, term (in years)","1 year"," "," "," "," "," "," "]
["Conversion price (in dollars per share) | $ / shares"," "," ",{"v":5.24,"d":"$ 5.24"}," ",{"v":1.16,"d":"$ 1.16"},{"v":5.24,"d":"$ 5.24"}," "]
["Notes and loans payable",{"v":6060,"d":"$ 6,060"}," "," ",{"v":26059,"d":"$ 26,059"}," "," "," "]
["Fair value adjustments of debt",{"v":10435,"d":"10,435 "}," "," "," "," "," "," "]
["Junior Secured SPA Notes | Notes Payable | Class A Common Stock"," "," "," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "," "," "]
["Debt conversion, converted amount",{"v":15400,"d":"$ 15,400"}," "," "," "," "," "," "]
["Shares issued from conversion (in shares) | shares",{"v":113958070,"d":"113,958,070 "}," "," "," "," "," "," "]
["Gain (loss) extinguishments of debt",{"v":-12800,"d":"$ (12,800)"}," "," "," "," "," "," "]

{"sheet":"Notes Payable - 2024 Unsecured ","index":55,"n_rows":20,"n_cols":6,"rows_kept":20,"merged":[[0,0,1,0],[0,1,0,2]]}
["Notes Payable - 2024 Unsecured SPA Notes Narrative (Details) $ / shares in Units, $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025 USD ($) day $ / shares","Mar. 31, 2024 USD ($)","Jan. 28, 2025 $ / shares","Dec. 31, 2024","Dec. 21, 2024 $ / shares"]
["Debt Instrument [Line Items]"," "," "," "," "," "]
["Payments of notes payable issuance costs",{"v":99,"d":"$ 99"},{"v":25,"d":"$ 25"}," "," "," "]
["2024 Unsecured SPA Warrants"," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "]
["Percent of purchaser's conversion shares",{"v":1,"d":"100%"}," "," "," "," "]
["Debt instrument, term (in years)","5 years"," "," "," "," "]
["2024 Unsecured SPA Notes"," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "]
["Debt instrument, convertible, threshold consecutive trading days | day",{"v":1,"d":"1 "}," "," "," "," "]
["2024 Unsecured SPA Notes | Notes Payable"," "," "," "," "," "]
["Debt Instrument [Line Items]"," "," "," "," "," "]
["Notes payable bearing interest rate",{"v":0.1,"d":"10%"}," "," ",{"v":0.1,"d":"10%"}," "]
["Conversion price (in dollars per share) | $ / shares",{"v":1.16,"d":"$ 1.16"}," ",{"v":1.16,"d":"$ 1.16"}," ",{"v":1.16,"d":"$ 1.16"}]
["Debt instrument, floor price (in dollars per share) | $ / shares",{"v":1.05,"d":"$ 1.05"}," "," "," "," "]
["Debt instrument, convertible, threshold consecutive trading days | day",{"v":5,"d":"5 "}," "," "," "," "]
["Debt instrument, term (in years)","1 year"," "," "," "," "]
["Proceeds from debt, net of issuance costs",{"v":20000,"d":"$ 20,000"}," "," "," "," "]
["Payments of notes payable issuance costs",{"v":0,"d":"$ 0"}," "," "," "," "]

{"sheet":"Notes Payable - 2025 March Unse","index":56,"n_rows":26,"n_cols":4,"rows_kept":26,"merged":[[0,0,1,0],[0,2,0,3]]}
["Notes Payable - 2025 March Unsecured SPA Notes Narrative (Details) $ / shares in Units, $ in Thousands",null,"3 Months Ended"]
[null,"Mar. 21, 2025 USD ($) day closing $ / shares","Mar. 31, 2025 USD ($)","Mar. 31, 2024 USD ($)"]
["Debt Instrument [Line Items]"," "," "," "]
["Payments of notes payable issuance costs"," ",{"v":99,"d":"$ 99"},{"v":25,"d":"$ 25"}]
["Notes Payable"," "," "," "]
["Debt Instrument [Line Items]"," "," "," "]
["Gain (loss) on fair value adjustment of debts"," ",{"v":21780,"d":"21,780 "},{"v":27721,"d":"$ 27,721"}]
["2025 March Unsecured SPA Notes"," "," "," "]
["Debt Instrument [Line Items]"," "," "," "]
["Aggregate principal amount",{"v":41000,"d":"$ 41,000"}," "," "]
["Debt instrument, number of closings | closing",{"v":4,"d":"4 "}," "," "]
["Debt instrument, term (in years)","5 years"," "," "]
["Notes payable bearing interest rate",{"v":0.1,"d":"10%"}," "," "]
["Debt instrument, redemption price, percentage",{"v":0.1,"d":"10%"}," "," "]
["Redemption price, percentage",{"v":0.25,"d":"25%"}," "," "]
["Conversion price (in dollars per share) | $ / shares",{"v":1.29,"d":"$ 1.29"}," "," "]
["Debt instrument, floor price (in dollars per share) | $ / shares",{"v":1.048,"d":"$ 1.048"}," "," "]
["2025 March Unsecured SPA Notes | Notes Payable"," "," "," "]
["Debt Instrument [Line Items]"," "," "," "]
["Proceeds from debt, net of issuance costs"," ",{"v":2300,"d":"$ 2,300"}," "]
["Notes payable bearing interest rate",{"v":0.18,"d":"18%"},{"v":0.1,"d":"10%"}," "]
["Redemption price, percentage",{"v":0.08,"d":"8%"}," "," "]
["Notes payable"," ",{"v":800,"d":"$ 800"}," "]
["Payments of notes payable issuance costs"," ",{"v":100,"d":"100 "}," "]
["Gain (loss) on fair value adjustment of debts"," ",{"v":44,"d":"$ 44"}," "]
["Debt instrument, convertible, threshold consecutive trading days | day",{"v":5,"d":"5 "}," "," "]

{"sheet":"Notes Payable - Notes Payable, ","index":57,"n_rows":4,"n_cols":3,"rows_kept":4}
["Notes Payable - Notes Payable, China Other Narrative (Details)","Mar. 31, 2025","Dec. 31, 2024"]
["Notes payable – China other | Notes Payable"," "," "]
["Debt Instrument [Line Items]"," "," "]
["Notes payable bearing interest rate",{"v":0,"d":"0%"},{"v":0,"d":"0%"}]

{"sheet":"Notes Payable - Auto Loans Narr","index":58,"n_rows":8,"n_cols":4,"rows_kept":8,"merged":[[0,0,1,0],[0,1,0,2]]}
["Notes Payable - Auto Loans Narrative (Details) - Notes Payable - USD ($)","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024"]
["Debt Instrument [Line Items]"," "," "," "]
["Repayments of debt",{"v":6000,"d":"$ 6,000"},{"v":10000,"d":"$ 10,000"}," "]
["Auto loans"," "," "," "]
["Debt Instrument [Line Items]"," "," "," "]
["Notes payable bearing interest rate"," "," ",{"v":0.07,"d":"7%"}]
["Repayments of debt",{"v":6000,"d":"$ 6,000"},{"v":10000,"d":"$ 10,000"}," "]

{"sheet":"Related Party Transactions - Sc","index":59,"n_rows":42,"n_cols":6,"rows_kept":42}
["Related Party Transactions - Schedule of Related Party Notes Payable (Details) - Related Party - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024","Feb. 29, 2024","Jan. 31, 2024","Nov. 30, 2023"]
["Related Party Transaction [Line Items]"," "," "," "," "," "]
["Net Carrying Value",{"v":7123,"d":"$ 7,123"},{"v":8064,"d":"$ 8,064"}," "," "," "]
["Related party notes payable, current",{"v":4298,"d":"4,298 "},{"v":5310,"d":"5,310 "}," "," "," "]
["Related party notes payable, long-term",{"v":2825,"d":"$ 2,825"},{"v":2754,"d":"$ 2,754"}," "," "," "]
["Unsecured Convertible Note"," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "]
["Contractual Interest Rates",{"v":0.0427,"d":"4.27%"},{"v":0.0427,"d":"4.27%"}," "," "," "]
["Net Carrying Value",{"v":451,"d":"$ 451"}," "," "," "," "]
["2025 March Unsecured SPA Notes"," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "]
["Contractual Interest Rates",{"v":0.1,"d":"10%"}," "," "," "," "]
["Net Carrying Value",{"v":143,"d":"$ 143"}," "," "," "," "]
["Unsecured Convertible Note"," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "]
["Net Carrying Value"," ",{"v":1364,"d":"$ 1,364"}," "," "," "]
["Notes Payable — China"," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "]
["Contractual Interest Rates",{"v":0.18,"d":"18%"},{"v":0.18,"d":"18%"}," "," "," "]
["Net Carrying Value",{"v":4215,"d":"$ 4,215"},{"v":4382,"d":"$ 4,382"}," "," "," "]
["Notes Payable on Demand — China"," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "]
["Contractual Interest Rates",{"v":0,"d":"0%"},{"v":0,"d":"0%"}," "," "," "]
["Net Carrying Value",{"v":413,"d":"$ 413"},{"v":417,"d":"$ 417"}," "," "," "]
["FFGP Note"," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "]
["Contractual Interest Rates",{"v":0.0427,"d":"4.27%"},{"v":0.0427,"d":"4.27%"}," "," "," "]
["Net Carrying Value",{"v":1576,"d":"$ 1,576"},{"v":1576,"d":"$ 1,576"}," ",{"v":1600,"d":"$ 1,600"},{"v":1600,"d":"$ 1,600"}]
["FFGP Note | Minimum"," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "]
["Contractual Interest Rates",{"v":0.0427,"d":"4.27%"}," "," "," "," "]
["FFGP Note | Maximum"," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "]
["Contractual Interest Rates",{"v":0.0527,"d":"5.27%"}," "," "," "," "]
["Convertible FFGP Note"," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "]
["Contractual Interest Rates",{"v":0.0427,"d":"4.27%"}," ",{"v":0.0427,"d":"4.27%"}," "," "]
["Net Carrying Value",{"v":250,"d":"$ 250"},{"v":250,"d":"$ 250"},{"v":300,"d":"$ 300"}," "," "]
["Other Notes"," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "]
["Contractual Interest Rates",{"v":0.12,"d":"12%"},{"v":0.12,"d":"12%"}," "," "," "]
["Net Carrying Value",{"v":75,"d":"$ 75"},{"v":75,"d":"$ 75"}," "," "," "]

{"sheet":"Related Party Transactions - _2","index":60,"n_rows":14,"n_cols":3,"rows_kept":14}
["Related Party Transactions - Schedule of Principal Maturities of Related Party Notes Payable (Details) - Related Party - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Related Party Transaction [Line Items]"," "," "]
["Total",{"v":7123,"d":"$ 7,123"},{"v":8064,"d":"$ 8,064"}]
["Notes Payable, Related Party"," "," "]
["Related Party Transaction [Line Items]"," "," "]
["Due on demand",{"v":488,"d":"488 "}," "]
["2025 (9 months remaining)",{"v":4813,"d":"4,813 "}," "]
["2026",{"v":1983,"d":"1,983 "}," "]
["2027",{"v":745,"d":"745 "}," "]
["2028",{"v":0,"d":"0 "}," "]
["2029",{"v":0,"d":"0 "}," "]
["2030",{"v":376,"d":"376 "}," "]
["Thereafter",{"v":0,"d":"0 "}," "]
["Total",{"v":8405,"d":"$ 8,405"}," "]

{"sheet":"Related Party Transactions - Na","index":61,"n_rows":103,"n_cols":12,"rows_kept":103,"merged":[[0,0,1,0],[0,4,0,5]]}
["Related Party Transactions - Narrative (Details)",null,null,"1 Months Ended","3 Months Ended",null,"12 Months Ended","51 Months Ended"]
[null,"Mar. 06, 2023","Feb. 01, 2023 USD ($)","Oct. 31, 2024 USD ($) shares","Mar. 31, 2025 USD ($) shares","Mar. 31, 2024 USD ($)","Dec. 31, 2024 USD ($)","Mar. 31, 2022 lease","Feb. 29, 2024 USD ($)","Jan. 31, 2024 USD ($)","Nov. 30, 2023 USD ($)","Jan. 31, 2023 USD ($)"]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Additional paid-in capital"," "," "," ",{"v":4456374000,"d":"$ 4,456,374,000"}," ",{"v":4421563000,"d":"$ 4,421,563,000"}," "," "," "," "," "]
["Debt instrument, penalties and interest accrued"," "," "," ",{"v":22200000,"d":"22,200,000 "}," ",{"v":23100000,"d":"23,100,000 "}," "," "," "," "," "]
["Accounts payable"," "," "," ",{"v":61492000,"d":"61,492,000 "}," ",{"v":56754000,"d":"56,754,000 "}," "," "," "," "," "]
["Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss on settlement of notes payable"," "," "," ",{"v":1180000,"d":"1,180,000 "},{"v":14295000,"d":"$ 14,295,000"}," "," "," "," "," "," "]
["Unpaid Principal Balance"," "," "," ",{"v":7123000,"d":"7,123,000 "}," ",{"v":8064000,"d":"8,064,000 "}," "," "," "," "," "]
["Change in fair value of notes payable, warrant liabilities, and derivative call options"," "," "," ",{"v":-277000,"d":"(277,000)"},{"v":-7000,"d":"(7,000)"}," "," "," "," "," "," "]
["Accounts payable"," "," "," ",{"v":11104000,"d":"11,104,000 "}," ",{"v":11077000,"d":"11,077,000 "}," "," "," "," "," "]
["2023 Unsecured SPA Notes | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid Principal Balance"," "," "," ",{"v":0,"d":"0 "}," "," "," "," "," "," "," "]
["2025 March Unsecured SPA Notes | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid Principal Balance"," "," "," ",{"v":143000,"d":"$ 143,000"}," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," "," "," ",{"v":0.1,"d":"10%"}," "," "," "," "," "," "," "]
["Change in fair value of notes payable, warrant liabilities, and derivative call options"," "," "," ",{"v":0,"d":"$ 0"}," "," "," "," "," "," "," "]
["Notes Payable — China | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss on settlement of notes payable"," "," "," "," ",{"v":14100000,"d":"14,100,000 "}," "," "," "," "," "," "]
["Unpaid Principal Balance"," "," "," ",{"v":4215000,"d":"$ 4,215,000"}," ",{"v":4382000,"d":"$ 4,382,000"}," "," "," "," "," "]
["Notes payable bearing interest rate"," "," "," ",{"v":0.18,"d":"18%"}," ",{"v":0.18,"d":"18%"}," "," "," "," "," "]
["Repayments of debt"," "," "," ",{"v":100000,"d":"$ 100,000"}," ",{"v":100000,"d":"$ 100,000"}," "," "," "," "," "]
["Additional paid-in capital"," "," "," ",{"v":700000,"d":"700,000 "}," "," "," "," "," "," "," "]
["Notes Payable on Demand — China | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid Principal Balance"," "," "," ",{"v":413000,"d":"$ 413,000"}," ",{"v":417000,"d":"$ 417,000"}," "," "," "," "," "]
["Notes payable bearing interest rate"," "," "," ",{"v":0,"d":"0%"}," ",{"v":0,"d":"0%"}," "," "," "," "," "]
["FFGP Note | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid Principal Balance"," "," "," ",{"v":1576000,"d":"$ 1,576,000"}," ",{"v":1576000,"d":"$ 1,576,000"}," "," ",{"v":1600000,"d":"$ 1,600,000"},{"v":1600000,"d":"$ 1,600,000"}," "]
["Debt instrument, term (in years)"," "," "," ","3 months"," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," "," "," ",{"v":0.0427,"d":"4.27%"}," ",{"v":0.0427,"d":"4.27%"}," "," "," "," "," "]
["FFGP Note | Related Party | Minimum"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," "," "," ",{"v":0.0427,"d":"4.27%"}," "," "," "," "," "," "," "]
["FFGP Note | Related Party | Maximum"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," "," "," ",{"v":0.0527,"d":"5.27%"}," "," "," "," "," "," "," "]
["Convertible FFGP Note | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid Principal Balance"," "," "," ",{"v":250000,"d":"$ 250,000"}," ",{"v":250000,"d":"$ 250,000"}," ",{"v":300000,"d":"$ 300,000"}," "," "," "]
["Notes payable bearing interest rate"," "," "," ",{"v":0.0427,"d":"4.27%"}," "," "," ",{"v":0.0427,"d":"4.27%"}," "," "," "]
["Rancho Palos Verdes Real Property Leases | Affiliated Entity"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Number of leases | lease"," "," "," "," "," "," ",{"v":2,"d":"2 "}," "," "," "," "]
["Accounts payable"," "," "," ",{"v":300000,"d":"$ 300,000"}," ",{"v":300000,"d":"300,000 "}," "," "," "," "," "]
["X-Butler | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Payments with related party (less than)"," "," "," ",{"v":100000,"d":"100,000 "},{"v":100000,"d":"100,000 "}," "," "," "," "," "," "]
["FF Top Executive Reimbursements | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Accounts payable"," "," "," ",{"v":2000000,"d":"2,000,000 "}," ",{"v":2000000,"d":"2,000,000 "}," "," "," "," "," "]
["Monthly fee"," ",{"v":200000,"d":"$ 200,000"}," "," "," "," "," "," "," "," "," "]
["Additional term and permitted (in months)","12 months"," "," "," "," "," "," "," "," "," "," "]
["Legal expense reimbursement requested"," "," "," ",{"v":6500000,"d":"6,500,000 "}," "," "," "," "," "," ",{"v":6500000,"d":"$ 6,500,000"}]
["Leshi Information Technology Co., Ltd. (“LeTV”) | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Accounts payable"," "," "," ",{"v":7800000,"d":"7,800,000 "}," ",{"v":7700000,"d":"7,700,000 "}," "," "," "," "," "]
["Grow Fandor | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Aggregate principal amount"," "," "," "," "," ",{"v":75000,"d":"75,000 "}," "," "," "," "," "]
["Donation received (in shares) | shares"," "," ",{"v":15000000,"d":"15,000,000 "}," "," "," "," "," "," "," "," "]
["Net profit percentage"," "," ",{"v":0.5,"d":"50%"}," "," "," "," "," "," "," "," "]
["Net sales revenue, percentage"," "," ",{"v":0.05,"d":"5%"}," "," "," "," "," "," "," "," "]
["Annual base license fee"," "," ",{"v":250000,"d":"$ 250,000"}," "," "," "," "," "," "," "," "]
["Grow Fandor | Related Party | Faraday Future"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Subsidiary, ownership percentage, parent"," "," ",{"v":0.1,"d":"10%"}," "," "," "," "," "," "," "," "]
["Notes Payable"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid Principal Balance"," "," "," ",{"v":52078000,"d":"52,078,000 "}," ",{"v":50577000,"d":"$ 50,577,000"}," "," "," "," "," "]
["Fair value adjustments of debt"," "," "," ",{"v":21780000,"d":"21,780,000 "},{"v":27721000,"d":"27,721,000 "}," "," "," "," "," "," "]
["Repayments of debt"," "," "," ",{"v":6000,"d":"6,000 "},{"v":10000,"d":"10,000 "}," "," "," "," "," "," "]
["Notes Payable | 2025 March Unsecured SPA Notes | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid Principal Balance"," "," "," ",{"v":400000,"d":"$ 400,000"}," "," "," "," "," "," "," "]
["Secured Notes | Notes Payable"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Shares issued from conversion (in shares) | shares"," "," "," ",{"v":1352767,"d":"1,352,767 "}," "," "," "," "," "," "," "]
["Secured Notes | Notes Payable | Class A Common Stock"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Loss on settlement of notes payable"," "," "," ",{"v":-1200000,"d":"$ (1,200,000)"}," "," "," "," "," "," "," "]
["Unsecured Notes | Notes Payable"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Fair value adjustments of debt"," "," "," ",{"v":0,"d":"0 "},{"v":100000,"d":"$ 100,000"}," "," "," "," "," "," "]
["Metaverse Horizon Limited and V W Investment Holding Limited | Unsecured SPA Notes and Warrants | Notes Payable"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Debt conversion, converted amount"," "," "," ",{"v":700000,"d":"$ 700,000"}," "," "," "," "," "," "," "]
["Conversion of notes payable and accrued interest into Class A Common Stock (in shares) | shares"," "," "," ",{"v":33107,"d":"33,107 "}," "," "," "," "," "," "," "]
["Loss on settlement of notes payable"," "," "," ",{"v":200000,"d":"$ 200,000"}," "," "," "," "," "," "," "]
["Loss on fair value of adjustments"," "," "," ",{"v":100000,"d":"$ 100,000"}," "," "," "," "," "," "," "]
["Metaverse Horizon Limited | Related Party Notes – Unsecured Convertible Note | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid Principal Balance"," "," "," "," "," "," "," "," ",{"v":1500000,"d":"$ 1,500,000"}," "," "]
["Senyun and Metaverse Horizon Limited | Related Party Notes – Unsecured Convertible Note | Related Party"," "," "," "," "," "," "," "," "," "," "," "]
["Related Party Transaction [Line Items]"," "," "," "," "," "," "," "," "," "," "," "]
["Debt instrument, term (in years)"," "," "," ","3 months"," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," "," "," ",{"v":0.0427,"d":"4.27%"}," "," "," "," "," "," "," "]
["Debt Instrument original issue discount percentage"," "," "," ",{"v":0.15,"d":"15%"}," "," "," "," "," "," "," "]

{"sheet":"Other Financing Liabilities - N","index":62,"n_rows":40,"n_cols":9,"rows_kept":40,"merged":[[0,0,1,0],[0,4,0,5]]}
["Other Financing Liabilities - Narrative (Details)",null,null,"1 Months Ended","3 Months Ended"]
[null,"Aug. 27, 2024 USD ($)","Oct. 19, 2023 USD ($)","Jan. 31, 2025 USD ($)","Mar. 31, 2025 USD ($)","Mar. 31, 2024 USD ($)","Dec. 31, 2024 USD ($)","Jul. 11, 2024 USD ($) payment","Mar. 14, 2024 USD ($)"]
["Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"," "," "," "," "," "," "," "," "]
["Proceeds from other financial obligations"," ",{"v":-1100000,"d":"$ (1,100,000)"}," ",{"v":1133000,"d":"$ 1,133,000"},{"v":0,"d":"$ 0"}," "," "," "]
["Liability, lease repayment plan"," "," "," "," "," "," "," ",{"v":1700000,"d":"$ 1,700,000"}]
["Security deposit"," "," "," "," "," "," "," ",{"v":1500000,"d":"1,500,000 "}]
["Security deposit, past due amount"," "," "," "," "," "," "," ",{"v":600000,"d":"$ 600,000"}]
["Payment for security deposit"," "," ",{"v":600000,"d":"$ 600,000"}," "," "," "," "," "]
["Proceeds from tenant allowance",{"v":12000000,"d":"$ 12,000,000"}," "," "," "," "," "," "," "]
["Reimbursing tenant improvement allowance",{"v":10000000,"d":"10,000,000 "}," "," "," "," "," "," "," "]
["Other improvement costs, tenant improvement allowance",{"v":2000000,"d":"$ 2,000,000"}," "," "," "," "," "," "," "]
["Other improvement costs, tenant improvement allowance, percentage",{"v":0.6667,"d":"66.67%"}," "," "," "," "," "," "," "]
["Leasehold improvements, gross"," "," "," ",{"v":8000000,"d":"8,000,000 "}," ",{"v":6900000,"d":"$ 6,900,000"}," "," "]
["Interest expense"," "," "," ",{"v":1900000,"d":"1,900,000 "},{"v":1700000,"d":"1,700,000 "}," "," "," "]
["Sale and leaseback transaction, liability, noncurrent"," "," "," ",{"v":36500000,"d":"36,500,000 "},{"v":33700000,"d":"33,700,000 "}," "," "," "]
["Other financing liabilities, current portion"," "," "," ",{"v":803000,"d":"803,000 "}," ",{"v":761000,"d":"761,000 "}," "," "]
["Other financing liabilities, long term portion"," "," "," ",{"v":40489000,"d":"40,489,000 "}," ",{"v":38698000,"d":"38,698,000 "}," "," "]
["Notes Payable"," "," "," "," "," "," "," "," "]
["Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"," "," "," "," "," "," "," "," "]
["Long-term debt"," "," "," ",{"v":24674000,"d":"24,674,000 "}," ",{"v":49488000,"d":"49,488,000 "}," "," "]
["Repayments of debt"," "," "," ",{"v":6000,"d":"6,000 "},{"v":10000,"d":"$ 10,000"}," "," "," "]
["Collateralized Loan Obligations"," "," "," "," "," "," "," "," "]
["Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"," "," "," "," "," "," "," "," "]
["Long-term debt"," "," "," ",{"v":4100000,"d":"4,100,000 "}," ",{"v":4300000,"d":"4,300,000 "}," "," "]
["Other financing liabilities, current portion"," "," "," ",{"v":800000,"d":"800,000 "}," ",{"v":800000,"d":"800,000 "}," "," "]
["Other financing liabilities, long term portion"," "," "," ",{"v":3300000,"d":"$ 3,300,000"}," ",{"v":3500000,"d":"$ 3,500,000"}," "," "]
["Collateralized Loan Obligations | Notes Payable"," "," "," "," "," "," "," "," "]
["Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"," "," "," "," "," "," "," "," "]
["Notes payable bearing interest rate"," "," "," ",{"v":0.23,"d":"23%"}," "," "," "," "]
["Number of monthly payments | payment"," "," "," "," "," "," ",{"v":51,"d":"51 "}," "]
["Debt instrument, periodic payment"," "," "," ",{"v":100000,"d":"$ 100,000"}," "," "," "," "]
["Debt instrument, periodic payment terms, balloon payment to be paid"," "," "," "," "," "," ",{"v":500000,"d":"$ 500,000"}," "]
["Repayments of debt"," "," "," ",{"v":200000,"d":"200,000 "}," "," "," "," "]
["Ocean West Capital Partners (“Landlord”) | Hanford Manufacturing Facility"," "," "," "," "," "," "," "," "]
["Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"," "," "," "," "," "," "," "," "]
["Tenant improvement allowance"," ",{"v":12000000,"d":"$ 12,000,000"}," "," "," "," "," "," "]
["Lease term (in years)"," ","5 years"," "," "," "," "," "," "]
["Monthly lease rate"," ",{"v":355197,"d":"$ 355,197"}," "," "," "," "," "," "]
["Lease term extension option (in years)"," ","5 years"," "," "," "," "," "," "]
["Loss from failed sale leaseback arrangement"," "," "," ",{"v":0,"d":"$ 0"}," "," "," "," "]

{"sheet":"Other Financing Liabilities - F","index":63,"n_rows":7,"n_cols":2,"rows_kept":7}
["Other Financing Liabilities - Future Scheduled Payments of Financing Obligations (Details) $ in Thousands","Mar. 31, 2025 USD ($)"]
["Organization, Consolidation and Presentation of Financial Statements [Abstract]"," "]
["2025 ( 9 months remaining)",{"v":582,"d":"$ 582"}]
["2026",{"v":951,"d":"951 "}]
["2027",{"v":1189,"d":"1,189 "}]
["2028",{"v":60455,"d":"60,455 "}]
["Future minimum lease payments, sale leaseback transactions, minimum liability requirements",{"v":63177,"d":"$ 63,177"}]

{"sheet":"Commitments and Contingencies (","index":64,"n_rows":89,"n_cols":28,"rows_kept":89,"merged":[[0,0,1,0],[0,16,0,20]]}
["Commitments and Contingencies (Details) shares in Thousands, $ in Thousands",{"$nulls":15},"1 Months Ended",{"$nulls":4},"3 Months Ended"]
[null,"Mar. 06, 2025 USD ($)","Aug. 09, 2024 USD ($) shares","Aug. 01, 2024 USD ($)","Apr. 10, 2024 USD ($)","Mar. 29, 2024 USD ($)","Mar. 26, 2024 USD ($)","Mar. 25, 2024 USD ($)","Mar. 11, 2024 USD ($)","Jan. 26, 2024 USD ($)","Dec. 08, 2023 USD ($)","Jul. 07, 2023 USD ($)","Jun. 29, 2023 USD ($)","Jun. 13, 2023 USD ($)","May 02, 2023 USD ($)","Apr. 14, 2022","Mar. 31, 2025 USD ($)","Dec. 31, 2024 USD ($)","Jun. 30, 2024 USD ($)","May 31, 2024 USD ($)","Feb. 29, 2024 USD ($)","Mar. 31, 2025 USD ($)","Jul. 31, 2024 USD ($)","Feb. 14, 2024 USD ($)","Oct. 19, 2023 USD ($)","Apr. 26, 2023 USD ($)","Jan. 31, 2023 USD ($)","Nov. 15, 2021 reservation"]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Accrued legal contingencies"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":6615,"d":"$ 6,615"},{"v":9091,"d":"$ 9,091"}," "," "," ",{"v":6615,"d":"$ 6,615"}," "," "," "," "," "," "]
["Legal claims were settled in cash"," "," "," "," "," "," "," "," "," "," "," ",{"v":7500,"d":"$ 7,500"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss contingency, initial deposit"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1900,"d":"1,900 "}," "," "," "," ",{"v":1900,"d":"1,900 "}," "," "," "," "," "," "]
["Loss continency, tooling equipment"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":12900,"d":"12,900 "}," "," "," "," ",{"v":12900,"d":"12,900 "}," "," "," "," "," "," "]
["Loss contingency, loss in period"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":2700,"d":"2,700 "}," "," "," "," "," "," "]
["Estimate of possible loss"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":500,"d":"500 "}," "," "," "," ",{"v":500,"d":"500 "}," "," "," "," "," "," "]
["Litigation settlement, amount awarded to other party"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":350,"d":"350 "}," "," "," "," "," "," "," "," "," "," "," "]
["Number of reservations received for vehicles | reservation"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":14000,"d":"14,000 "}]
["Number of unpaid indications of interest | reservation"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":14000,"d":"14,000 "}]
["Probation period"," "," "," "," "," "," "," "," "," "," "," "," "," "," ","6 months"," "," "," "," "," "," "," "," "," "," "," "," "]
["Chief Executive Officer"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Annual base salary reduction"," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.25,"d":"25%"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Chief Product and User Ecosystem Officer"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Annual base salary reduction"," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":0.25,"d":"25%"}," "," "," "," "," "," "," "," "," "," "," "," "]
["Raymond Handling Solutions, Inc. (“Raymond”) | Pending Litigation"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Estimate of possible loss"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1100,"d":"$ 1,100"}," "]
["Palantir Technologies Inc."," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages sought"," "," "," "," "," "," "," "," "," "," ",{"v":41500,"d":"$ 41,500"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss contingency, unpaid invoices"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":12300,"d":"$ 12,300"}," "," "]
["Damages awarded"," "," "," "," "," "," "," ",{"v":5000,"d":"$ 5,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages awarded, liquidation damages clause"," "," "," "," "," "," "," ",{"v":300,"d":"$ 300"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss contingency, remaining damages to be awarded, value"," ",{"v":4800,"d":"$ 4,800"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issuance of common stock (in shares) | shares"," ",{"v":11100,"d":"11,100 "}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Palantir Technologies Inc. | Stock Issuance, Tranche One"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issuance of common stock"," ",{"v":2400,"d":"$ 2,400"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Palantir Technologies Inc. | Stock Issuance, Tranche Two"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Issuance of common stock"," ",{"v":2400,"d":"$ 2,400"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Envisage Group Developments Inc. USA (“Envisage”)"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages sought"," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1100,"d":"$ 1,100"}," "," "," ",{"v":1100,"d":"$ 1,100"}," "," "," "," "," "," "," "," "," "]
["Litigation settlement, amount awarded to other party"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":800,"d":"800 "}," "," "," "," "," "," "," "," "," "]
["Damages awarded"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1400,"d":"$ 1,400"}," "," "," "," "," "," "," "," "," "]
["L & W LLC (“Autokiniton”)"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Estimate of possible loss"," "," "," "," "," "," "," "," "," "," "," "," ",{"v":8100,"d":"$ 8,100"}," "," "," "," "," "," "," "," ",{"v":8100,"d":"$ 8,100"}," "," "," "," "," "]
["Litigation settlement, amount awarded to other party"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":3700,"d":"$ 3,700"}," "," "," "," "," "," "," "," "," "," "]
["Damages awarded"," "," "," "," "," "," "," "," "," "," "," "," ",{"v":4600,"d":"$ 4,600"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Rexford Industrial - 18455 Figueroa, LCC (\"Rexford\")"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid rent"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":900,"d":"$ 900"}," "," "," "," "]
["Draexlmaier Automotive Technologies of America LLC"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages sought"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":5000,"d":"$ 5,000"},{"v":3200,"d":"$ 3,200"}," "," "," "," "," "," "," "]
["Tesca USA vs. Faraday&Future Inc."," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Payments for property, plant and equipment, preproduction design and development costs",{"v":36000,"d":"$ 36,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages sought",{"v":36000,"d":"$ 36,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Cooper Standard GmbH vs. Faraday&Future Inc. | Pending Litigation"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages sought"," "," "," "," "," "," ",{"v":1500,"d":"$ 1,500"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Jose Guerrero and Victoria Xie vs. Faraday&Future Inc. | Pending Litigation"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages sought"," "," "," "," ",{"v":1000,"d":"$ 1,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Yun Han vs. Faraday&Future Inc. | Pending Litigation"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages sought"," "," ",{"v":1200,"d":"$ 1,200"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Bankruptcy Matter, Deposit Write-off"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss contingency, loss in period"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1400,"d":"1,400 "}," "," "," "," "," "," "]
["Bankruptcy Matter, Additional Payments"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss contingency, loss in period"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1300,"d":"$ 1,300"}," "," "," "," "," "," "]
["Unpaid Rent, October - December 2023 | 10701 Idaho Owner, LLC (“Landlord”)"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Rental defaults"," "," "," "," "," "," "," "," "," ",{"v":600,"d":"$ 600"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages sought, late fee (in percent)"," "," "," "," "," "," "," "," "," ",{"v":0.05,"d":"5%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages sought, annual interest (in percent)"," "," "," "," "," "," "," "," "," ",{"v":0.18,"d":"18%"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid Rent"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss contingency, alleging unpaid rent"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1000,"d":"$ 1,000"}," "," "," "," "," "," "," "," "," "," "," "]
["Unpaid Rent | 10701 Idaho Owner, LLC (“Landlord”)"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Loss Contingencies [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages sought"," "," "," "," "," ",{"v":1000,"d":"$ 1,000"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Rental defaults"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1100,"d":"$ 1,100"}," "," "," "]
["Rental defaults, partial payment"," "," "," "," "," "," "," "," ",{"v":100,"d":"$ 100"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Rental defaults, late fees and charges"," "," "," "," "," "," "," "," ",{"v":200,"d":"$ 200"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Rental defaults payable"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":1200,"d":"1,200 "}," "," "," "]
["Amount of letter of credit required to be replenished or provided"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," ",{"v":600,"d":"$ 600"}," "," "," "]
["Damages sought, maximum payment term (in days)"," "," "," "," "," ","5 days"," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]
["Damages paid"," "," "," ",{"v":200,"d":"$ 200"}," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "," "]

{"sheet":"Stockholders_ Equity - Schedule","index":65,"n_rows":18,"n_cols":10,"rows_kept":18}
["Stockholders’ Equity - Schedule of Common Stock (Details) - shares","Mar. 31, 2025","Mar. 06, 2025","Dec. 31, 2024","Aug. 31, 2024","Aug. 04, 2024","Jul. 31, 2024","Feb. 23, 2024","Feb. 05, 2024","Feb. 04, 2024"]
["Authorized \u2028Shares"," "," "," "," "," "," "," "," "," "]
["Preferred stock, shares authorized (in shares)",{"v":10000000,"d":"10,000,000 "}," ",{"v":10000000,"d":"10,000,000 "}," "," ",{"v":114245313,"d":"114,245,313 "},{"v":12582813,"d":"12,582,813 "}," "," "]
["Common stock, shares authorized (in shares)"," ",{"v":104245313,"d":"104,245,313 "}," ",{"v":104245313,"d":"104,245,313 "},{"v":104245313,"d":"104,245,313 "},{"v":104245313,"d":"104,245,313 "},{"v":11582813,"d":"11,582,813 "},{"v":34748438,"d":"34,748,438 "},{"v":3860938,"d":"3,860,938 "}]
["Authorized Shares (in shares)",{"v":139245313,"d":"139,245,313 "}," ",{"v":114245313,"d":"114,245,313 "}," "," "," "," "," "," "]
["Issued Shares"," "," "," "," "," "," "," "," "," "]
["Preferred stock, shares issued (in shares)",{"v":0,"d":"0 "}," ",{"v":1,"d":"1 "}," "," "," "," "," "," "]
["Shares issued (in shares)",{"v":86793415,"d":"86,793,415 "}," ",{"v":65925795,"d":"65,925,795 "}," "," "," "," "," "," "]
["Class A Common Stock"," "," "," "," "," "," "," "," "," "]
["Authorized \u2028Shares"," "," "," "," "," "," "," "," "," "]
["Common stock, shares authorized (in shares)",{"v":124815625,"d":"124,815,625 "}," ",{"v":99815625,"d":"99,815,625 "}," "," "," "," "," "," "]
["Issued Shares"," "," "," "," "," "," "," "," "," "]
["Common stock, shares issued (in shares)",{"v":86786748,"d":"86,786,748 "}," ",{"v":65919127,"d":"65,919,127 "}," "," "," "," "," "," "]
["Class B Common Stock"," "," "," "," "," "," "," "," "," "]
["Authorized \u2028Shares"," "," "," "," "," "," "," "," "," "]
["Common stock, shares authorized (in shares)",{"v":4429688,"d":"4,429,688 "}," ",{"v":4429688,"d":"4,429,688 "}," "," "," "," "," "," "]
["Issued Shares"," "," "," "," "," "," "," "," "," "]
["Common stock, shares issued (in shares)",{"v":6667,"d":"6,667 "}," ",{"v":6667,"d":"6,667 "}," "," "," "," "," "," "]

{"sheet":"Stockholders_ Equity - Amendmen","index":66,"n_rows":20,"n_cols":13,"rows_kept":20}
["Stockholders’ Equity - Amendments to the Company’s Certificate of Incorporation (Details)","Aug. 04, 2024 shares","Aug. 01, 2024","Jul. 31, 2024 $ / shares shares","Feb. 29, 2024","Feb. 05, 2024 shares","Mar. 31, 2025 shares","Mar. 07, 2025 shares","Mar. 06, 2025 shares","Dec. 31, 2024 shares","Aug. 31, 2024 shares","Feb. 23, 2024 shares","Feb. 04, 2024 shares"]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Preferred stock, shares authorized (in shares)"," "," ",{"v":114245313,"d":"114,245,313 "}," "," ",{"v":10000000,"d":"10,000,000 "}," "," ",{"v":10000000,"d":"10,000,000 "}," ",{"v":12582813,"d":"12,582,813 "}," "]
["Common stock, shares authorized (in shares)",{"v":104245313,"d":"104,245,313 "}," ",{"v":104245313,"d":"104,245,313 "}," ",{"v":34748438,"d":"34,748,438 "}," "," ",{"v":104245313,"d":"104,245,313 "}," ",{"v":104245313,"d":"104,245,313 "},{"v":11582813,"d":"11,582,813 "},{"v":3860938,"d":"3,860,938 "}]
["Exercise price (in dollars per share) | $ / shares"," "," ",{"v":110400,"d":"$ 110,400"}," "," "," "," "," "," "," "," "," "]
["Authorized shares (in shares)"," "," "," "," "," ",{"v":139245313,"d":"139,245,313 "}," "," ",{"v":114245313,"d":"114,245,313 "}," "," "," "]
["Stockholder's equity, stock split, conversion ratio",0.025," "," "," "," "," "," "," "," "," "," "," "]
["Common Stock"," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Common stock, shares authorized (in shares)"," "," "," "," "," "," ",{"v":129245313,"d":"129,245,313 "}," "," "," "," "," "]
["Stockholder's equity, stock split, conversion ratio"," ",0.025," ",0.333,0.333," "," "," "," "," "," "," "]
["Common Stock | Minimum"," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Stockholder's equity, stock split, conversion ratio"," "," ",0.5," "," "," "," "," "," "," "," "," "]
["Common Stock | Maximum"," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Stockholder's equity, stock split, conversion ratio"," "," ",0.025," "," "," "," "," "," "," "," "," "]
["Common Stock and Preferred Stock"," "," "," "," "," "," "," "," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "," "," "," "," "," "," "," "]
["Authorized shares (in shares)"," "," "," "," "," "," ",{"v":139245313,"d":"139,245,313 "},{"v":114245313,"d":"114,245,313 "}," "," "," "," "]

{"sheet":"Stockholders_ Equity - Series A","index":67,"n_rows":8,"n_cols":6,"rows_kept":8}
["Stockholders’ Equity - Series A Preferred Stock (Details)","Aug. 04, 2024","Mar. 31, 2025 $ / shares","Mar. 07, 2025 $ / shares","Jan. 28, 2025 $ / shares","Dec. 31, 2024 $ / shares"]
["Class of Stock [Line Items]"," "," "," "," "," "]
["Preferred stock, par value (in dollars per share)"," ",{"v":0.0001,"d":"$ 0.0001"}," "," ",{"v":0.0001,"d":"$ 0.0001"}]
["Stockholder's equity, stock split, conversion ratio",0.025," "," "," "," "]
["Series A Preferred Stock"," "," "," "," "," "]
["Class of Stock [Line Items]"," "," "," "," "," "]
["Preferred stock, par value (in dollars per share)"," "," "," ",{"v":0.0001,"d":"$ 0.0001"}," "]
["Purchase price per share (in dollars per share)"," "," ",{"v":100,"d":"$ 100"},{"v":100,"d":"$ 100"}," "]

{"sheet":"Stockholders' Equity - Common S","index":68,"n_rows":3,"n_cols":2,"rows_kept":3}
["Stockholders' Equity - Common Stock (Details)","Mar. 31, 2025 vote"]
["Equity [Abstract]"," "]
["Common stock, number of votes per share",{"v":10,"d":"10 "}]

{"sheet":"Stockholders_ Equity - Schedu_2","index":69,"n_rows":34,"n_cols":4,"rows_kept":34}
["Stockholders’ Equity - Schedule of Warrants (Details) - $ / shares","Mar. 31, 2025","Dec. 31, 2024","Jul. 31, 2024"]
["Class of Stock [Line Items]"," "," "," "]
["Exercise price (in dollars per share)"," "," ",{"v":110400,"d":"$ 110,400"}]
["Class A Common Stock"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Warrants (in shares)",{"v":41039308,"d":"41,039,308 "},{"v":22514744,"d":"22,514,744 "}," "]
["Ares Warrants | Class A Common Stock"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Warrants (in shares)",{"v":5776657,"d":"5,776,657 "},{"v":5776657,"d":"5,776,657 "}," "]
["Exercise price (in dollars per share)",{"v":1.16,"d":"$ 1.16"},{"v":1.16,"d":"$ 1.16"}," "]
["SPA Warrants | Class A Common Stock"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Warrants (in shares)",{"v":15238,"d":"15,238 "},{"v":15238,"d":"15,238 "}," "]
["Exercise price (in dollars per share)",{"v":1.16,"d":"$ 1.16"},{"v":1.16,"d":"$ 1.16"}," "]
["Junior SPA Warrants | Class A Common Stock"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Warrants (in shares)",{"v":5931638,"d":"5,931,638 "},{"v":5931638,"d":"5,931,638 "}," "]
["Exercise price (in dollars per share)",{"v":1.16,"d":"$ 1.16"},{"v":1.16,"d":"$ 1.16"}," "]
["2024 Unsecured SPA Warrants | Class A Common Stock"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Warrants (in shares)",{"v":25874953,"d":"25,874,953 "},{"v":10788746,"d":"10,788,746 "}," "]
["Exercise price (in dollars per share)",{"v":1.39,"d":"$ 1.39"},{"v":1.39,"d":"$ 1.39"}," "]
["2025 March Unsecured SPA Warrants | Class A Common Stock"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Warrants (in shares)",{"v":3438357,"d":"3,438,357 "}," "," "]
["Exercise price (in dollars per share)",{"v":1.55,"d":"$ 1.55"}," "," "]
["Public Warrants | Class A Common Stock"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Warrants (in shares)",{"v":2453,"d":"2,453 "},{"v":2453,"d":"2,453 "}," "]
["Exercise price (in dollars per share)",{"v":110400,"d":"$ 110,400"},{"v":110400,"d":"$ 110,400"}," "]
["Private Warrants | Class A Common Stock"," "," "," "]
["Class of Stock [Line Items]"," "," "," "]
["Warrants (in shares)",{"v":12,"d":"12 "},{"v":12,"d":"12 "}," "]
["Exercise price (in dollars per share)",{"v":110400,"d":"$ 110,400"},{"v":110400,"d":"$ 110,400"}," "]

{"sheet":"Stockholders_ Equity - Warrants","index":70,"n_rows":11,"n_cols":4,"rows_kept":11,"merged":[[0,0,1,0]]}
["Stockholders’ Equity - Warrants (Details) - $ / shares","3 Months Ended","12 Months Ended"]
[null,"Mar. 31, 2025","Dec. 31, 2024","Jul. 31, 2024"]
["Class of Warrant or Right [Line Items]"," "," "," "]
["Class of warrant or right, exercised during the period",{"v":0,"d":"0 "},{"v":0,"d":"0 "}," "]
["Exercise price (in dollars per share)"," "," ",{"v":110400,"d":"$ 110,400"}]
["SPA Warrants | Class A Common Stock"," "," "," "]
["Class of Warrant or Right [Line Items]"," "," "," "]
["Exercise price (in dollars per share)",{"v":1.16,"d":"$ 1.16"},{"v":1.16,"d":"$ 1.16"}," "]
["Ares Warrants | Class A Common Stock"," "," "," "]
["Class of Warrant or Right [Line Items]"," "," "," "]
["Exercise price (in dollars per share)",{"v":1.16,"d":"$ 1.16"},{"v":1.16,"d":"$ 1.16"}," "]

{"sheet":"Stock-Based Compensation - Narr","index":71,"n_rows":28,"n_cols":7,"rows_kept":28,"merged":[[0,0,1,0]]}
["Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions",null,"3 Months Ended"]
[null,"Jul. 31, 2024","Mar. 31, 2025","Dec. 31, 2024","Jul. 31, 2021","May 02, 2019","Feb. 01, 2018"]
["Stock Incentive Plan"," "," "," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "," "," "]
["Stock available for future issuance (in shares)"," ",{"v":535027,"d":"535,027 "},{"v":2469957,"d":"2,469,957 "},{"v":5164,"d":"5,164 "}," "," "]
["Percent threshold of common stock issued and outstanding for annual increase of shares available for issue"," "," "," ",{"v":0.05,"d":"5%"}," "," "]
["Share-based compensation arrangement by share-based payment award, number of additional shares authorized",{"v":2206324,"d":"2,206,324 "}," "," "," "," "," "]
["Granted (in shares)"," ",{"v":0,"d":"0 "}," "," "," "," "]
["Stock-based compensation expense for unvested awards"," ",{"v":0.5,"d":"$ 0.5"}," "," "," "," "]
["Stock Incentive Plan | Share-based Payment Arrangement, Option"," "," "," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "," "," "]
["Stock-based compensation expense for unvested stock options"," ",{"v":0.1,"d":"$ 0.1"}," "," "," "," "]
["Expected weighted average period (in years)"," ","2 years 7 months 13 days"," "," "," "," "]
["Stock Incentive Plan | Restricted Stock Units (RSUs)"," "," "," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "," "," "]
["Expected weighted average period (in years)"," ","1 year 6 months 3 days"," "," "," "," "]
["Equity Incentive Plan"," "," "," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "," "," "]
["Authorized to grant (in shares)"," "," "," "," "," ",{"v":4416,"d":"4,416 "}]
["Equity Incentive Plan | Share-based Payment Arrangement, Option"," "," "," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "," "," "]
["Expected weighted average period (in years)"," ","1 year 7 months 9 days"," "," "," "," "]
["Share-based payment arrangement, nonvested award, cost not yet recognized, amount (less than)"," ",{"v":0.1,"d":"$ 0.1"}," "," "," "," "]
["STI Plan"," "," "," "," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "," "," "," "," "]
["Expected weighted average period (in years)"," ","1 year 7 months 28 days"," "," "," "," "]
["Authorized to grant (in shares)"," "," "," "," ",{"v":1472,"d":"1,472 "}," "]
["Share-based payment arrangement, nonvested award, cost not yet recognized, amount (less than)"," ",{"v":0.1,"d":"$ 0.1"}," "," "," "," "]

{"sheet":"Stock-Based Compensation - Stoc","index":72,"n_rows":13,"n_cols":3,"rows_kept":13,"merged":[[0,0,1,0],[0,1,0,2]]}
["Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "]
["Stock-based compensation expense",{"v":301077,"d":"$ 301,077"},{"v":542171,"d":"$ 542,171"}]
["Research and development"," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "]
["Stock-based compensation expense",{"v":268299,"d":"268,299 "},{"v":375350,"d":"375,350 "}]
["Sales and marketing"," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "]
["Stock-based compensation expense",{"v":22700,"d":"22,700 "},{"v":63330,"d":"63,330 "}]
["General and administrative"," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"," "," "]
["Stock-based compensation expense",{"v":10078,"d":"$ 10,078"},{"v":103491,"d":"$ 103,491"}]

{"sheet":"Fair Value of Financial Instr_3","index":73,"n_rows":16,"n_cols":3,"rows_kept":16}
["Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value (Details) - Fair Value, Recurring - USD ($) $ in Thousands","Mar. 31, 2025","Dec. 31, 2024"]
["Level 1"," "," "]
["Liabilities:"," "," "]
["Warrant liabilities",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}]
["Derivative call options",{"v":0,"d":"0 "}," "]
["Notes payable",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Level 2"," "," "]
["Liabilities:"," "," "]
["Warrant liabilities",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Derivative call options",{"v":0,"d":"0 "}," "]
["Notes payable",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Level 3"," "," "]
["Liabilities:"," "," "]
["Warrant liabilities",{"v":23624,"d":"23,624 "},{"v":28864,"d":"28,864 "}]
["Derivative call options",{"v":17057,"d":"17,057 "},{"v":46628,"d":"46,628 "}]
["Notes payable",{"v":21136,"d":"$ 21,136"},{"v":29709,"d":"$ 29,709"}]

{"sheet":"Fair Value of Financial Instr_4","index":74,"n_rows":37,"n_cols":3,"rows_kept":37,"merged":[[0,0,1,0]]}
["Fair Value of Financial Instruments - Schedule of Changes in Liability for Unobservable Inputs (Details) - USD ($) $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"," "," "]
["Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income Flag","Change in fair value of notes payable, warrant liabilities, and derivative call options"," "]
["Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease)",{"v":-11349,"d":"$ (11,349)"}," "]
["Debt issuance costs, net",{"v":429,"d":"429 "},{"v":25,"d":"$ 25"}]
["Nonrelated Party"," "," "]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"," "," "]
["Debt issuance costs, net",{"v":429,"d":"429 "}," "]
["Related Party"," "," "]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"," "," "]
["Debt issuance costs, net",{"v":76,"d":"76 "}," "]
["Warrant Liabilities"," "," "]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"," "," "]
["Beginning balance",{"v":28864,"d":"28,864 "}," "]
["Additions",{"v":16341,"d":"16,341 "}," "]
["Change in fair value measurements",{"v":-21581,"d":"(21,581)"}," "]
["Ending balance",{"v":23624,"d":"23,624 "}," "]
["Warrant Liabilities | Class A Common Stock"," "," "]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"," "," "]
["Conversions of notes to Class A Common Stock",{"v":0,"d":"0 "}," "]
["Derivative Call Option"," "," "]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"," "," "]
["Beginning balance",{"v":29709,"d":"29,709 "}," "]
["Additions",{"v":19730,"d":"19,730 "}," "]
["Change in fair value measurements",{"v":-32382,"d":"(32,382)"}," "]
["Conversions of notes to Class A Common Stock",{"v":0,"d":"0 "}," "]
["Ending balance",{"v":17057,"d":"17,057 "}," "]
["Notes Payable"," "," "]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"," "," "]
["Beginning balance",{"v":46628,"d":"46,628 "}," "]
["Additions",{"v":12525,"d":"12,525 "}," "]
["Change in fair value measurements",{"v":-22445,"d":"(22,445)"}," "]
["Ending balance",{"v":21136,"d":"21,136 "}," "]
["Notes Payable | Class A Common Stock"," "," "]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"," "," "]
["Conversions of notes to Class A Common Stock",{"v":-15572,"d":"$ (15,572)"}," "]

{"sheet":"Fair Value of Financial Instr_5","index":75,"n_rows":18,"n_cols":3,"rows_kept":18,"merged":[[0,0,1,0],[0,1,0,2]]}
["Fair Value of Financial Instruments - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Fair Value Measurement Inputs and Valuation Techniques [Line Items]"," "," "]
["Net loss",{"v":-10278,"d":"$ (10,278)"},{"v":-48217,"d":"$ (48,217)"}]
["Class A Common Stock"," "," "]
["Weighted average common shares used in computing net loss per share of Class A and Class B Common Stock:"," "," "]
["Basic (in shares)",{"v":75749893,"d":"75,749,893 "},{"v":1837959,"d":"1,837,959 "}]
["Diluted (in shares)",{"v":75749893,"d":"75,749,893 "},{"v":1837959,"d":"1,837,959 "}]
["Net loss per share of Class A and B Common Stock attributable to common stockholders:"," "," "]
["Basic (in dollars per share)",{"v":-0.14,"d":"$ (0.14)"},{"v":-26.23,"d":"$ (26.23)"}]
["Diluted (in dollars per share)",{"v":-0.14,"d":"$ (0.14)"},{"v":-26.23,"d":"$ (26.23)"}]
["Class B Common Stock"," "," "]
["Weighted average common shares used in computing net loss per share of Class A and Class B Common Stock:"," "," "]
["Basic (in shares)",{"v":75749893,"d":"75,749,893 "},{"v":1837959,"d":"1,837,959 "}]
["Diluted (in shares)",{"v":75749893,"d":"75,749,893 "},{"v":1837959,"d":"1,837,959 "}]
["Net loss per share of Class A and B Common Stock attributable to common stockholders:"," "," "]
["Basic (in dollars per share)",{"v":-0.14,"d":"$ (0.14)"},{"v":-26.23,"d":"$ (26.23)"}]
["Diluted (in dollars per share)",{"v":-0.14,"d":"$ (0.14)"},{"v":-26.23,"d":"$ (26.23)"}]

{"sheet":"Net Loss per Share - Potentiall","index":76,"n_rows":31,"n_cols":3,"rows_kept":31,"merged":[[0,0,1,0],[0,1,0,2]]}
["Net Loss per Share - Potentially Dilutive Shares Excluded From Computation of Diluted Net Income/(Loss) (Details) - shares","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive shares (in shares)",{"v":87305630,"d":"87,305,630 "},{"v":2990763,"d":"2,990,763 "}]
["Shares issuable upon conversion of SPA Portfolio Notes"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive shares (in shares)",{"v":44298705,"d":"44,298,705 "},{"v":2331077,"d":"2,331,077 "}]
["Shares issuable upon conversion of Unsecured Convertible Notes"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive shares (in shares)",{"v":1809969,"d":"1,809,969 "},{"v":390601,"d":"390,601 "}]
["Shares issuable upon exercise of equity classified SPA Portfolio Note warrants"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive shares (in shares)",{"v":15238,"d":"15,238 "},{"v":13968,"d":"13,968 "}]
["Shares issuable upon exercise of liability classified SPA Portfolio Note warrants"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive shares (in shares)",{"v":35244948,"d":"35,244,948 "},{"v":0,"d":"0 "}]
["Other warrants"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive shares (in shares)",{"v":5776657,"d":"5,776,657 "},{"v":228482,"d":"228,482 "}]
["Stock-based compensation awards – Options"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive shares (in shares)",{"v":2514,"d":"2,514 "},{"v":2731,"d":"2,731 "}]
["Stock-based compensation awards – RSUs"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive shares (in shares)",{"v":155134,"d":"155,134 "},{"v":21439,"d":"21,439 "}]
["Public Warrants"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive shares (in shares)",{"v":2453,"d":"2,453 "},{"v":2453,"d":"2,453 "}]
["Private Warrants"," "," "]
["Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"," "," "]
["Antidilutive shares (in shares)",{"v":12,"d":"12 "},{"v":12,"d":"12 "}]

{"sheet":"Subsequent Events (Details)","index":77,"n_rows":41,"n_cols":11,"rows_kept":41,"merged":[[0,0,1,0]]}
["Subsequent Events (Details) $ / shares in Units, $ in Thousands",{"$nulls":3},"3 Months Ended","4 Months Ended"]
[null,"May 08, 2025 USD ($) day shares","Apr. 18, 2025 USD ($)","Apr. 07, 2025 USD ($) $ / shares","Mar. 31, 2025 USD ($) day","Jun. 30, 2025 USD ($) installment","Apr. 09, 2025 shares","Apr. 08, 2025 shares","Mar. 28, 2025 USD ($)","Mar. 21, 2025 $ / shares","Dec. 31, 2024"]
["Envisage Settlement And Release Agreement"," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Settlement liabilities, judgment amount"," "," "," "," "," "," "," ",{"v":1500,"d":"$ 1,500"}," "," "]
["Preferred Class B"," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Purchase price per share (in dollars per share) | $ / shares"," "," "," "," "," "," "," "," ",{"v":0.0001,"d":"$ 0.0001"}," "]
["Subsequent Event"," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Preferred stock, shares, certificate of designation (in shares) | shares"," "," "," "," "," ",{"v":9000000,"d":"9,000,000 "}," "," "," "," "]
["Subsequent Event | Envisage Settlement And Release Agreement"," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Settlement liabilities, payment for shares issued in transaction"," "," ",{"v":425,"d":"$ 425"}," "," "," "," "," "," "," "]
["Share price (in dollars per share) | $ / shares"," "," ",{"v":1.08,"d":"$ 1.08"}," "," "," "," "," "," "," "]
["Settlement liabilities, number of shares issued in transaction (in shares) | shares"," "," "," "," "," "," ",{"v":393519,"d":"393,519 "}," "," "," "]
["Settlement liabilities, periodic payment"," "," "," "," ",{"v":375,"d":"$ 375"}," "," "," "," "," "]
["Number of monthly installments | installment"," "," "," "," ",{"v":4,"d":"4 "}," "," "," "," "," "]
["Subsequent Event | Utica Leaseco, LLC"," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Proceeds from debt, net of issuance costs"," ",{"v":700,"d":"$ 700"}," "," "," "," "," "," "," "," "]
["2024 Unsecured SPA Notes"," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Debt instrument, convertible, threshold consecutive trading days | day"," "," "," ",{"v":1,"d":"1 "}," "," "," "," "," "," "]
["2024 Unsecured SPA Notes | Notes Payable"," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Contractual Interest Rates"," "," "," ",{"v":0.1,"d":"10%"}," "," "," "," "," ",{"v":0.1,"d":"10%"}]
["Debt instrument, convertible, threshold consecutive trading days | day"," "," "," ",{"v":5,"d":"5 "}," "," "," "," "," "," "]
["Proceeds from debt, net of issuance costs"," "," "," ",{"v":20000,"d":"$ 20,000"}," "," "," "," "," "," "]
["2024 Unsecured SPA Notes | Notes Payable | Related Party | Subsequent Event"," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Aggregate principal amount",{"v":6600,"d":"$ 6,600"}," "," "," "," "," "," "," "," "," "]
["Contractual Interest Rates",{"v":0.1,"d":"10%"}," "," "," "," "," "," "," "," "," "]
["Debt instrument, convertible, threshold consecutive trading days | day",{"v":5,"d":"5 "}," "," "," "," "," "," "," "," "," "]
["SPA Loans | Subsequent Event"," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Debt conversion, converted amount",{"v":10600,"d":"$ 10,600"}," "," "," "," "," "," "," "," "," "]
["Converted interest",{"v":900,"d":"$ 900"}," "," "," "," "," "," "," "," "," "]
["SPA Loans | Subsequent Event | Class A Common Stock"," "," "," "," "," "," "," "," "," "," "]
["Subsequent Event [Line Items]"," "," "," "," "," "," "," "," "," "," "]
["Shares issued from conversion (in shares) | shares",{"v":10894406,"d":"10,894,406 "}," "," "," "," "," "," "," "," "," "]